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ABSTRACT AND AIM 
 
Uropathogenic Escherichia coli (UPEC) are the major cause of urinary tract infections 
(UTI), which is one of the most common infectious disease worldwide. Women 
belong to the most affected population, with every second woman experiencing at 
least one symptomatic UTI during her lifetime. Additionally, UTI is a major problem in 
the clinics, being the most common hospital acquired infection. To avoid 
complications like kidney infections, irreversible kidney damage or urosepsis, all 
symptomatic infections should be treated with antibiotics. The use of antibiotics for 
the treatment of UTI, is continuosly increasing the development of resistant 
pathogens against most of the currently available antimicrobials. Therefore, new 
treatment strategies targeting alternative mechanisms are urgently needed, avoiding 
selection pressure on bacteria and thereby implying a reduced risk of resistance. 
An alternative approach for the treatment of UTI is the anti-adhesion therapy using 
FimH antagonists. FimH is an adhesin, located on the distal tip of type 1 pili, 
expressed on the surface of UPEC. The type 1 pilus contains a carbohydrate 
recognition domain, binding to mannose glycans expressed on urothelial cells. This 
allows UPEC to adhere to and to invade host cells within the urinary tract epithelium 
and is the initial step for a successful establishment of a UTI. 
FimH antagonists are highly active anti-adhesion molecules, targeting the virulence 
factor FimH. In vitro and in vivo studies clearly indicate the potential of FimH 
antagonists for the prevention and treatment of UTI, with a higher therapeutic efficacy 
compared to antibiotics. 
The anti-adhesion therapy is focusing on the development of a new class of 
antimicrobials exhibiting less selection pressure and therefore a reduced potential for 
the emergence of resistance. In addition, a reduction of the antibiotic associated side 
effects (e.g. the disruption of the commensal microbiota) is expected. Thus, the 
availability of a novel class of antimicrobials based on an alternative mode of action 
would have a huge impact on the treatment of UTI, being a substantial contribution to 
public health. 
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The aim of this thesis was to evaluate the therapeutic potential of FimH antagonists 
in the UTI mouse model. In order to select a candidate for in vivo studies, the activity 
in cell-based assays had to be evaluated first. Following aims were investigated 
throughout my thesis: 
 
• The development of a cell-based assay, quantitatively measuring the 
aggregation potency of UPEC with yeast or guinea pig erythrocytes, 
respectively. 
 
• The development of a cell-based assay, measuring the adhesion rate of GFP-
labeled E. coli with human bladder carcinoma cells. 
 
• The establishment of the UTI mouse model followed by the evaluation of the 
therapeutic efficacy of selected FimH antagonists for their in vivo 
pharmacokinetic and pharmacodynamic properties. 
 
• Evaluation of the PK/PD profile of a FimH antagonist in the UTI mouse model. 
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INTRODUCTION 
Antimicrobial Chemotherapy – History and Current Problems 
The discovery of β-lactam antibiotics in the 1930s as well as the introduction of 
hygienic standards in hospitals (hand washing, use of disinfectants) were incisive 
steps in the development of public healthcare. Humans gained control over a 107 
times smaller organism and the mortality from bacterial infections rapidly diminished 
and concomitantly also the interest to develop new antimicrobials. However, shortly 
after it was assumed that bacterial infections are under control, the first emergence of 
resistant strains evolved. The ability of our tiny cohabitants to adapt to new living 
conditions was severely underrated and only insufficient efforts were undertaken to 
contain the emerging bacterial threat with new antibiotics [1]. Therefore, since the 
1990s, infectious diseases developed to the top five causes of death in high-income 
countries [2]. 
 
The majority of the classes of antimicrobials still used today have their origin in the 
1940s to 1970s (Figure 1 top) [3]. Although numerous chemically modified 
derivatives entered the market in recent years, real innovation only occurred in the 
last 10 years when new classes of antibiotics were approved for clinical use 
(oxazolidinones, lipopeptides and mutilins) [4, 5]. The diminished interest to develop 
new antibiotics and the rapidly increasing emergence of resistance led to the highly 
prevalent problem that for an increasing number of multidrug-resistant (MDR) and 
pandrug-resistant (PDR) bacteria no effective therapeutic treatment is available [5]. 
 
 
Figure 1. Timeline of the major steps of the development of antibiotics (top [5]) and the FimH 
anti-adhesion therapy for the treatment of urinary tract infection (UTI) (bottom [6 – 9, Paper 
II, 10]). The asterisk (*) is indicating the time when the first 
pharmacokinetic/pharmacodynamic (PK/PD) concept was described [11]. 
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Originally, antibiotics were developed to kill or inhibit bacterial growth, by targeting 
functions, which are essential for their survival (Figure 2 A). Although the traditional 
mode of action of antibiotics proved to be highly effective, their threat forced bacteria 
to evolve survival strategies like the development of resistance [12]. An essential 
cause for the emergence of antimicrobial resistance is the extensive use of 
antibiotics, leading to treatment failure, a reduced range of therapeutic options for 
consecutive bacterial infections and ultimately a serious threat for the patient [13, 14]. 
Thus, there is an alarming rise of antimicrobial resistance against fluoroquinolones, 
which are highly effective and commonly used as a 3-day standard treatment for 
acute uncomplicated urinary tract infection (UTI). Therefore, the Infectious Diseases 
Society of America (IDSA), recommend to limit the use of fluoroquinolones for more 
severe infections than uncomplicated UTIs. With this guideline the IDSA hope to 
reduce not only fluoroquinolone resistant uropathogens, but also other more 
pathogenic and difficult-to-treat microorganisms [15]. Therefore, the search for 
alternative treatment options against infectious diseases is indispensable. 
 
Bacterial Virulence – A Target for Antimicrobial Chemotherapy 
A successful pathogen-host interaction is crucial for microorganisms to survive in the 
hostile host environment and to establish an infection. Bacteria have developed 
multiple virulence factors to ensure their survival in various and varying environments 
(e.g. quorum sensing, adhesins, toxins, iron acquisition systems, protectins, 
lipopolysaccharide proteases, biofilms, hemolysins, secretion systems, capsules [16, 
17]). Many virulence factors are involved in the initial steps of the bacterial interaction 
with the host and they are essential for the establishment of an infection. Therefore 
virulence mechanisms are potential new targets for the development of antibacterial 
agents [18]. Selected currently pursued approaches and perspectives of anti-
virulence therapies are listed below. 
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Figure 2. Targets for antimicrobial chemotherapy. A. Traditional antimicrobial targets, either 
acting bacteriocidal or bacteriostatic. They inhibit essential bacterial functions: cell wall 
synthesis (e.g. β-lactams), DNA replication (e.g. flouroquinolones), RNA transcription (e.g. 
tetracyclines), protein (e.g. aminoglycosides) or folate (e.g. sulfa drugs) synthesis. B. Targets 
for anti-virulence therapy. Toxin function and delivery can be prevented by inhibition of type II 
or type III (T3SS) secretion, respectively or by inhibition of the effect of lethal factor (LF), 
edema factor (EF) and protective antigen (PA). Disturbance of virulence gene regulation can 
either be achieved by quorum sensing (QS) alteration (e.g. acyl-homoserine lactone (AHL)-
mediated QS by interference with LuxI or LuxR homologs) or by down-regulation of virulence 
gene expression on the transcriptional level. Bacterial adhesion to host cells can either be 
inhibited by pilus degradation (e.g. pilicides) or by inhibition of bacterial adhesion (e.g. FimH 
antagonists for type 1 pili mediated adhesion) [12]. 
 
 
Targeting toxin function and delivery. Toxins are proteins produced by bacteria to 
damage host cells and usually result in cell death or disruption of signal transduction. 
Three approaches are pursued in targeting bacterial toxins; first, attenuation of the 
toxin activity using antibodies (e.g. against Corynebacterium diphteriae, Clostridium 
botulinum or Clostridium tetani toxins) [12] or small molecules (e.g. hydroxymate 
from Merck, inhibiting lethal factor (LF) protease activity against Bacillus anthracis 
toxin [19]); second, modification of the host response to the toxin (e.g. thiazolidinone 
to inhibit Cl- dependent intestinal fluid secretion against the effect of Vibrio cholerae 
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toxin) and third, inhibition of toxin delivery to the target site (e.g. cholestyramine 
binding and inactivating Clostridium difficile toxin) [20] (Figure 2 B). 
 
Targeting virulence expression. A further approach in anti-virulence therapy is to 
directly inhibit the expression of the essential structures or mechanisms needed by 
microorganisms to establish an infection. A widely used target is the interference with 
bacterial quorum sensing (QS). QS is a chemically mediated cell-cell signaling 
mechanism, that enables bacteria to interact with their environment and to react upon 
changes with the expression of different genes (e.g. for bioluminescence, biofilm 
formation, signaling) or virulence factors (e.g. proteases, adhesins, toxins) [12, 21, 
22] (Figure 2 B). Three approaches are used for targeting QS mechanisms; first, 
inhibition of the QS molecules producing enzymes (e.g. LuxI homologs in 
Pseudomonas aeruginosa) [23]; second, degradation of QS molecules (e.g. acyl-
homoserine lactone (AHL) in Bacillus spp.) [24] and third, antagonizing the QS 
initiated transcription cascade (e.g. LuxR homologs in P. aeruginosa) (Figure 2 B) 
[25, 26]. 
Additional targets are transcriptional regulators, which are involved in the expression 
of various genes, e.g. adhesins, toxin production or secretion. One example is the 
small molecule virstatin, inhibiting two virulence mechanisms of V. cholerae, toxin-
coregulated pili and cholera toxin, respectively, protecting mice from intestinal 
colonization [27]. 
 
Targeting adhesion. An important virulence mechanism for infecting bacteria are 
adhesive structures (fimbriae or pili), being the first direct cell-cell contact of the 
invading pathogen with the host (Figure 2 B and Figure 5 infection step 1.). Several 
well-known adhesins, recognizing carbohydrate structures on mucosal epithelial cell 
surfaces, are essential for pathogenesis in many bacterial species (e.g. Helicobacter 
pylori, P. aeruginosa, Escherichia coli, Klebsiella pneumoniae) [28 - 30]. Two 
approaches are followed in the development of anti-adhesive strategies; either, 
inhibition of pili or fimbriae formation (e.g. inhibition of the chaperone usher pathway 
in E. coli using bicyclic 2-pyridones as pilicides) [31] or inhibition of pili mediated 
pathogen-host interaction (e.g. inhibition of type 1 pili mediated bacterial adhesion 
using FimH antagonists) [32]. 
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Urinary Tract Infection and Uropathogenic Escherichia coli 
Urinary tract infection (UTI) is one of the most common bacterial infection worldwide. 
Women are the most affected population and every second woman will experience at 
least one UTI during her lifetime. Furthermore, catheter-associated UTI accounts for 
the most common hospital acquired (nosocomial) infection and UTI is the third most 
acquired infection in intensive care units (ICUs) in Europe [33]. Although UTI is not a 
life threatening disease, all symptomatic infections should be treated with antibiotics 
to prevent potential devastating complications, like kidney infections (pyelonephritis), 
irreversible kidney damage and dissemination from the kidneys to the bloodstream 
(urosepsis) [34]. 
 
The leading pathogen causing UTI is uropathogenic E. coli (UPEC), responsible for 
over 90% of all infections [35]. Bacteria invade the bladder via the urethra from 
outside. The most common source for E. coli is the host’s own bowel flora [36], 
furthermore UPEC may be transmitted via ingestion of contaminated food [37, 38] or 
occasionally also by sexual transmission [39]. 
 
Although E. coli is a symbiotic inhabitant of the gastrointestinal tract, it is able to 
shape its genome by horizontal gene transfer in a pathogenic manner to cause 
various diseases in different niches. The gain and loss of mobile genetic elements 
like pathogenicity islands (PAIs), transferring virulence genes, can shape the genome 
of E. coli into different pathovars. Eight intensively studied E. coli pathovars are 
known, which can be divided in two main groups; diarrhoeagenic E. coli (responsible 
for intestinal diseases) and extraintestinal pathogenic E. coli (ExPEC). The following 
pathovars belong to the first group: enteropathogenic E. coli (EPEC), 
enterohaemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. 
coli (ETEC), enteroaggregative E. coli (EAEC) and diffusely adherent E. coli (DAEC). 
Two pathovars, uropathogenic E. coli (UPEC) and neonatal meningitis E. coli 
(NMEC), are responsible for extraintestinal infections [40]. All of the above mentioned 
pathovars have their origin in the commensal flora of the intestinal tract and, 
depending on their acquired PAIs, they can diverge into different pathovars and 
colonize different niches in the human host (Figure 3). 
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Figure 3: Sites of infection of different E. coli pathovars in humans. Extraintestinal 
pathogenic E. coli (ExPEC) cause diseases outside the intestinal tract: uropathogenic E. coli 
(UPEC) express distinctive adhesins to colonize the urinary tract and if left untreated can 
lead to urosepsis; neonatal meningitis E. coli (NMEC) is able to cross the blood brain barrier 
and cause meningitis in newborn children. Diarrhoeagenic E. coli cause intestinal diseases: 
enterohaemorrhagic E. coli (EHEC) and enteroinvasive E. coli (EIEC) colonize the large 
bowel; enteroaggregative E. coli (EAEC) colonize both, the large and the small bowel; 
enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC) and diffusely adherent E. 
coli (DAEC) colonize the small bowel, causing diarrhea [40]. 
 
 
UPEC colonize the normally sterile urinary tract in an ascending manner. The 
decisive virulence mechanism of UPEC colonization is their adhesion capability, 
using filamentous multi-subunit membrane proteins (pili or fimbriae) [41]. The first 
and most important pili employed for the initial entry into the urethra (urethritis) and 
the bladder (cystitis) are type 1 pili (Figure 4 and Figure 6), where the mannose-
dependent attachment to the glycosylated uroplakin Ia (UPIa) present on bladder 
cells is mediated by the fimbrial adhesin H (FimH) (Figure 5, infection step 1.). 
Furthermore, expression of flagella is important for the continuative ascension 
through the urethers into the kidneys (pyelonephritis) [42], where the adhesion is 
specifically mediated via P pili in a galactose dependent manner [40, 43, 44]. 
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Figure 4: Uropathogenic E. coli (UPEC) expressing type 1 pili (transmission electron 
micrographs, A at a magnification of 34’000 and B at a magnification of 64’000) [45]. 
 
 
Adhesion can enhance the fitness of UPEC in multiple ways. First, the initial 
attachment prevents the rapid clearance of E. coli from the urinary tract by the bulk 
flow of urine and at the same time initiates the infection process [29]. Second, 
adhesion is activating bacterial cell signaling and third, it enables the transfer of 
bacterial products to the host cells, which finally leads to the bacterial invasion into 
the superficial bladder cells (Figure 5, infection step 2.) [46]. Once within the bladder 
cells, bacteria can either start to replicate or to form intracellular biofilms (Figure 5, 
infection step 3.), where they are well-protected from host defense and antibiotic 
treatment. Bacteria can persist in the intracellular biofilms for weeks or months and 
are a possible source for recurrent UTIs. In a later stage, bacteria are able to either 
efflux from superficial bladder cells and at the same time disseminate and invade 
other cells or penetrate deeper into the underlying tissue cells (Figure 5, infection 
steps 4. and 5.) [47].  
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Figure 5. Schematic overview of the urinary tract infection cycle. 1. The first and most 
important step in the development of UTI is the type 1 pili dependent adhesion of UPEC 
(green) to uroplakin Ia (UPIa) on urothelial cells. 2. Adhesion triggers the invasion of the 
bacteria into the superficial bladder cells, lining the urinary tract. Once inside the cells, 
bacteria start to replicate and form 3. intracellular biofilms, where they are well protected 
from the host defense mechanisms and antibiotic treatment. 4. Later on, cells start to 
exfoliate and bacteria exit the cells in filamentous structures and 5. disperse in the 
environment ready to infect new cells (infection cycle adapted from Ref 47). 
 
 
UPEC employ various virulence mechanisms to ensure their persistence in the 
urinary tract, which are upregulated during the infection process in the host. Although 
the most extensively studied virulence factor are type 1 pili, UPEC evolved further 
survival strategies, like the release of various toxins (hemolysin, cytotoxic necrotizing 
factor 1 and secreted autotransporter toxin) to damage the host epithelium [48], the 
production of polysaccharide capsules and immunosuppressive proteins to evade 
host immune response [49], and the expression of iron acquisition systems (e.g. iron 
uptake transport lutA) to survive in the iron-limited environment of the urinary tract 
[17, 50]. 
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Also host defense evolved several self-protecting mechanisms for the defence 
against invading microorganisms. The main host strategies to defend the urinary tract 
are the bulk flow of urine to clear unattached bacteria, FimH dependent exfoliation of 
infected umbrella cells lining the bladder and production of inflammatory cells by 
activation of proinflammatory genes [51]. 
 
FimH – A Target for Anti-Adhesion Therapy 
Adhesion of UPEC to carbohydrate structures on urothelial cell surfaces is mediated 
via the lectin FimH. Lectins are carbohydrate-binding proteins, being an evolutionary 
conserved cell-cell recognition strategy [52, 53]. The four subunits FimA, FimF, FimG 
and FimH compose a type 1 pilus, which is approximately 1 – 2 µm long (Figure 6) 
[54]. The pilus is built by a 6.9 nm wide rod, formed by a series of right-handed, 
helical sequences of FimA subunits. The tip fibrillum is composed of several copies 
of FimF and FimG subunits, concluding with a FimH subunit. As a part of the FimH 
subunit, a carbohydrate-recognition domain (CRD) is responsible for bacterial 
attachment to oligomannosides of the integral membrane glycoprotein uroplakin Ia 
(UPIa) located on the surface of the urinary bladder cells [55, 56]. Type 1 pili are 
assembled by the chaperone-usher pathway (Figure 6) [57]. The periplasmatic 
biogenesis is mediated via a protein-folding catalyst, the chaperone FimC, binding 
and transporting the pilus subunits to the outer membrane. On the assembly platform 
in the outer membrane, subunits dissociate from FimC, followed by the assembly of 
the subunits via the usher FimD, translocating and anchoring the pili to the bacterial 
cell surface [58]. 
 
Bacterial adhesins usually exhibit a relatively low affinity to their target structures in 
the millimolar range. Therefore, bacteria developed several mechanisms to 
overcome the low adhesion capability by clustering of adhesins on their surface, or in 
the case of UPEC by expression of a high number of adhesins (100 - 400 pili per 
bacterium) as well as sheer force enhanced binding capacity [59, 60]. The latter 
enables UPEC to resist the first line defense of the host, the urine flow, generating 
sheer stress for the bacteria, which tightens their FimH dependent attachment to 
UPIa on the bladder cells [61]. 
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Figure 6. A. Schematic representation of the type 1 pilus assembly by the chaperone-usher 
pathway. The long and rigid fibrillum rod is composed of thousands of FimA subunits. The 
thin and flexibal tip fibrillum consists of the subunits FimF, FimG, and the adhesin FimH. The 
periplasmatic chaperone FimC binds intracellular to each subunit, catalyzing folding of the 
subunits, which are translocated by the Sec apparatus, located in the inner membrane. The 
subunits are delivered to the assembly platform FimD (usher) in the outer membrane, which 
forms a channel, allowing the pilus subunits to be assembled and expressed on the bacterial 
surface [62, 63]. B. Electron microscopic picture of a type 1 pilus (magnification = 300'000; 
bar = 20 nm) [55]. 
 
 
Previous studies clearly demonstrated that type 1 pili deficient UPEC strains are not 
able to initiate an infection in mice [43]. Furthermore, the immunization of mice, with 
antibodies directed against FimH, protected animals from bladder-colonization with 
UPEC [41]. These findings strongly suggest that the inhibition of the initial host-
pathogen interaction with FimH antagonists is a suitable approach to prevent and 
treat UTI. 
 
The host defense system exerts a FimH related mechanism to protect the sterile 
urinary tract from invading UPECs. The most abundant protein in the urine is the 
Tamm-Horsfall protein (THP; also called uromodulin). It is a high-mannosylated 
glycoprotein and is exclusively produced in the kidneys. It is able to neutralize UPEC 
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by binding to their type 1 pili and it thereby prevents the adhesion to urothelial cells 
[54]. Interestingly, it is highly conserved during evolution and THP-deficient mice are 
more susceptible to UTI [56]. Once the bacteria are trapped by THP, the 
THP/bacteria cluster is eliminated by the urine flow from the urinary tract. FimH 
antagonists would support the host defense mechanism to clear excessively invading 
bacteria. In addition, type 1 pili exhibit several important target-qualities for the 
development of an anti-adhesion therapy: 
 
(i) they are the most prevalent fimbriae encoded by UPEC, 
(ii) they are highly conserved during evolution,  
(iii) they mediate the adhesion, which is the first and most important step for 
the establishment of the infection cycle (Figure 5) and 
(iv) they target specific bacterial structures and are therefore expected to 
cause less side effects. 
 
In vitro and in vivo Evaluation of FimH Antagonists 
In the 1970s, Sharon and coworkers pioneered the discovery of anti-adhesion 
molecules targeting FimH (Figure 1 bottom). They reported on the in vitro inhibitory 
potential of methyl α-D-mannopyranoside (1a) [29] (Figure 8) and p-nitrophenyl α-D-
mannopyranoside [64] and investigated (in vitro and in vivo) the FimH lectin as a 
potential target for anti-adhesion therapy (Figure 7). Since no crystal structure was 
available, they explored the FimH binding site (CRD) by testing a series of simple α-
D-mannopyranosides with varying aglycons [65]. The structure-activity relationship 
investigations showed that substitutions on the aromatic ring have a favorable effect 
on the binding affinity of the α-D-mannopyranosides with an over 700-fold increase in 
affinity for o-chlorophenyl-p-nitrophenyl-α-D-mannopyranoside compared to methyl 
α-D-mannopyranoside (1a) (Figure 8). 
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Figure 7. Principle of the anti-adhesion therapy. In the presence of FimH antagonists, type 1 
pili expressing UPECs are not able to adhere to urothelial cells and are therefore washed out 
with the flow of urine. As a result, the infection cycle (Figure 5) can not be initiated. 
 
 
After crystal structures of FimH and FimH co-crystallized with antagonists became 
available [66 a-c, 67, 68], research focused on the rational design of more potent 
antagonists following two major directions. First, multivalent FimH antagonists were 
investigated [69], showing that tri- and tetravalent glycoclusters exhibit the highest 
activities with an up to 780-fold increase in affinity compared to methyl α-D-
mannopyranoside (1a). In a second approach, monovalent, high-affinity antagonists 
were designed and synthesized [32, 70]. Three main classes show a promising 
profile for affinity and in vitro pharmacokinetics and were therefore intensively 
investigated (in vitro and in vivo): (i) long-chain alkyl α-D-mannopyranosides [66 b, 
71, 72] (e.g. Figure 8, 1), (ii) α-D-mannopyranosides with aromatic aglycons [66 d, 
68, 71, 73, Paper II, Manuscript I] (e.g. Figure 8, 2, 5 and 6) and (iii) α-D-
mannopyranosides with extended aglycons [66 b, 68, 71, Paper IV, Paper V] (e.g. 
Figure 8, 3 and 4). 
Although both, mono- and multivalent FimH antagonists were designed and tested 
for their in vitro potencies, only with monovalent α-D-mannopyranosides (small-
molecules) the hurdle to in vivo studies was taken, due to their favorable drug-like 
properties (solubility, permeability through enterocytes, metabolic stability, renal 
excretion). 
 
INTRODUCTION 
 
19 
In vitro Target-Based and Cell-Based Assays 
At the beginning of the 20th century it was first discovered that E. coli cause 
hemagglutination (the ability to agglutinate erythrocytes) (Figure 1 bottom) [6]. Later 
on, correlation between agglutination capability and filamentous appendages present 
on the bacterial surface was identified and in the middle of the 20th century the ability 
of mannose to inhibit E. coli hemagglutination was first described [7]. Since then, the 
agglutination capability was used in most in vitro assays to evaluate the potential of 
FimH antagonists and is still used today (65, 72, 74 - 76, Paper I). 
 
Later on, more complex assay set-ups were developed for the quantitative 
determination of the inhibitory potency of FimH antagonists (Table 1). The in vitro 
assays can be divided in two main groups: either whole E. coli cells or isolated type 1 
pili or recombinant FimH protein, respectively are used for measurements. 
Furthermore, the assay either requires the immobilization of one of the binding 
partners on a specialized surface (e.g. enzyme linked immunosorbent assay (ELISA), 
surface plasmon resonance (SPR), human cell-based assays) or both partners are in 
solution (e.g. agglutination, hemagglutination, isothermal titration calorimetry (ITC), 
imaging and radioactive assays) (Table 1). 
 
Besides agglutination, the enzyme linked immunosorbent assay (ELISA) is a further 
frequently used method to evaluate the binding potential of FimH antagonists. 
Traditionally, the assay format is based on the addition of a monoclonal antibody, 
followed by incubation of a secondary antibody, which is conjugated with horseradish 
peroxidase (HRP) to allow an optical detection [67, 77, 78]. To avoid the need of a 
specific primary monoclonal antibody, further ELISA set-ups have been developed 
with alternative, easier and direct detection methods. Direct detection without the 
need of antibodies was allowed by the use of biotinylated type 1 fimbriated E. coli 
[79], or in a cell-free competitive binding assay, by the interactions of a biotinylated 
polyacrylamide glycopolymer (trimannose-polyacrylamide) with the mannose 
receptors [80]. For both approaches, the complexation of the biotinylated 
glycompolymer with streptavidin coupled to HRP allows for the quantification of the 
binding potencies of the tested FimH antagonists. In a further approach, GFP labeled 
bacteria were used, to allow a fluorescence read-out [79]. 
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Table 1: In vitro assays for the evaluation of the inhibitory potencies of FimH antagonists. 
BSA: bovine serum albumin; CRD: carbohydrate recognition domain; GFP: green 
fluorescence protein; HRP: horseradish peroxidase. 
Method Target/Ligand Detection Ref 
Agglutination 
Yeast (Candida albicans, 
Streptomyces cerevisiae)/ 
E. coli 
Aggregometry 
74, 
Paper I 
Hemagglutination 
Guinea pig erythrocytes/ E. coli Visual (by eye) 
68 
72 
  Aggregometry 
74, 
Paper I 
  
Microtiter plate 
mirror 
76 
Enzyme linked 
immunosorbent 
assay (ELISA) 
Mannan coated polystyrene 
surface/ E. coli 
Immunostaining 
(405 nm) 
77 
 
D-Mannose coated polystyrene 
surface/ isolated type 1 
fimbriae 
Immunostaining 
(415 nm) 
78 
 Mannose-BSA/ isolated FimCH 
Immunostaining 
(450 nm) 
67 
 
Mannan-coated plates/ 
biotinylated E. coli 
Streptavidin-HRP 
conjugation, 
detection by 
enzymatic 
staining (415 nm) 
79 
 
Isolated FimH-CRD-Th-6His/ 
Trimannose polymer coupled 
to HRP 
80 
 
Mannan-coated plates/ GFP 
expressing E. coli 
Fluorescence 
(485 nm) 
79 
Surface plasmon 
resonance (SPR) 
Immobilized anti-FimH 
antibody/ isolated FimH 
Residence units 
(RUs) 
66 b 
 
Immobilized BSA-mannoside 
conjugate/ isolated FimH 
66 b 
 
Immobilized low-molecular-
weight FimH antagonist/ 
isolated FimH 
71 
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Continuation of table 1: 
Method Target/Ligand Detection Ref 
Human cell-based 
assays 
Human granulocytes/ 
biotinylated type 1 fimbriae 
Flow cytometric 
detection of 
fluorescently 
labeled 
streptavidin 
81 
 Human urothelial cells/ E. coli 
Colony forming 
units (CFU) after 
cell lysis 
66 c 
 
Human bladder cells/ GFP 
labeled E. coli 
Flow cytometry Paper III 
Isothermal 
titration 
calorimetry (ITC) 
Mannosylated ligands/ isolated 
FimH Temperature 
changes (Kd) 
71 
 
FimH antagonists/ isolated 
FimH CRD 
82 
Imaging Mannose-encapsuled gold 
nanoparticles/ E. coli 
Transmission 
electron 
microscopy 
(TEM) 
83 
 
Mannose functionalized 
hematite (iron oxide)/ E. coli 
84 
Radioactive 
assays 
Mannosides coupled with 125I-
labelled human serum 
albumin/ E. coli Radioactivity 
72 
 
3H-labelled mannose/ isolated 
FimH 
66 b 
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UTI Mouse Model - The Therapeutic Potential of FimH Antagonists 
In the first in vivo proof of concept study, FimH antagonist 1a was pre-incubated with 
type 1 pili expressing UPEC strains and the mixture was instilled transurethral into 
the bladder of mice (Figure 1 bottom and Figure 8) [8]. Urine samples were analyzed 
for bacterial counts, resulting in a significant reduction of bacteriuric mice after 5-16 
days. In a second experiment, an additional dose of 1a was injected intraperitoneal 
(i.p.) two and three days after infection with the bacteria/antagonist mixture, leading 
to no significant supplemental benefit. As mentioned by Sharon and coworkers [8], a 
major drawback of the UTI mouse model is the spontaneous clearance of bacteria 
from the urinary tract 14 days after infection (up to 45%). Nevertheless, when the 
sampling of urine was conducted for up to 16 days, a significant reduction of 
bacteriuric mice treated with the FimH antagonist compared to the control group was 
observed. 
 
After the initial in vivo investigations of the therapeutic potential of FimH antagonists 
[8, 9], no further in vivo studies, testing the efficacy of antagonists were published for 
almost three decades (Figure 1 bottom). At the same time, however, based on the 
promising in vivo experiments, research directed to the identification of improved 
FimH antagonists [32]. Furthermore, the UTI mouse model was extensively used for 
the elucidation of the underlying mechanisms of this host-pathogen interaction (e.g. 
type 1 and P-pili [85], phase variation of type 1 pili [86], immune response [87] etc.) 
and the evaluation of antibiotic efficacy [46, 88]. 
 
The ascending UTI mouse model is the primarily used in vivo model, sharing 
following similarities to humans: 
• The infection route, starting in the urethra, ascending to the bladder and 
finally infecting the kidneys [85, 89]. 
• The expression of the uroplakin Ia (UPIa) receptor on the urothelial cells, 
responsible for the type 1 pili dependent adhesion of UPEC [90]. 
• Equal susceptibility of bacterial strains used [85]. 
• No vesicourethral reflux [91]. 
• Similar intracellular bacterial communities (IBC) formation in urothelial 
cells [91]. 
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Orally Available FimH Antagonists 
Recently, the in vivo investigations of potential FimH antagonists were resumed and 
the initial treatment experiments, where bacteria/antagonist mixtures were directly 
applied into the bladder [8, 9] were replaced by a therapeutically more relevant 
protocol. In further in vivo studies, FimH antagonists were either applied orally (p.o.) 
or intravenously (i.v.), which closer simulates conditions used for later patient 
application [Paper II, Paper V, Manuscript I, Manuscript II, 10, 92]. More in depth 
investigations of high affinity antagonists according to their in vitro and in vivo 
pharmacokinetic (PK) profile were conducted, aiming an oral application of the drug. 
 
In vitro and in vivo PK data of small molecule FimH antagonists showed that an 
optimal balance between solubility, permeability and lipophilicity is required for oral 
availability (Paper II, Paper V). In addition, to ensure the availability of the antagonist 
at the target organ (bladder), a prodrug approach was applied. The ester 2a of a 
biphenyl α-D-mannopyranoside is orally absorbed and hydrolyzed to the renally 
excretable acid 2b (Figure 8). When a single dose of 50 mg/kg is orally applied to the 
UTI mouse model ten minutes prior to infection (prevention study), a substantial 
reduction of 4 log10 of colony forming units (CFU) in the bladder could be detected 
(Paper II). 
In a further prevention study, newly designed indolylphenyl (3) and indolinylphenyl (4) 
derivatives were investigated for their PK and pharmacodynamic (PD) profile in the 
UTI mouse model after i.v. application of 1 mg/kg and 0.05 mg/kg, respectively. They 
exhibited an availability in bladder for over eight hours, leading to a reduction of 
bacterial counts by -3.7 log10 CFU (4), being equally potent as the standard 
therapeutic, ciprofloxacin (Paper V). 
 
The potential of biphenyl α-D-mannopyranosides for the treatment as well as 
prevention of UTI in mice was also evaluated by Cusumano et al. [10]. For treatment 
studies, animals with a two weeks chronic infection received a single oral dose of 5a 
(100 mg/kg), 5b and 6 (both 50 mg/kg), resulting in an 3 log10 CFU reduction of 
bladder counts for 5a and up to 4 log10 CFU reduction for 5b and 6 six hours after 
treatment. In comparison, the antibiotic trimethoprim-sulfamethoxazole (TMP-SMZ, 
applied in the drinking water) only reduced bacterial counts by 1.5 log10 CFU. 
Furthermore, antagonists applied together with antibiotics were reported to have a 
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synergistic effect on the treatment outcome. In a 24 hours multiple dosage study 
(three times 50 mg/kg p.o. of 6, every eight hours) for the treatment of chronic 
infections, bacterial counts in the bladder were reduced by 4.5 log10 CFU. For 
prevention studies, a single oral dose of 5a (50 mg/kg) was applied 30 minutes prior 
to infection, resulting in a 1.5 log10 CFU reduction of bladder counts, 6 h after 
infection. 
 
 
 
Figure 8: α-D-Mannopyranosides tested in the UTI mouse model. Methyl and n-heptyl α-D-
mannopyranosides (1a & 1b) [8, 9, Paper II], biphenyl α-D-mannopyranosides 2a and 2b 
[Paper II], indoline and indolinyl α-D-mannopyranosides 3 & 4, diamidobiphenyl α-D-
mannopyranosides 5a and 5b [10] and monoamidobiphenyl α-D-mannopyranoside 6 [10]. 
 
 
Additionally, the treatment with FimH antagonists prevented invasion of UPECs into 
the bladder cells leading to a reduction of biofilm formation, which was further 
evaluated in a mouse catheter model using optimized biphenyl α-D-
mannopyranoside FimH antagonists (higher potency and improved PK properties) 
[10, 92, 93]. They showed that intraperitoneal (i.p.) applied mannopyranosides were 
able to improve the efficacy of TMP-SMZ treatment on catheter associated UTI. 
 
Several in vivo studies confirmed the promising potential of orally applied FimH 
antagonists for both, prevention and treatment of UTI in mice. In addition, FimH 
antagonists proofed to be equally effective than antibiotics. Both aspects highlight the 
great potential of anti-adhesives for further clinical development (e.g. PK/PD studies). 
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Pharmacokinetic/Pharmacodynamic Studies – The Effect Profile of FimH 
Antagonists 
A central aspect in antimicrobial development is the prediction of the efficacy for each 
individual antibiotic agent and the corresponding disease under varying 
concentrations, application time points and exposure times. The pharmacology of an 
antimicrobial determines its behavior in the organism and is composed of two main 
components, pharmacokinetics and pharmacodynamics (Figure 9) [94]. The first 
component, pharmacokinetics (PK), defines the absorption, distribution and 
elimination of a drug, determining the time course of drug concentration at the site of 
infection (tissue or body fluids). The second component, pharmacodynamics (PD), 
describes the correlation between serum concentration of a drug and its treatment 
efficacy. Together, they allow the simulation of the varying drug concentration over 
time in combination with efficacy, using pharmacokinetic/pharmacodynamic (PK/PD) 
modeling. PK/PD studies are important during drug development to find the optimal 
dosage regimen for later clinical trials and to minimize antimicrobial resistance 
development (by ensuring total bacterial eradication) [95, 96]. 
 
 
 
Figure 9: The concept of pharmacokinetic/pharmacodynamic (PK/PD) modeling. PK/PD 
studies combine the knowledge of the concentration-time profile (PK) of a drug with its 
efficacy-concentration (PK) profile, resulting in an efficacy over time (PK/PD) profile. The 
PK/PD profile is used to predict further dosage regimens and the therapeutic outcome in vivo 
(mouse model and human clinical trials) [97]. 
INTRODUCTION 
 
26 
In the 1950s a time-dependent bactericidal efficacy of penicillin was first described in 
a rodent model, being the hour of birth for the PK/PD concept [11] (Figure 1 asterisk). 
However, the significance from the initial PK/PD investigations were understood only 
two decades later and the research was successfully revived. Hence, today patients 
profit from the gained PK/PD knowledge, incorporating virtually every antimicrobial 
class [95]. 
 
 
The three predictive PK/PD dosing indices for antimicrobials are (Figure 10) [94 - 96, 
98]: 
i) The duration of time a drug concentration remains above the minimal 
inhibitory concentration (MIC) (T>MIC), indicating the time-dependent 
activity. The bactericidal activity increases with a longer exposure time, but 
not with higher concentrations (e.g. penicillins, cephalosporins, 
carbapenems, vancomycin, clarithromycin, linezolid, doxycycline). 
ii) The maximal reached drug concentration above the MIC (Cmax/MIC or 
Peak/MIC), indicating the concentration-dependent activity. The 
bactericidal activity increases with higher drug concentration, but not with 
prolonged exposure time (e.g. aminoglycosides, daptomycin, 
streptomycin, metronidazole, fluoroquinolones).  
iii) The area under the concentration time curve (AUC) over a time range of 
24 hours above the MIC (AUC0-24/MIC), indicating both, time- and 
concentration-dependent activity (e.g. aminoglycosides, fluoroquinolones, 
tetracyclines, vancomycin). 
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Figure 10: Pharmacokinetic/pharmacodynamic (PK/PD) indices of a drug used for the 
prediction of the therapeutic outcome in vivo [adapted from 96]. Cmax: maximal concentration 
in the tested site (tissue or body fluids); MIC: minimal inhibitory concentration; AUC0-24: area 
under the curve over a time period of 24 hours; T: time. 
 
 
Several static and dynamic in vitro assay set-ups have been developed to determine 
the PK/PD measures for each drug [Refs 99]. However, in vivo studies remain 
indispensable, because they allow the evaluation of the efficacy of a drug at the 
infection site under changing time courses of drug availability and other host 
influence factors (e.g. immune system). To identify the PK/PD profile most closely 
correlated with efficacy, dose-fraction studies (same total drug-concentration 
administered in different dosing intervals) are performed [94, 95, 98]. Such 
experimental studies are usually easily conducted in animal models and decrease 
the risk (dose guessing in patients) and cost in drug development. They provide 
information for the selection of dose and dosing-intervals for human clinical trials and 
recent studies suggest that the PK/PD index most predictive for the efficacy of an 
antimicrobial agent in animal infection models correlate well with human infections 
[94]. Therefore, the preclinical determination of the PK/PD indices for FimH 
antagonists (Manuscript II) could provide valuable information for the later on clinical 
outcome of an anti-adhesive therapy against UTI. 
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ABSTRACT 
 
Urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia 
coli (UPEC) belong to the most prevalent infectious diseases worldwide. For the 
successful establishment of an UTI, the adhesion of bacteria to urothelial cells is a 
crucial first step, protecting the bacteria from the natural defense mechanisms as 
urine flow or the host immune system. The attachment of UPEC to host cells is 
mediated by FimH, a mannose-binding adhesin at the tip of type 1 pili, which are 
expressed on the bacterial surface. To date, UTIs are mainly treated with antibiotics, 
leading to the ubiquitous problem of increasing resistance against most of the 
currently available antimicrobials. Therefore, new treatment strategies are urgently 
needed, avoiding selection pressure and thereby affording a reduced risk of 
resistance. Here, we describe the development of an orally available FimH 
antagonist. Starting from the carboxylate substituted biphenyl α-D-mannoside 6 
affinity as well as the relevant pharmacokinetic parameters (solubility, permeability, 
renal excretion) could be substantially improved by a bioisosteric approach. With 3’-
chloro-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (11j) a FimH antagonist 
with an optimal in vitro PK/PD profile was identified. The para-cyano substituent 
conferred lipophilicity and high binding to plasma proteins, which slowed down the 
rate of renal excretion. Despite higher lipophilicity, antagonist 11j was insusceptible 
to CYP450 mediated metabolism, and as a consequence predominantly eliminated 
via the renal pathway. Finally, in vivo experiments confirmed the excellent PK-profile 
of 11j with steady renal excretion for more than eight hours after oral application, 
suggesting a long-lasting anti-adhesive effect. Finally, orally applied 11j was effective 
in a mouse model of UTI by reducing the bacterial load in the bladder by over 1000-
fold. 
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INTRODUCTION 
 
Urinary tract infection (UTI) is one of the most frequent infectious diseases worldwide 
and affects millions of people every year.1 In more than 70% of the reported cases, 
uropathogenic Escherichia coli (UPEC) is the causal pathogen.2 Acute, 
uncomplicated lower urinary tract infection, commonly referred to as cystitis, requires 
an antibiotic treatment for symptom relief (i.e. reduction of dysuria, frequent and 
urgent urination, bacteriuria, pyuria) and for prevention of more devastating or even 
life threatening complications like pyelonephritis and urosepsis.3,4 However, the 
repeated use of antibacterial chemotherapeutics provokes antimicrobial resistance 
leading to treatment failure.5 Hence, a new approach for the prevention and 
treatment of UTI with orally applicable therapeutics is urgently needed.6 
 
UPEC undergo a well-defined infection cycle within the host.7 The key step in 
pathogenesis is bacterial adhesion to the epithelial cells in the lower urinary tract.8 
This interaction prevents UPEC from clearance by the bulk flow of urine and enables 
the bacteria to colonize the epithelial cells. The adhesion is mediated by the virulence 
factor FimH located at the tip of bacterial type 1 pili.9,10 FimH consists of two 
immunoglobulin-like domains: the N-terminal lectin domain and – connected by a 
short linker – the C-terminal pilin domain.11 The lectin domain encloses the 
carbohydrate recognition domain (CRD) that binds to the oligomannosides of the 
glycoprotein uroplakin Ia on the epithelial cell surface.12 The pilin domain anchors the 
adhesin to the pilus and regulates the switch between the two conformational states 
of the CRD with high and low affinity for mannosides, respectively. 
 
More than three decades ago, Sharon and co-workers described various 
oligomannosides and aryl α-D-mannosides as potential antagonists of the FimH-
mediated bacterial adhesion.13,14 However, only weak interactions in the milli- to 
micromolar range were observed. In recent years, several high-affinity monovalent α-
D-mannopyranosides have been reported.15-24 Their improved affinities are based on 
optimal interactions with the main structural features of the CRD.25-28 First, the 
mannose binding pocket accommodating the mannose moiety by means of an 
extended hydrogen bond network and, second, the entrance to the binding site 
composed of three hydrophobic amino acids (Tyr48, Tyr137, and Ile52) and therefore 
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referred to as ‘tyrosine gate’ hosting aliphatic and aromatic aglycones. As an 
example, n-heptyl α-D-mannopyranoside (1) exhibits nanomolar affinity due to 
hydrophobic contacts of the alkyl aglycone with the hydrophobic residues of the 
tyrosine gate.15 Furthermore, aromatic aglycones, such as present in the mannosides 
2-10 (Figure 1), provide strong π-π stacking interactions with the tyrosine gate. These 
interactions are further favored by the addition of an electron withdrawing substituent 
on the terminal ring of the biaryl portion.18,19 
 
 
 
Figure 1. Monovalent FimH antagonists exhibiting nanomolar affinities. 
 
Recent in vivo PK studies in mice proved the high potential of the biphenyl α-D-
mannosides 4 and 7 for an oral treatment, although high doses (≥ 50 mg/kg) were 
necessary to achieve the minimal concentrations required for the anti-adhesive effect 
in the urinary bladder.19,21,22 Moreover, the therapeutic effect could only be 
maintained for a few hours, i.e. four hours for a po (per os) single-dose application of 
7 (50 mg/kg), because of rapid elimination by glomerular filtration and low 
reabsorption from the primary urine in the renal tubules.19 
 
To date, the physicochemical properties affecting the rate of renal excretion, i.e. 
lipophilicity and plasma protein binding (PPB), or metabolic liabilities promoting non-
renal elimination pathways have been barely investigated for FimH antagonists. The 
goal of the present study was to optimize the biphenyl α-D-mannoside with respect to 
oral bioavailability and renal excretion. Starting from antagonist 6, we synthesized 
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new biphenyl derivatives, characterized their affinity to the CRD, structurally 
investigated their binding mode, and determined physicochemical and 
pharmacokinetic parameters predictive for intestinal absorption and renal elimination. 
Furthermore, we determined in vivo PK (pharmacokinetic) of the most promising new 
antagonists in a mouse model. The compound with the best PK profile proofed 
effective in reducing the bacterial loads upon bladder infection in a mouse model of 
UTI. 
 
 
RESULTS AND DISCUSSION 
 
As previously reported, the carboxylate substituent present in the biphenyl 
mannoside 6 – its electron withdrawing potential being essential for an enhanced 
drug target interaction – strongly decreases the lipophilicity of the antagonist (log D7.4 
< -1.519) in comparison to the n-heptyl (→ 1, log P = 1.719) or the unsubstituted 
biphenyl aglycone (→ 10, log P = 2.124). Since low lipophilicity is a major reason for 
low intestinal absorption and rapid renal excretion of the systemically available 
antagonist,19,23 we aspired to improve oral bioavailability as well as renal excretion by 
replacing the carboxylate in 6 with various bioisosteric groups29 (Figure 2). 
 
 
Figure 2. Bioisosteric replacement of the carboxylic acid substituent of biphenyl α-D-mannopyranoside 
6. 
 
Synthesis. Iodide 12 was prepared from peracetylated mannose and 4-iodophenol in 
the presence of BF3·Et2O.24 In a palladium-catalyzed Miyaura-Suzuki coupling30 with 
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the boronic acid or boronate derivatives 13a-g, the biphenyl derivatives 14a-g were 
obtained in good to excellent yields. Final deprotection yielded the test compounds 
11a-g. Utilizing microwave-assisted reaction condition,31 the conversion of arylnitrile 
14g to tetrazole 15 proceeded rapidly and with good yield. After deprotection of 15 
using Zemplén conditions, the test compound 11h was obtained (Scheme 1). 
 
 
Scheme 1. a) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C, 4 h (14a-g, 44-99%); b) NaOMe, MeOH, rt, 4 
h (11a-h, 29-86%); c) TMSN3, Bu2Sn(O), DME, 150 °C, µW, 10 min, 81%. 
 
The cyanobenzamide derivative 11i (Scheme 2) was obtained from 6 by 
peracetylation (→ 16) followed by conversion of the carboxylic acid into its acid 
chloride with 1-chloro-N,N,2-trimethyl-1-propenylamine.32 Without isolation, the acid 
chloride was reacted with sodium hydrogen cyanamide in DMF followed by 
deacetylation under Zemplén conditions to yield the test compound 11i. 
 
 
 
Scheme 2. a) i) Ac2O, DMAP, pyridine, 0 °C to rt, overnight; ii) satd. NaHCO3 aq., DCM, rt, 2 h (16, 
53%); b) 1-chloro-N,N,2-trimethyl-1-propenylamine, toluene, 0 °C to rt, 2 h; c) NaH, NH2CN, DMF, 0 
°C to rt, overnight; d) NaOMe, MeOH, rt, 4 h (11i, 21% for three steps). 
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Finally, to further improve the pharmacokinetic properties of mannoside 11g (see 
Table 3), a chloride substituent was introduced to the ortho-position of the aromatic 
ring adjacent to the anomeric oxygen. For its synthesis, peraceylated α-D-mannose 
(17) was coupled with 2-chloro-4-iodophenol (18) using BF3⋅Et2O as promotor (→ 19, 
76%). After the introduction of the second aromatic ring by Miyaura-Suzuki coupling 
(→ 20, 75%), deprotection yielded mannoside 11j (Scheme 3). 
 
 
 
Scheme 3. a) BF3⋅Et2O, CH2Cl2, 40 °C (76%); b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C (75%); c) 
NaOMe, MeOH, rt, 4 h (48%). 
 
Binding Affinity. The binding affinity of heptyl mannoside 1, the biphenyl 
mannosides 5, 6, 10, and the bioisosteres 11a-j was determined in a competitive 
fluorescence polarization assay (FP-assay) and with isothermal titration calorimetry 
(ITC). A protein construct consisting of the CRD with a C-terminal His-tag with a 
thrombin cleavage site (FimH-CRD-Th-His6) was used for all experiments.33 
 
Competitive Fluorescence Polarization Assay. For the rapid evaluation of binding 
affinity, we established a competitive binding assay based on fluorescence 
polarization (FP). Similar formats have been applied before for the detection of 
carbohydrate-lectin interactions.18,34 In this assay, the antagonist of interest displaces 
a fluorescently labeled competitor from the binding site, thereby causing a reduction 
in fluorescence polarization.35 To identify the optimal competitor, fluorescein 
isothiocyanate (FITC) was connected to the FimH ligand 8 by three linkers of 
different lengths (→ 21-23, Scheme 4). For optimal sensitivity and signal-to-noise 
ratio, three main parameters need to be considered: (i) the affinity of the competitor 
should not be impaired by the fluorescent label, (ii) the conformational flexibility of the 
label upon binding of the competitor to the CRD should be low and (iii) the 
fluorescence properties of the label should not be affected by the connected 
ligand.36-38 A change in fluorescence properties was observed for reporter ligand 21 
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in which the label was linked to the biphenyl agylcone by an amide bond. The 
absorption spectrum revealed a lack of the characteristic fluorescein absorption peak 
at 494 nm (Scheme 4), likely due to an extension of the conjugated system to the 
biphenyl moiety of the ligand. The elongated saturated spacer groups in competitors 
22 and 23 ensured that the expected spectral properties of the dye were retained 
(Scheme 4). 
 
 
 
Scheme 4. a) 1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-
morpholinomethylene)] methanaminium hexafluorophosphate (COMU), NEt3, fluoresceinamine, DMF, 
rt, 7 h (21, 19%); b) i. DIC, NHS, N-Boc-ethylenediamine, DMF, rt, 12 h; ii. TFA, DCM, rt, 10 min (68% 
over two steps), iii. fluorescein isothiocyanate (FITC), NEt3, DMF, rt, 3 h (22, 48%); c) i. DIC, NHS, N-
Boc-PEG2-NH2, DMF, rt, 14 h; ii. TFA, DCM, rt, 30 min (62% over two steps); iii. FITC, DMF, rt (23, 
65%). 
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For the determination of their binding affinity, fixed concentrations of the reporter 
ligands 22 and 23 were incubated for 24 h with a linear dilution of the FimH-CRD (0-
100 nM). FP was measured using a plate reader, with polarized excitation at 485 nm, 
and emission at 528 nm measured through appropriately oriented polarizers. Fitting 
the single-site binding function of Cooper39 to the observed FP data resulted for 
compound 22 in a dissociation constant (KD = 1.7 nM, Figure 3A) similar to that of the 
unlabeled parent compound 8,19 whereas 23 showed a five-fold lower affinity (9.9 
nM) (Scheme 4). Therefore, the reporter ligand 22 fulfills all characteristics as an 
optimal competitor and was used for the FP assay. 
 
Figure 3. A) Direct binding curve of the labeled competitor 22 obtained by adding a linear dilution of 
FimH-CRD (0-100 nM) and a constant concentration of competitor 22 (5 nM). The KD was determined 
by fitting the experimental data to a single-site binding fit that accounts for ligand depletion. In three 
FP based direct binding experiments the KD of competitor 22 was determined to be 1.7 nM. B) 
Inhibition curve of n-heptyl mannoside (1) from the competitive FP assay. The IC50 value was 
determined by nonlinear least-squares fitting to a standard 4-parameter equation. A modified Cheng-
Prusoff equation was used to calculate the corresponding KD value (KD = 28.3 nM). 
 
For the test compounds 1, 5, 6, 10, and 11a-j, a 24 h incubation time was applied 
before FP was measured due to the long residence time of FimH antagonists (t1/2 > 
3.5 h, Figure 3B40). The 24 h incubation period was empirically determined to be 
necessary to reach equilibrium between reporter ligand and compound of interest. 
IC50 values were obtained by nonlinear least-squares regression (standard four-
parameter dose response curve) and converted to KD values using a modified 
Cheng-Prusoff equation.35 This equation accounts for the ligand depletion effect in 
competitive titrations involving high-affinity interaction partners present in similar 
concentrations. Under these conditions, the free concentration of an interacting 
species cannot be assumed to equal the total concentration. 
 
The KD values determined for the test compounds 1, 5, 6, 10, and 11a-j are 
summarized in Table 1. Against our expectations, the biphenyl mannosides 6 and 10 
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exhibit similar affinities (Table 1), despite the presence of an electron withdrawing 
carboxylate substituent in antagonist 6. According to the crystal structure of FimH co-
crystallized with the sulfonamide derivative 11e (Figure 4A), the outer aromatic ring 
of the biphenyl aglycone forms π-π interactions with the electron rich Tyr48, which is 
part of the tyrosine gate of FimH.15 A reduction of electron density of the aglycone by 
the electron withdrawing carboxylate was expected to enforce these π-π stacking 
interactions and lead to improved affinity. However, this beneficial effect might be 
compensated by an entropic penalty originating from the improved π-π stacking to 
Tyr48 that might lead to the reduced flexibility of both protein and antagonist. 
Furthermore, a beneficial enthalpy effect might be partially compensated by an 
enthalpy penalty originating from the desolvation of the charged 10 carboxylate41 
(see also experimental part). Although this substituent is solvent exposed, at least a 
partial desolvation may be necessary upon antagonist binding. To prove this 
assumption, we replaced the carboxylate by the corresponding methyl ester (→ 5)19 
in order to reduce the desolvation penalty and, as predicted by the Hammett constant 
σp,42 to further improve the π-π stacking. Indeed, a six-fold improvement in affinity 
was achieved. However, since the methyl ester undergoes rapid enzyme-mediated 
hydrolysis in vivo,19 it will not be available at the place of action in the urinary 
bladder. The methyl ester was therefore replaced by metabolically stable 
bioisosteres29 exhibiting comparable electron withdrawing properties42 (Table 1, 
entries 5-13). The most potent derivatives 11d, 11e and 11g showed affinities in the 
low nanomolar range. 
 
As previously reported,24 a chloro substituent in the ortho-position of the aromatic 
ring adjacent to the anomeric oxygen is favorable for affinity and improves the 
physicochemical properties relevant for oral bioavailability. Indeed, the corresponding 
antagonist 11j was the most potent compound tested in this study. 
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Table 1. Affinities (KD) of FimH antagonists to FimH-CRD-Th-His6; dissociation constants (KD) were 
determined in a competitive fluorescence polarization assay. 
Entry Compd 
 
Affinity 
KD [nM] 
1 1  28.3 ± 5.0 
2 10 
 
15.1 ± 2.2 
3 6 
 
17.9 ± 1.5 
4 5 
 
3.6 ± 0.9  
5 11a 
 
2.8 ± 0.3 
6 11b 
 
2.9 ± 0.5 
7 11c 
 
3.0 ± 0.1 
8 11d 
 
1.7 ± 0.2 
9 11e 
 
2.7 ± 0.4 
10 11f 
 
3.7 ± 0.2 
11 11g 
 
2.0 ± 0.6 
12 11h 
 
5.7 ± 0.1 
13 11i 
 
8.4 ± 0.3 
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14 11j 
 
< 1a) 
 
a) The KD value of 11j was approximated to be in the subnanomolar range. The IC50 value obtained in 
the competitive FP assay was equal to the lowest value that can be resolved by the assay, indicating 
stoichiometric titration of 11j due to its high affinity. Consequently, its KD must be below the KD of 
competitor 22. 
 
Isothermal Titration Calorimetry (ITC). To further confirm our hypothesis regarding 
π-π stacking and desolvation, we performed ITC experiments with unsubstituted 
biphenyl mannoside 10, the carboxylic acid 6, and the bioisosteres 11b-e, g and j 
(Table 2). ITC allows the simultaneous determination of the stoichiometry (N), the 
change in enthalpy (∆H) and the dissociation constant (KD) for ligand-protein 
binding.43,44 The reliable determination of these three parameters requires well-
defined sigmoidal titration curves characterized by the dimensionless Wiseman 
parameter c (c = Mt(0) KD-1, where Mt(0) is the initial macromolecule concentration).45 
To be sure that data can be fitted with confidence, the c-value should be between 1 
and 1,000 (ideally between 5 and 500),46 which could be achieved for the antagonists 
6 and 10. For titrations involving low micromolar Mt(0) and interactions in the low 
nanomolar or picomolar range, as suggested for the bioisosteres 11b-j, c-values 
above 1,000 were expected. Since these conditions lead to steep titration curves that 
do not allow the determination of the curve slope representing 1/KD, we applied an 
alternative, competitive format referred to as displacement assay.47,48 First, FimH-
CRD-Th-His6 was pre-incubated with the low affinity antagonist n-heptyl 2-deoxy-α-D-
mannopyranoside (24, for synthesis see supporting information). The high-affinity 
bioisosteres of interest were titrated into the protein-ligand complex giving well-
defined sigmoidal titration curves.  
 
O
CN
Cl
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Table 2. Thermodynamic parameters from ITC for selected FimH-antagonists binding to FimH-CRD-
Th-His6; n, stoichiometric correction factor; CI, confidence interval from fitting.  
 
Entry Compd 
 
KD [nM] 
(95 % CI) 
ΔG 
[kJ/mol] 
ΔH [kJ/mol] 
(95 % CI) 
-TΔS 
[kJ/mol] n 
Type of 
measurem
ent 
1 10 
 
17.7 
(14.1 – 
22.3) 
-44.2 
-45.0 
(-44.5 – -
45.6) 
0.8 1.07 direct 
2 6 
 
15.0 
(13.4 – 
16.7) 
-44.7 
-48.7 
(-48.4 – -
49.0) 
4.0 1.05 direct 
3 11b 
 
4.3 
(3.2 – 5.6) -47.8 
-54.5 
(-54.1 – -
54.9) 
6.7 1.02 competitive vs. 24 
4 11c 
 
5.0 
(3.8 – 6.6) -47.4 
-54.5 
(-54.1 – -
54.8) 
7.1 0.97 competitive vs. 24 
5 11d 
 
3.0 
(2.1 – 4.2) -48.7 
-52.3 
(-51.5 – -
53.1) 
3.6 0.99 competitive vs. 24 
6 11e 
 
3.5 
(2.9 – 4.3) -48.2 
-52.2 
(-51.6 – -
52.8) 
3.9 1.06 competitive vs. 24 
7 11g 
 
2.8 
(2.3 – 3.3) -48.8 
-58.2 
(-57.8 – -
58.6) 
9.4 1.00 competitive vs. 24 
8 11j 
 
1.3 
(1.1 – 1.6) -50.7 
-60.9 
(-60.4 – -
61.4) 
10.1 1.01 competitive vs. 24 
9 24 
 
9’386 
(8’555 – 
10’287) 
-28.7 
-19.5 
(-19.1 – -
20.0) 
-9.1 1.00 direct 
 
The resulting KD values (Table 2) correspond well with the data obtained from the FP 
assay (Table 1). A comparison of the thermodynamic fingerprints of antagonists 10 
and 6 reveals that the more favorable enthalpic contribution resulting from facilitated 
π-π stacking leads to a net enthalpy gain (ΔΔH: -3.7 kJ/mol). However, an even 
greater increase in enthalpy is likely countered by the enthalpy costs for desolvation 
of the electron withdrawing carboxylate.  
 
The gain in enthalpy is in turn compensated by an unfavorable entropy (-TΔΔS: 3.2 
kJ/mol) as a result of the reduced flexibility of both the antagonist and the Tyr48 side-
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chain caused by the improved interaction. This is not entirely outweighed by the 
beneficial entropy contribution related to the partial desolvation of the carboxylate 
and the related release of water into the bulk. Added together, the enthalpy and 
entropy contributions of antagonists 10 and 6 result in similar affinities (KD: 17.7 and 
15.0 nM, respectively).  
 
In contrast, the replacement of the carboxylate group by various neutral bioisosteres 
(entries 3-6) reduces the enthalpy costs for desolvation (see calculated free energies 
of desolvation, experimental part) and therefore leads to a markedly improved 
enthalpy (ΔΔH: -3.5 to -5.8 kJ/mol). As a result, an up to fivefold improvement of the 
KD values was achieved. Finally, with a cyano substituent (entries 7 & 8), the 
enthalpy term was further improved (ΔΔH: -3.7 kJ/mol) due to a reduced desolvation 
penalty and improved π-π stacking interactions. However, this beneficial component 
is again partially compensated by a decrease in entropy. This can be attributed, first, 
to the loss of flexibility of the tightly bound ligand (Figure 4B) and, second, to the 
smaller surface area of the cyano substituent compared to amide, sulfonamide and 
sulfone, which results in a smaller number of water molecules being released to bulk 
upon binding. 
 
X-ray Crystallography. To determine the binding poses of the bioisosters, we co-
crystallized the compounds 11e or 11j with FimH-CRD (Figure 4). Atomic resolution 
crystal structures were obtained at 1.07 Å (11e) and 1.10 Å (11j). As observed in 
previous mannoside co-crystal structures,15,18,27 the mannose moiety forms an 
extensive hydrogen bond network to the well-defined binding site with all of its 
hydroxyl groups.  The biphenyl aglycone is located between the tyrosine gate 
residues (Tyr48/Tyr137). The π-π stacking of the second aromatic ring of the 
aglycone to the side chain of Tyr48 contributes most to the interaction energy of the 
aglycone moiety. Interactions to the Tyr137 side-chain on the other hand are only 
limited. Whereas a previously published crystal structure of a biphenyl mannoside in 
complex with FimH-CRD suffers from crystal contacts of binding site residues (Tyr48 
side-chain to backbone oxygen of Val27) possibly causing the distortion of the 
binding site,18 the binding site of our structures are mostly solvent exposed. This 
revealed the flexibility of the aglycone in the FimH-CRD/11e structure, since the 
electron density towards the solvent-exposed sulfonamide indicates that there is not 
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one single orientation. Therefore, the aglycone was modeled in two distinct poses. In 
contrast, in the FimH-CRD/11j structure the amino acid side chain of Y48 can be 
modeled in two distinct rotamers, suggesting flexibility also of the receptor. 
 
 
Figure 4. Ligand binding poses determined by X-ray co-crystallization with compounds 11e resolved 
to 1.07 Å (A) and 11j resolved to 1.10 Å (B). The electron density surrounding the aglycone of 11e 
indicates flexibility of the aglycone and was modeled in two poses. Both compounds bind in a similar 
pose with a well-defined hydrogen network surrounding the mannose moiety and π-π stacking 
interactions between the second aromatic ring and Tyr48 side-chain (A). In contrast, in the FimH-
CRD/11j structure the amino acid side chain of Y48 can be modeled in two distinct rotamers, 
suggesting flexibility also of the receptor (B). 
 
Physicochemical Properties and In Vitro Pharmacokinetics. Intestinal absorption 
and renal excretion are prerequisites for a successful oral treatment of UTI with FimH 
antagonists. Furthermore, reabsorption of antagonist from the renal ultrafiltrate is 
desirable for maintaining the minimal anti-adhesive concentration in the target organ, 
namely the bladder, over an extended period of time. To estimate the influence of the 
bioisostere approach on oral bioavailability and the rate of renal excretion, we 
determined lipophilicity by means of the octanol-water distribution coefficient (log 
D7.4),49 aqueous solubility, and membrane permeability in the artificial membrane 
permeability assay (PAMPA)50 and the colorectal adenocarcinoma (Caco-2) cell 
monolayer model.51 
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Table 3. Physicochemical and in vitro pharmacokinetic parameters. 
 
Compd pKaa) log D7.4b) 
Solubility 
[µg/mL] / p
Hc) 
PAMPA 
log Pe 
[cm/s] / pHd) 
Caco-2 Papp, 
[10-6 cm/s]e) PPB fb 
[%]f) 
Metabolic 
stability 
t1/2 [min]g) a→b b→a 
1 --- 1.65 > 3000 -4.89 7.0 ± 0.6 9.4 ± 0.2 81 13 
10 --- 2.1 ± 0.1 21 ± 1 / 7.4 
-4.7 ± 0.1 / 
7.4 
10.0 ± 
0.9 19.0 ± 1.2 93 ± 1 n.d. 
5 --- 2.14 33.8 / 6.51 -4.7 4.23 n.d. 93 1.0 
6 3.88 < -1.5 > 3000 / 6.61 
no 
permeation n.d. n.d. 73 > 60 
11a --- 0.5 ± 0.1 12 ± 1 / 7.4 
-6.8 ± 0.3 / 
7.4 
0.12 ± 
0.01 
0.61 ± 
0.03 n.d. n.d. 
11b --- 0.8 ± 0.0 
122 ± 13 / 
7.4 
-9.2 ± 1.4 / 
7.4 
1.10 ± 
0.82 
0.87 ± 
0.15 n.d. n.d. 
11c --- 0.2 ± 0.1 > 250 / 7.4 
-7.8 ± 0.3 / 
7.4 
0.18 ± 
0.07 
1.30 ± 
0.03 48 ± 2 > 60 
11d --- 0.4 ± 0.0 
246 ± 17 / 
7.4 
-7.2 ± 0.0 / 
7.4 
0.36 ± 
0.01 
1.76 ± 
0.12 99 ± 1 > 60 
11e --- 0.7 ± 0.1 > 250 / 7.4 
-8.6 ± 0.2 / 
7.4 
0.28 ± 
0.23 
1.82 ± 
0.14 > 99 > 60 
11f 6.5 1.1 ± 0.0 
> 150 / 3.0 
> 150 / 7.4 
-7.7 ± 0.8 / 
5.0 
-8.8 ± 0.1 / 
7.4 
0.40 ± 
0.02 
1.90 ± 
0.17 n.d. n.d. 
11g --- 1.4 ± 0.0 
186 ± 4 / 
7.6 
-5.7 ± 0.0 / 
7.4 2.0 ± 0.1 13.2 ± 2.1 99 ± 0 > 60 
11h 3.7 
-
1.4 ± 0.
1 
11 ± 0 / 3.0 
273 ± 2 / 
7.4 
-9.3 ± 1.4 / 
5.0 
-8.8 ± 1.4 / 
7.4 
0.17 ± 
0.00 
0.22 ± 
0.01 n.d. n.d. 
11i 2.5 
-
1.1 ± 0.
1 
> 150 / 3.0 
> 150 / 7.4 
-6.8 ± 0.2 / 
5.0 
-7.0 ± 0.1 / 
7.4 
0.22 ± 
0.14 
0.29 ± 
0.03 n.d. n.d. 
11j --- 2.1 ± 0.0 
192 ± 5 / 
7.4 
-5.2 ± 0.0 / 
7.4 2.2 ± 0.4 22.1 ± 1.5 89 ± 1 > 60 
 
a) pKa values were determined by NMR spectroscopy; b) Octanol-water distribution coefficients (log 
D7.4) were determined by a miniaturized shake-flask procedure at pH 7.4, values represent the mean ± 
SD of sextuplicate measurements;49 c) Kinetic solubility was measured in a 96-well format using the 
µSOL Explorer solubility analyzer at the indicated pH in triplicate; d) Pe = effective permeability: 
passive permeation through an artificial membrane was determined by the parallel artificial membrane 
permeation assay (PAMPA), values represent the mean ± SD of quadruplicate measurements 
performed at the indicated pH;50 e) Papp = apparent permeability: permeation through a Caco-2 cell 
monolayer was assessed in the absorptive (a→b) and secretory (b→a) directions in triplicate;51 f) 
Plasma protein binding (PPB) was determined by equilibrium dialysis in triplicate;52 g) Metabolic 
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stability was determined by incubating the compounds (2 µM) with pooled rat liver microsomes (RLM, 
0.5 mg/mL) in presence of NADPH (1 mM, compounds 1, 6, 11c-e, g, j) or without NADPH (compound 
5);53 n.d. = not determined. 
 
Oral Bioavailability. Oral bioavailability relies on compound dissolution in the 
gastrointestinal fluids, permeation through the membranes lining the intestine, and 
stability against first pass metabolism.54,55 In turn, permeability and potency define 
the minimum aqueous solubility required for an orally dosed compound.56 For our 
FimH antagonist, we therefore aimed to exceed the solubility limit of 50 µg/mL in 
order to achieve substantial absorption through the intestinal mucosa. Sufficient 
aqueous solubility was reported for n-heptyl α-mannopyranoside (1).19 The 
unsubstituted biphenyl α-D-mannopyranoside 10 as well as the antagonists bearing a 
methylcarboxylate, carboxamide, or tetrazole substituent in its unionized state 
(compounds 5, 11a and 11h) were found to be scarcely soluble due to the apolar and 
planar character of the aglycone.24,57 By contrast, the polar carboxylic acid moiety 
present in antagonist 6 or the substituents in the bioisosteres 11b-j enhanced the 
observed solubility beyond the limit of 50 µg/mL. Permeability data derived from 
PAMPA58 and the Caco-2 model59 suggest high permeation of the moderately 
lipophilic antagonists 1, 10, and 5 (log D7.4 > 1.6) through the intestinal membranes. 
The bioisosteres 11a-f, h, i, although slightly more permeable than the strongly 
hydrophilic carboxylic acid derivative 6, show only moderate values of permeability 
compared to n-heptyl α-mannopyranoside (1) or the unsubstituted biphenyl 
mannoside 10. However, the para-cyanobiphenyl derivatives 11g and 11j display 
elevated log D7.4 and effective permeability (log Pe) in the range for successful 
intestinal absorption. Featuring both high aqueous solubility and elevated membrane 
permeability, the para-cyano substituted bioisosteres 11g and 11j are thus the most 
promising candidates for oral absorption. Moreover, combining the bioisosteric 
replacement with the addition of a chloro substituent in the ortho-position of the 
aromatic ring adjacent to the anomeric oxygen (→ 11j)24 resulted in the most 
advantageous physicochemical profile for oral bioavailability. 
 
Renal Excretion. The rate of renal excretion depends on the rate of glomerular 
filtration and the propensity to tubular secretion and reabsorption of an antagonist.60 
Only the fraction that is not bound to plasma proteins is expected to enter the 
glomerular filtrate.61 Plasma protein binding (PPB) data indicating the fraction bound 
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(fb) are listed in Table 2.52 The biphenyls 6 and 11c were identified as moderate 
binders to plasma proteins (fb ≤ 65%), which suggests a low impact of PPB on 
antagonist filtration. The fb values of the antagonists 1, 10, 5, and 11j were between 
80 and 93%, whereas the bioisosteres 11d, e, and g showed particularly high protein 
binding (fb ≥ 99%) implying slow compound entry into the primary urine. However, the 
kinetic aspects of PPB, that is, association and dissociation rate constants, remain to 
be determined to quantify precisely the influence of PPB on filtration.62 
 
Furthermore, log D7.4 was identified as key determinant of tubular reabsorption.63-65 
Accordingly, lipophilic compounds are predominantly reabsorbed from the renal 
filtrate. Given that renal clearance is the major route of elimination, this will result in a 
slow but steady excretion into the bladder. In contrast, hydrophilic compounds are 
poorly reabsorbed and thus quickly renally eliminated, which leads to high initial 
compound levels in the urine but narrows the time range where the minimal anti-
adhesive concentration is maintained. Consequently, low log D7.4 as shown for the 
antagonists 6, 11h, and 11i implies low tubular reabsorption and rapid elimination of 
the filtered molecules by the urine. Otherwise, log D7.4 between 0.2 and 0.7, such as 
determined for the bioisosteres 11a-e, suggests increasing propensity to tubular 
reuptake, whereas log D7.4 > 1 as shown for heptyl mannoside 1 and the biphenyl 
mannosides 10, 5, 11g, 11f, and 11j is optimal for tubular reabsorption from the 
glomerular filtrate and thus for slow renal clearance. 
 
Metabolic Stability. Increasing lipophilicity is usually paralleled by increasing 
susceptibility to metabolism.66 Liabilities towards metabolic clearance pathways 
which prevent the intact antagonist from reaching the target in the bladder were 
therefore of interest. To assess their propensity to cytochrome P450 (CYP450)-
mediated metabolism, heptyl mannoside 1, the carboxylic acid derivative 6, and the 
bioiosteres 11c-e, g, j were incubated with rat liver microsomes (RLM, 0.5 mg/mL) in 
presence of the cofactor β-nicotinamide adenine dinucleotide phosphate (NADPH).53 
To confirm the high propensity of the methyl ester present in antagonist 5 to 
carboxylesterase (CES)-mediated hydrolysis, this antagonist was incubated with 
RLM only. The profiles of unchanged compound versus time revealed high 
susceptibility of heptyl mannoside 1 to CYP450-mediated metabolism (t1/2 = 13 min) 
and rapid hydrolysis of the ester 5 by the hepatic CES (t1/2 = 1.0 min). Otherwise, the 
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bioisosteres 11c-e,g & j were stable against enzyme-mediated bioconversion (t1/2 > 
60 min) suggesting lower propensity to metabolic, non-renal elimination pathways. 
 
Considering PPB, lipophilicity, and metabolic stability data, we therefore expected (i) 
a steady release of compounds 11d, e, g, j into the bladder because of high PPB 
decelerating glomerular filtration (11d, e, g) and/or high log D7.4 supporting tubular 
reabsorption (11g, j), (ii) a fast excretion of antagonist 6 and 11c via the urine due to 
low PPB and low log D7.4, and (iii) a rapid clearance of heptyl mannoside 1 from the 
body by renal and metabolic pathways. Compounds featuring high propensity to 
renal excretion as major route of elimination (11c, 11e and 11j) were selected for in 
vivo PK studies in a mouse model.  
 
Pharmacokinetic Studies in C3H/HeN Mice. This first part of our study explored the 
predicted effects of lipophilicity, PPB, and metabolic stability on antagonist 
disposition and elimination upon a single dose iv application (50 mg/kg) of 
compounds 11c and 11e. The PK parameters of these applications and those of the 
previously published carboxylate 6 are summarized in Table 4. The Table also 
contains the results of the iv administration of compound 11j (0.625 mg/kg). 
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Table 4. Pharmacokinetic parameters determined after a single iv application of compounds 6a, 11c, 
11e and 11j in female C3H/HeN mice. Values were calculated using PKSolver.67 C0, initial 
concentration; Vz, volume of distribution in terminal phase; AUC, Area under the curve; CLtot, total 
clearance; Cmax, maximal concentration. 
 
Compd Plasma Urine 
 
C0 
(µg/mL) 
Dose 
(mg/kg) 
Vz 
(mL) 
t1/2 
(h) 
AUC0-inf (µg 
x h/mL) 
CLtot 
(mL/h) 
Cmax (µg/mL) 
619 40 50 25.2 0.33 23.5 53.1 300 
11c 109.7 50 28.3 0.4 25.3 49.4 4611 
11e 151.6 50 19.5 1.9 175.1 7.1 387 
11j 0.36 0.625 52.8 0.17 0.07 218 10 
 
In contrast to the fast plasma clearance of antagonists 6 and 11c (Figure 5A), the 
methyl sulfonamide bioisostere 11e attained higher initial concentration in plasma 
(C0) and lower total clearance (CLtot). Therefore, it could be detected until six hours 
post application, resulting in markedly higher plasma AUC. The observed high C0 of 
compound 11e may be attributed to a small volume of distribution (Vz) resulting from 
the high PPB (fb ≥ 99%).61 In urine (Figure 5B), the carboxylic acid 6 and the 
morpholinomethanone 11c displayed high levels immediately following administration 
and a rapid concentration decrease within the first two hours, reflecting the rapid 
elimination from plasma. Fast renal excretion as major route of elimination can be 
rationalized by the physicochemical properties of the antagonists 6 and 11c, that is, 
moderate PPB and log D7.4, as well as high metabolic stability. Otherwise, the methyl 
sulfonamide bioisostere 11e showed sustained compound levels in urine over a 
period of two hours and subsequent slow decrease until six hours post 
administration. This sustained renal excretion is a result of the interplay of the 
antagonist’s elevated PPB and log D7.4. 
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Figure 5. Antagonist concentrations in (A) plasma and (B) urine after a single iv application of 6, 11c, 
and 11e (50 mg/kg).  
 
In a second study, the para-cyano bioisostere 11j, characterized by a high oral 
absorption potential, but low solubility, was administered as a single dose iv (0.625 
mg/kg) and po (1.25 mg/kg). The plasma concentration curve upon iv dosing displays 
a steep decline within the first hour post application, while the po curve shows a 
prolonged period where absorption and elimination are in equilibrium (Figure 6A). 
The urine concentration profiles (Figure 6B) parallel the plasma curves obtained by 
the two modes of application, i.e. high plasma clearance upon iv bolus injection led to 
high initial antagonist levels in urine and a rapid concentration decline. By contrast, 
sustained plasma concentrations upon po administration resulted in prolonged urine 
levels. As a result, urine concentrations exceed the minimum level required for the 
anti-adhesive effect (minimal anti-adhesion concentration, MAC90),23 determined by 
flow cytometry68 (0.094 µg/ml), for more than eight hours upon oral single-dose 
administration, proving the high potential of the para-cyano biphenyl mannoside for 
the oral treatment of UTI (Figure 6B). 
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Figure 6. Antagonist concentrations in (A) plasma and (B) urine after a single iv and po application of 
compound 11j (iv: 0.625 mg/kg; po: 1.25 mg/kg). MAC90, minimal anti-adhesive concentration to inhibit 
90% adhesion (0.094 µg/ml). 
 
Infection study in C3H/HeN Mice. Based on the promising PK profile of 11j, six 
mice were inoculated with UTI89 following an oral application of 11j (1.25 mg/kg) 40 
min prior to infection. Three hours after inoculation, animals were sacrificed and 
bladder and kidneys were removed. Organs were homogenized and analysed for 
bacterial counts. The results were compared to ciprofloxacin (CIP), used as standard 
antibiotic therapy against UTI89.69 The median reduction in bacterial counts of the 
mice treated with 11j and CIP compared to the control group are displayed in Figure 
7.  
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Figure 7. Treatment efficacy in the UTI mouse model 3 h after infection. The bars depict the median 
reduction of bacterial counts after application of 1.25 or 10 mg/kg 11j p.o. or 8 mg/kg CIP s.c. 
(representing the murine dose equivalent to a human standard dose).70 The baseline represents the 
median counts of the untreated control group. 
The median value in the untreated control group showed bacterial counts of 6.6 
Log10 colony forming units (CFU) in the bladder and 6 Log10 CFU in the kidneys. 
After oral application of 1.25 mg/kg of 11j, bacterial loads in the bladder decreased 
by 1.7 Log10 CFU and 1.08 Log10 CFU in the kidneys. The lower reduction in the 
kidneys is most likely due to the differing adhesion mechanisms between bladder and 
kidneys (type 1 pili vs P-pili), which is not targeted by 11j.71 With CIP (8 mg/kg s.c.) a 
substantial reduction in both, bladder and kidneys (median reductions of 2.44 Log10 
and 2.47 Log10, respectively) was observed. Despite the low oral dose of 11j, the 
approximately 100-fold reduction of CFU in the bladder promised en even higher 
effect upon dose increase. To increase solubility of 11j, a basic formulation was 
used,. When 10 mg/kg were applied, bacterial loads in the bladder decreased by 3.4 
Log10 CFU/ml, exceeding the effect of CIP, but only 0.5 Log10 CFU in the kidneys. 
Based on this large reduction after an oral application of 10 mg/kg, 11j has a large 
potential for further development.  
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SUMMARY AND CONCLUSION 
 
Recently, numerous monovalent alkyl and aryl α-D-mannopyranosides have been 
described as potent FimH antagonists. However, most of them suffer from insufficient 
pharmacokinetic properties, i.e. modest bioavailability and short duration of the 
therapeutic effect in the bladder, their site of action. As a consequence, high doses at 
short intervals are required to achieve anti-adhesive effects over an extended period 
of time. Therefore, the goal of the present study was an appropriate optimization of 
the pharmacokinetic profile of biphenyl α-D-mannopyranosides while keeping their 
high affinity to the CRD of FimH. The starting point was the biphenyl-carboxylate 6 
where the critical carboxylate was replaced by bioisosteres.29,72 
With a series of bioisosteres a three- to fivefold improvement of affinity was achieved 
compared to 6. Although binding necessitates only partial desolvation of the 
carboxylate and its bioisosteric replacements, a reduction of the enthalpy penalty for 
desolvation41 was identified as the source of the improved affinity exhibited by the 
bioisosteres. Thermodynamic evaluation of antagonists 11b-e revealed almost 
identical enthalpy contribution to binding. However, for antagonists with the para-
cyano substituent (11g & 11j) an enhancement of up to -8.7 kJ/mol was observed, 
indicating a reduced desolvation penalty and an improved stacking as derived from 
the crystal structure of 11j co-crystallized with the CRD of FimH (Figure 4B). On the 
other hand, higher affinity originating from a reduction of conformational flexibility of 
ligand and protein resulted in a concomitant entropy penalty of up to 6.5 kJ/mol. 
 
In addition to the improved pharmacodynamics, the relevant pharmacokinetic 
parameters (solubility, permeability, renal excretion) could also be substantially 
improved. With 3’-chloro-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (11j), a 
FimH antagonist with an optimal in vitro PK/PD profile was identified. The para-cyano 
substituent conferred lipophilicity and high binding to plasma proteins, which slowed 
down the rate of renal excretion. Despite higher lipophilicity, antagonist 11j was 
insusceptible to CYP450 mediated metabolism, and therefore predominantly 
eliminated via the renal pathway. In vivo experiments confirmed the excellent PK-
profile of 11j with steady renal excretion for more than eight hours after oral 
application, suggesting a long-lasting anti-adhesive effect. Finally, orally applied 11j 
(10 mg/kg) was effective in a mouse model of UTI by reducing the bacterial load 
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inthe bladder by over 1000-fold. Improvement of solubility, enabling the application of 
higher dosages of 11j, will possibly lead to an even higher bacterial reductions, which 
will be the subject of future investigations. 
 
 
EXPERIMENTAL SECTION 
 
Synthesis 
 
The synthesis of compounds 11a-f, 11i, 14a-f, 16, 19, and 24, including compound 
characterization data, can be found in the Supporting Information. 
 
General methods. NMR spectra were recorded on a Bruker Avance DMX-500 
(500.1 MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved 
using 2D methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm 
using residual CHCl3, CHD2OD or HDO as references. Optical rotations were 
measured using Perkin-Elmer Polarimeter 341. Electron spray ionization mass 
spectra (ESI-MS) were obtained on a Waters micromass ZQ. The LC/HRMS analysis 
were carried out using a Agilent 1100 LC equipped with a photodiode array detector 
and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Microwave-
assisted reactions were carried out with a CEM Discover and Explorer. Reactions 
were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) and 
visualized by using UV light and/or by charring with a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10% H2SO4). MPLC separations were carried out on a 
CombiFlash Companion or Rf (Teledyne Isco) equipped with RediSep normal-phase 
or RP-18 reversed-phase flash columns. LC-MS separations were done on a Waters 
system equipped with sample manager 2767, pump 2525, PDA 2525 and micromass 
ZQ. All compounds used for biological assays are at least of 95% purity based on 
HPLC analytical results. Commercially available reagents were purchased from 
Fluka, Aldrich, Alfa Aesar or abcr GmbH & Co. KG (Germany). Solvents were 
purchased from Sigma-Aldrich or Acros and were dried prior to use where indicated. 
Methanol (MeOH) was dried by refluxing with sodium methoxide and distilled 
immediately before use. Dimethoxyethane (DME) was dried by filtration over Al2O3 
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(Fluka, type 5016 A basic).  
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile 
(14g). A Schlenk tube was charged with aryl iodide 1224 (330 mg, 0.60 mmol), 4-
cyanophenylboronic acid (13g, 96 mg, 0.65 mmol), Pd(dppf)Cl2⋅CH2Cl2 (15 mg, 
0.018 mmol), K3PO4 (192 mg, 0.90 mmol) and a stirring bar. The tube was closed 
with a rubber septum and was evacuated and flushed with argon. This procedure 
was repeated once, and then anhydrous DMF (2 mL) was added under a stream of 
argon. The mixture was degassed in an ultrasonic bath and flushed with argon for 5 
min, and then stirred at 80 °C overnight. The reaction mixture was cooled to rt, 
diluted with EtOAc (50 mL), and washed with water (50 mL) and brine (50 mL). The 
organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by MPLC on silica gel (petroleum ether/EtOAc) to afford 14g (187 mg, 59%) 
as colorless oil. [α]D20 +72.9 (c 0.8, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.73-
7.71 (m, 2H, Ar-H), 7.65-7.64 (m, 2H, Ar-H), 7.57-7.53 (m, 2H, Ar-H), 7.21-7.19 (m, 
2H, Ar-H), 5.60-5.57 (m, 2H, H-1, H-3), 5.47 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.40 (t, J 
= 10.1 Hz, 1H, H-4), 4.30 (dd, J = 5.1, 12.2 Hz, 1H, H-6a), 4.14-4.08 (m, 2H, H-6b, H-
5), 2.22, 2.07, 2.06, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, CD3OD): δ = 
170.62, 170.14, 170.11, 169.83 (4 CO), 156.16, 144.87, 134.05, 132.77, 128.64, 
127.46 (Ar-C), 119.05 (CN), 117.15, 110.77 (Ar-C), 95.86 (C-1), 69.42 (2C, C-2, C-
5), 68.90 (C-3), 65.94 (C-4), 62.16 (C-6), 21.01, 20.84, 20.82 (4C, 4 COCH3); ESI-
MS: m/z: Calcd for C27H27NNaO10 [M+Na]+: 548.2, found: 548.2. 
 
4’-(α-D-Mannopyranosyloxy)-biphenyl-4-carbonitrile (11g). To a solution of 14g 
(40 mg, 0.08 mmol) in dry MeOH (5 mL) was added freshly prepared 1 M 
NaOMe/MeOH (0.1 eq) under argon. The mixture was stirred at rt until the reaction 
was complete (monitored by TLC), then neutralized with Amberlyst-15 (H+) ion-
exchange resin, filtered and concentrated in vacuo. The residue was purified by 
MPLC on silica gel (DCM/MeOH, 10:1-7:1) to afford 11g (16 mg, 60%) as white solid. 
1H NMR (500 MHz, CD3OD): δ = 7.82-7.75 (m, 4H, Ar-H), 7.69-7.63 (m, 2H, Ar-H), 
7.30-7.23 (m, 2H, Ar-H), 5.58 (d, J = 1.7 Hz, 1H, H-1), 4.05 (dd, J = 1.8, 3.4 Hz, 1H, 
H-2), 3.94 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.83-3.71 (m, 3H, H-4, H-6a, H-6b), 3.62 
(ddd, J = 2.5, 5.3, 9.8 Hz, 1H, H-5). The spectroscopic data were in accordance with 
literature values.18 
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5-(4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-yl)-1H-
tetrazole (15). A Schlenk tube was charged with 14g (30 mg, 0.06 mmol), 
trimethylsilyl azide (16 µL, 0.12 mmol), dibutyltin oxide (2 mg, 0.006 mmol), DME (1 
mL) and a stirring bar. The mixture was heated to 150 °C for 10 min by microwave 
irradiation. The reaction mixture was cooled to rt, and then concentrated in vacuo. 
The residue was purified by MPLC on silica gel (DCM/MeOH, 9:1-8:1) to afford 15 
(26 mg, 81%) as colorless oil. [α]D20 +56.1 (c 0.3, MeOH); 1H NMR (500 MHz, 
CDCl3): δ = 8.25-8.15 (m, 2H, Ar-H), 7.75-7.65 (m, 2H, Ar-H), 7.60-7.55 (m, 2H, Ar-
H), 7.20-7.17 (m, 2H, Ar-H), 5.64-5.55 (m, 2H, H-1, H-3), 5.49 (dd, J = 1.7, 3.3 Hz, 
1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.3, 12.4 Hz, 1H, H-6a), 4.17-
4.06 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3); 13C NMR (126 
MHz, CDCl3): δ = 170.67, 170.14, 170.11, 169.81 (4 CO), 155.61, 128.36, 127.84, 
127.49, 116.93 (Ar-C), 95.78 (C-1), 69.36 (C-5), 69.26 (C-2), 68.90 (C-3), 65.89 (C-
4), 62.12 (C-6), 20.92, 20.76, 20.73 (4 COCH3); ESI-MS: m/z: Calcd for 
C27H28N4NaO10 [M+Na]+: 591.2, found: 591.1. 
 
5-(4’-(α-D-Mannopyranosyloxy)-biphenyl-4-yl)-1H-tetrazole (11h). Prepared 
according to the procedure described for 11g from 15 (26 mg, 0.03 mmol). Yield: 18 
mg (quant.) as a white solid. [α]D20 +112.1 (c 0.1, MeOH/H2O, 2:1); 1H NMR (500 
MHz, CD3OD): δ = 7.98-7.96 (m, 2H, Ar-H), 7.72-7.71 (m, 2H, Ar-H), 7.58-7.54 (m, 
2H, Ar-H), 7.16-7.13 (m, 2H, Ar-H), 5.46 (d, J = 1.7 Hz, 1H, H-1), 3.94 (dd, J = 1.9, 
3.5 Hz, 1H, H-2), 3.83 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.68-3.61 (m, 3H, H-4, H-6a, H-
6b), 3.52 (ddd, J = 2.5, 5.4, 9.7 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): δ = 
158.19, 145.07, 134.97, 129.29, 128.74, 128.55, 118.26 (Ar-C), 100.13 (C-1), 75.52 
(C-5), 72.42 (C-3), 71.98 (C-2), 68.33 (C-4), 62.69 (C-6); HRMS: m/z: Calcd for 
C19H21N4O6 [M+H]+: 401.1456, found: 401.1450. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-chloro-biphenyl-4-
carbonitrile (20). Prepared according to the procedure described for 14g from aryl 
iodide 1923 (79 mg, 0.135 mmol), 13g (22 mg, 0.15 mmol), Pd(dppf)Cl2⋅CH2Cl2 (3.3 
mg, 4 µmol) and K3PO4 (57 mg, 0.27 mmol). Yield: 57 mg (75%) as a white solid. 
[α]D20 +77.7 (c 0.5, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.72 (d, J = 8.3 Hz, 2H, 
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Ar-H), 7.63 (m, 3H, Ar-H), 7.43 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.27 (d, J = 8.6 Hz, 
1H, Ar-H), 5.64-5.59 (m, 2H, H-1, H-2), 5.54 (dd, J = 1.9, 3.2 Hz, 1H, H-3), 5.41 (t, J 
= 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.2, 12.3 Hz, 1H, H-6a), 4.17 (ddd, J = 2.1, 5.1, 
10.0 Hz, 1H, H-5), 4.10 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.21 (s, 3H, COCH3), 2.12- 
2.00 (m, 9H, 3 COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.54, 170.08, 169.90, 
169.84, (4C, CO) 151.67, 143.61, 135.29, 132.87, 129.41, 127.53, 126.60, 125.20, 
118.79, 117.36, 111.47 (Ar-C, CN), 96.72 (C-1), 70.00 (C-5), 69.39 (C-3), 68.82 (C-
2), 65.86 (C-4), 62.16 (C-6), 20.98, 20.81, 20.79, 20.78 (4 COCH3); ESI-MS: m/z: 
Calcd for C27H26ClNNaO10 [M+Na]+: 582.1, found: 582.1. 
 
3’-Chloro-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (11j). Prepared 
according to the procedure described for 11g from 20 (36 mg, 0.06 mmol). Yield: 12 
mg (48%) as a white solid. [α]D20 +109.4 (c 0.23, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 7.80-7.72 (m, 5H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J 
= 8.7 Hz, 1H, Ar-H), 5.62 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 
4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.83-3.68 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 
2.3, 5.4, 9.6 Hz, 1H, H-5); 13C NMR  (126 MHz, CD3OD): δ = 153.65, 145.15, 135.42, 
133.86, 129.82, 128.53, 127.87, 125.47, 119.70, 118.59 (Ar-C), 111.97 (CN), 100.66 
(C-1), 76.05 (C-5), 72.39 (C-3), 71.80 (C-2), 68.20 (C-4), 62.65 (C-6); IR (KBr), ν = 
3400 (OH), 2227 (C≡N), 1606, 1487 (Ar-C=C) cm-1; HRMS: m/z: Calcd for 
C19H18ClNNaO6 [M+Na]+: 414.0715, found: 414.0721. 
 
3'-Chloro-N-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-
4'-(α-D-mannopyranosyloxy)-biphenyl-4-carboxamide (21). Compound 8 (10.0 
mg, 0.024 mmol), fluoresceinamine isomer I (12.7 mg, 0.037 mmol) and COMU (20.9 
mg, 0.049 mmol) were dissolved in dry DMF (1 mL), then NEt3 (10 mL, 0.073 mmol) 
was added and the mixture was stirred at rt for 7 h. 1 N HCl in DMF was added until 
acid reaction on pH paper and the mixture was concentrated. The residue was 
dissolved in DCM/MeOH (3:1) and loaded onto a silica gel column. The complex 
mixture of compounds was only partially resolved. The fractions containing the 
product were collected, concentrated and purified by preparative HPLC (gradient 
water/MeCN containing 0.2% HCO2H), to afford compound 21 (5 mg, 19%). [α]D20 
+21.1 (c 0.1, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.26 (d, J = 8.4 Hz, 2H, Ar-H), 
7.88-7.74 (m, 3H, Ar-H), 7.66 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.51 (d, J = 8.7 Hz, 1H, 
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Ar-H), 7.29 (dd, J = 1.9, 5.3 Hz, 2H, Ar-H), 7.19 (dd, J = 2.1, 8.3 Hz, 1H, Ar-H), 7.08-
6.99 (m, 2H, Ar-H), 6.95 (d, J = 8.7 Hz, 1H, Ar-H), 6.72 (dd, J = 5.5, 10.6, Hz, 2H, Ar-
H), 6.61 (dd, J = 2.3, 8.7 Hz, 1H, Ar-H), 5.65 (s, 1H, H-1), 4.15 (dd, J = 1.8, 3.2 Hz, 
H-2), 4.03 (dd, J = 3.4, 9.5, Hz, H-3), 3.87-3.72 (m, 3H, H-4, H-6a, H-6b), 3.65 (m, 
1H, H-5); 13C NMR (126 MHz, CD3OD): δ = 137.50, 136.01, 131.90, 130.24, 130.20, 
129.87, 129.24, 128.03, 127.91, 125.79, 125.46, 124.73, 118.99, 118.76, 118.65 (Ar-
C), 100.73 (C-1), 76.06 (C-5), 72.42 (C-3), 71.85 (C-2), 68.24 (C-4), 62.69 (C-2); 
ESI-MS: m/z: Calcd for C39H31ClNO12 [M+H]+: 740.2, found: 740.2. 
 
3'-Chloro-N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)-thioureido)ethyl)-4'-(a-D-mannopyranosyloxy)-biphenyl-4-carboxamide (22). 
To a stirred solution of compound 8 (25 mg, 0.061 mmol) in dry DMF (1 mL), NHS 
(21 mg, 0.183 mmol) was added, followed by DIC (9.2 mg, 0.073 mmol). The mixture 
was stirred at rt for 2 h, then N-Boc-ethylendiamine (10.7 mg, 0.067 mmol) was 
added and the reaction was stirred for 10 h. It was then cooled down to 0 °C, diluted 
with water and concentrated. Chromatography on silica gel (DCM/MeOH) yielded 23 
mg (0.042 mmol, 68%) of tert-butyl (3’-chloro-4’-(a-D-mannopyranosyloxy)-biphenyl-
4-yl-carboxamido)ethyl)carbamate. This product was dissolved in CH2Cl2 (3 mL) and 
TFA (1 mL) was added. The solid dissolved during addition of TFA. After 10 min the 
reaction was complete. The mixture was evaporated and excess TFA was removed 
in high vacuum. The intermediate N-(2-aminoethyl)-3'-chloro-4'-(a-D-manno-
pyranosyloxy)-biphenyl-4-carboxamide TFA salt (23 mg, 0.042 mmol, quant.) was 
used directly in the next step. It was dissolved in dry DMF (0.5 mL) and NEt3 (12.8 
mg, 0.127 mmol) was added. The mixture was cooled to 0 °C, then FITC (14.8 mg, 
0.038 mmol) was added and the mixture was stirred for 3 h in the dark. The mixture 
was then co-evaporated with water, taken up in MeOH/10% aq. acetic acid and 
evaporated. Chromatography on silica gel (DCM/MeOH) yielded compound 22, 
contaminated with triethylammonium acetate. The compound was then re-dissolved 
in MeOH, and 0.5 N HCl in MeOH was added. The mixture was evaporated and 
chromatographed on silica gel, to yield pure 22 (15 mg, 47%). [α]D20 +12.1 (c 0.3, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.12 (s, 1H), 7.92 (d, J = 8.3 Hz, 2H, Ar-H), 
7.70 (dd, J = 5.0, 13.1 Hz, 2H, Ar-H), 7.64 (d, J = 8.3 Hz, 2H, Ar-H), 7.54 (dd, J = 2.2, 
8.6 Hz, 1H, Ar-H), 7.46 (d, J = 8.7 Hz, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H), 6.74 
(s, 2H), 6.69 (d, J = 1.4 Hz, 2H, Ar-H), 6.55 (d, J = 8.4 Hz, 2H, Ar-H), 5.63 (d, J = 1.3 
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Hz, H-1), 4.15 (dd, J = 1.8, 3.1 Hz, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, H-3), 3.94 (s, 2H, 
CH2), 3.86-3.64 (m, 6H, H-4, H-5, H-6, CH2); 13C NMR (126 MHz, CD3OD): δ = 
153.21, 143.84, 136.41, 129.66, 129.18, 127.76, 127.70, 125.37, 118.64, 103.62 (Ar-
C), 100.75 (C-1), 76.00 (C-5), 72.41 (C-3), 71.86 (C-2), 68.24 (C-4), 62.69 (C-6), 
40.76 (CH2); ESI-MS: m/z: Calcd for C42H37ClN3O12S [M+H]+: 842.2, found: 842.2. 
 
3'-Chloro-N-(2-(2-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-
xanthen]-5-yl)thioureido)ethoxy)ethoxy)ethyl)-4'-(α-D-mannopyranosyloxy)-
biphenyl-4-carboxamide (23). Compound 8 (280 mg, 0.68 mmol) was dissolved in 
dry DMF (5 mL) under argon, then NHS (235 mg, 2.04 mmol) was added, followed by 
DIC (0.12 mL, 0.78 mmol) and the mixture was stirred at rt for 4 h, then Boc-PEG2-
NH2 (186 mg, 0.75 mmol) was added, and the mixture was stirred at rt under argon 
for 10 h. It was then slowly diluted with water and concentrated. The residue was 
purified by chromatography on silica gel (DCM/MeOH) to give tert-butyl (2-(2-(2-(3'-
chloro-4'-(α-D-mannopyranosyloxy)-biphenyl-4-
ylcarboxamido)ethoxy)ethoxy)ethyl)carbamate (300 mg, 0.468 mmol, 69%). Then, 
the carbamate was suspended in DCM (3 mL) and TFA (1 mL) was added dropwise 
at rt. After 30 min, the solvents were evaporated and the crude mixture was dissolved 
in CHCl3/MeOH (6:4 + 0.5% conc. NH4OH) and transferred to a silica gel column, 
eluting with the same solvent mixture, to yield N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-
3'-chloro-4'-(α-D-mannopyranosyloxy)-biphenyl-4-carboxamide (228 mg, 90 %). A 
fraction of the amine (10 mg, 0.018 mmol) was dissolved in dry DMF (0.5 mL) and 
cooled to 0 °C. FITC (6.5 mg, 0.017 mmol) was added and the mixture was stirred for 
1 h. The mixture was concentrated and the residue was purified by chromatography 
on silica (DCM/MeOH), to yield 23 (10 mg, 65%). 1H NMR (500 MHz, CD3OD): δ = 
8.21 (d, J = 1.4 Hz, 1H, Ar-H), 7.88 (d, J = 8.3 Hz, 2H, Ar-H), 7.68 (d, J = 2.2 Hz, 2H, 
Ar-H), 7.63 (d, J = 8.3 Hz, 2H, Ar-H), 7.53 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.43 (d, J = 
8.7 Hz, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H), 6.68 (d, J = 2.3 Hz, 2H, Ar-H), 6.65 
(dd, J = 2.6, 8.6 Hz, 2H, Ar-H), 6.53 (dd, J = 1.6, 8.7 Hz, 2H, Ar-H), 5.61 (d, J = 1.3 
Hz, 1H, H-1), 4.14 (dd, J = 1.8, 3.2, Hz, 1H, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.93-3.53 (m, 16H), 3.37 (s, 2H, NCH2), 1.30 (s, 2H, CH2); 13C NMR (126 MHz, 
CD3OD): δ = 170.01 (CO), 153.17, 143.72, 136.37, 134.37, 130.39, 129.69, 129.04, 
127.78, 127.73, 125.35, 118.60, 103.60 (Ar-C), 100.72 (C-1), 75.97 (C-5), 72.41 (C-
3), 71.86, 71.40, 70.59 (5C, C-2, OCH2), 68.23 (C-4), 62.64 (C-6), 49.88, 45.49, 
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40.97 (CH2);  ESI-MS: m/z: Calcd for C46H45ClN3O14S [M+H]+: 930.2, found: 930.4. 
 
Competitive Fluorescence Polarization Assay 
 
Expression and purification of CRD of FimH. A recombinant protein consisting of 
the CRD of FimH linked to a 6His-tag via a thrombin cleavage site (FimH-CRD-Th-
His6) was expressed in E. coli strain HM125 and purified by affinity chromatography 
as previously described.33 
 
KD determination of FITC-labeled ligands. The functionalized ligands (22, 23) were 
prepared as a 10 mM stock solution in pure DMSO (Sigma Aldrich, Buchs, 
Switzerland). All further dilutions of compounds and FimH-CRD-Th-His6 protein were 
prepared in assay buffer (20 mM HEPES, 150 mM NaCl, 50 µg/mL BSA, pH 7.4). 
BSA was added to the assay buffer to prevent non-specific binding of protein to the 
plastic surface. Binding isotherms for the fluorescent ligands were obtained in direct 
binding studies by adding a constant concentration of ligand (final concentration 5 
nM) and a linear dilution of protein (final concentration 0-100 nM) to a final volume of 
200 µL in 96-well, black, flat bottom NBSTM plates (Corning Inc., Corning, NY, USA). 
After incubating the plate for 24 h at rt with gentle shaking, the fluorescence 
polarization was measured with the SynergyTM H1 Hybrid Multi-Mode Microplate 
Reader (BioTek Instruments Inc., Winooski, VT, USA) with polarized excitation at 485 
nm and emission measured at 528 nm through polarizing filters parallel and 
perpendicularly oriented to the incident polarized light. KD values were determined by 
plotting the FP readout as a function of the protein concentration and applying the 
following single-site binding equation (Equation 1) that accounts for ligand depletion: 
 
€ 
Sobs = SF + (SB − SF ) ⋅ (
CP +CL + KD − (CP +CL + KD )2 − 4CPCL
2CL
) (1) 
where Sobs is the observed signal from the ligand, SF is the signal from free ligand, SB 
is the signal from bound ligand, CP is the total concentration of protein, and CL is the 
total concentration of ligand.39 
 
KD Determination of FimH Antagonists. The fluorescently labeled ligand 22 was 
used for the competitive fluorescence polarization assay. A linear dilution of non-
labeled FimH antagonist with final concentrations ranging from 0-10 µM was titrated 
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into 96-well, black, flat bottom NBSTM plates (Corning Inc.) to a final volume of 200 
µL containing a constant concentration of protein (final concentration 25 nM) and 
FITC-labeled ligand which was fixed at a higher concentration in competitive binding 
assays than in direct binding experiments to obtain higher fluorescence intensities 
(final concentration 20 nM). Prior to measuring the fluorescence polarization, the 
plates were incubated on a shaker for 24 h at rt until the reaction reached 
equilibrium. The IC50 value was determined with Prism (GraphPad Software Inc., La 
Jolla, CA, USA) by applying a standard four-parameter IC50 function. The obtained 
IC50 values were converted into their corresponding KD values using the derivation of 
the Cheng-Prusoff equation.35 This variation of the Cheng-Prusoff equation is applied 
to competition assays with tight-binding inhibitors, and includes terms to correct for 
ligand depletion effects. However, the KD for antagonists having a higher affinity 
towards FimH than the labeled ligand could not be accurately determined.35 
 
Isothermal Titration Calorimetry (ITC) 
 
All ITC experiments were performed with the FimH-CRD-Th-His6 protein using a VP-
ITC instrument from MicroCal, Inc. (GE Healthcare, Northampton, MA, USA) with a 
sample cell volume of 1.4523 mL. The measurements were performed with 2.5 or 5% 
DMSO at 25 °C, a stirring speed of 307 rpm, and 10 µcal s-1 reference power. The 
protein samples were dialyzed in assay buffer prior to all experiments. Compounds 6, 
10, and 24 were measured in a direct fashion by titration of ligand (120-2,000 µM) 
into protein (10-55 µM) with injections of 3-6 µL at intervals of 10 min to ensure non-
overlapping peaks. The quantity c = Mt(0) KD–1, where Mt(0) is the initial 
macromolecule concentration, is of importance in titration microcalorimetry. The c-
values of the direct titrations were below 1’000 and thus within the reliable range. For 
the compounds 11b-e, 11g and 11j additional competitive ITC experiments were 
performed due to their high affinity resulting in c-values above 1’000 for direct 
titrations. These ligands (600 µM) were titrated into protein (30 µM), which was 
preincubated with compound 24 (300 µM) resulting in sigmoidal titration curves. Due 
to slow reaction kinetics, titration intervals of 20 min were used. 
 
Baseline correction and peak integration was performed using the Origin 7 software  
(OriginLab, Northampton, MA, USA). An initial 2 µL injection was excluded from data 
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analysis. Baseline subtraction and curve-fitting with the three variables N 
(concentration correction factor), KD (dissociation constant), and ∆H° (change in 
enthalpy) was performed with the SEDPHAT software version 10.40 (National 
Institute of Health). A global fitting analysis was performed for the competition 
titration (compounds 11b-e, 11g or 11j competing for the protein binding site with 
compound 24) and the direct titration of the competitor (compound 24 binding to 
protein) to fit for KD. ∆H° and N were fitted from direct titrations of compounds 11b-e, 
11g or 11j into protein. For the compounds 6, 10 and 24 binding to protein all 
variables could be determined from a global analysis of the direct titration.   
 
The thermodynamic parameters were calculated with the following equation 
(Equation 2): 
 
€ 
ΔG° = ΔH°−TΔS° = RT lnKD = −RT lnKA  (2) 
where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of 
binding, respectively, T is the absolute temperature, and R is the universal gas 
constant (8.314 J mol-1 K-1). The 95 %-confidence intervals of the measurements 
were calculated for the two variables KD and ∆H° with the 1-dimensional error surface 
projection within the SEDPHAT software. 
 
Calculation of the Free Energy of Desolvation. The three dimensional 
representation for each of the aglycons (4-methoxy biphenyl scaffold, Figure 7) was 
built in the Maestro73 modeling environment and the global minimum conformation 
was identified by performing 500 iterations of the mixed torsional/low-mode 
conformational sampling in combination with the OPLS-2005 force-field and the 
implicit solvent model (water) as implemented in the Macromodel 9.9.74 The global 
minimum structures were used as input for the AMSOL 7.1 program76 to obtain the 
free energy of desolvation DGdes  (Table 5) with the SM5.4A solvation model76 and 
the AM177 level of theory (used keywords “AM1 SM5.4A SOLVNT=WATER 
TRUES”). 
 
 
Figure 7. The 4-methoxy biphenyl scaffold of aglycons. 
 
 
RO
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Table 5. Aqueous free energy of desolvation.    
R DGdes [kJ/mol] 
neutral  
H 15.6 
CONHCH3 39.9 
COOCH3 23.0 
SO2NHCH3 65.5 
SO2CH3 56.4 
4-morpholine 
amide 
45.3 
CN 22.0 
  
deprotonated  
COO- 298.2 
SO2-N--Me 342.0 
 
 
Determination of the MAC90 by flow cytometry 
 
The MAC90 was determined in principle as in the previously published flow cytometry 
assay,68 but with some modifications. The human epithelial bladder carcinoma cell 
line 5637 (DSMZ, Braunschweig, Germany) was grown in RPMI 1640 medium, 
supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin and 100 µg/mL 
streptomycin at 37 °C, 5% CO2. All solutions were purchased from Invitrogen (Basel, 
Switzerland). The cells were subcultured 1:6 twice per week [using Trypsin/EDTA 
(Sigma-Aldrich) for the detachment]. Two days before infection, 1.8 × 105 cells were 
seeded in each well of a 24-well plate in RPMI 1640 containing 10% FCS without 
antibiotics. The cell density was approximately 3-5 × 105 cells/well at the assay day. 
For infection, the GFP-expressing clinical E. coli isolate UTI8978 (UTI89 wt) and the 
GFP-expressing FimA-H knock-out strain UTI89 ∆fimA-H were used (strains were 
provided by Prof. Urs Jenal, Biocenter, University of Basel, Switzerland).68 Bacteria 
were cultivated at 37 °C in 10 mL Luria-Bertani (LB) broth (Becton, Dickinson and 
Company) overnight, harvested by centrifugation (3800 rpm, 10 min) and washed 
three times in phosphate buffered saline (PBS, Sigma-Aldrich) and a bacterial 
solution of OD600 of 0.75 in RPMI + 10% FCS was prepared. For the determination of 
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the MAC90 value, the IC90, linear dilutions of the FimH-antagonist were prepared in 
5% DMSO and PBS. Bacteria and antagonists were pre-incubated for 10 min at 37 
°C, before cells were infected with either only 200 µL bacterial solution of UTI89 or 
UTI89 ∆fimA-H (positive and negative controls), or 225 µL of the pre-incubated 
bacteria-antagonist mixture. Infection lasted for 1.5 h, during this time infected cells 
were incubated at 37 °C. Then, cells were washed with PBS and detached from wells 
by the addition of 150 µL trypsin and incubation at 37 °C for 10 min, before flushing 
from wells PBS containing 2% FCS and transferred to tubes. To dilute the trypsin, 
cells were centrifuged at 13000 rpm, 1 min, 600 µL of the supernatant was discarded 
and the pellet was re-suspended in the remaining 300 µL PBS containing 2% FCS. 
Samples were stored on ice until measurement. Before analysis with the flow 
cytometer (Becton Dickinson, FACSCanto II), the samples were gently mixed and 
filtered using a 35 µm nylon mesh (Corning Life Sciences) to prevent cellular 
aggregation. Cells were gated with linear scaling for side scatter (SSC) and forward 
scatter (FSC) and GFP intensity of live cells was evaluated. IC90 values were 
determined by plotting the concentration of the antagonist in a logarithmic mode 
versus the mean fluorescence intensity (MFI) of living cells and by fitting a dose 
response curve (variable slope, four parameters) with the prism software (GraphPad 
Prism). 
 
X-ray analysis of the antagonists 11e and 11j co-crystallized with FimH-CRD 
 
FimH-CRD-11e co-crystallization. Initial FimH-CRD (18 mg/mL in 20 mM HEPES 
pH 7.4) crystals were obtained in complex with 4-(5-nitroindolin-1-yl)phenyl α-D-
mannopyranoside (5 mM).23 Crystals were grown in sitting-drop vapor diffusion at 20 
°C with 200 nL of protein-antagonist mixture together with 200 nL precipitant solution 
in well D3 (0.2 M sodium phosphate monobasic monohydrate, 20% w/v PEG 3,350) 
of the PEG/Ion HTTM screen (Hampton Research, CA, USA). Cubic crystals appeared 
within one week, which served as cross-seeding crystals. A solution of FimH-CRD 
(20 mg/mL) and 11e (5 mM) was mixed with 0.2 M sodium phosphate monobasic 
monohydrate, 20% w/v PEG 400 with 0.5 µL of each solution. Streak-seeding was 
performed after one day of incubation. Cubic FimH-CRD-11e crystals formed within 
24 h. Crystals were flash cooled to 100 K with perfluoropolyether cryo oil (Hampton 
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Research, CA, USA) as cryoprotectant. Data was collected with synchrotron radiation 
(λ = 0.99999 Å) at the PXIII beamline, Swiss Light Source, Switzerland. 
 
FimH-CRD-11j co-crystallization. Co-crystals were initially grown in sitting-drop 
vapor diffusion at 20 °C with 0.5 µL of a mixture of FimH-CRD (20 mg/mL) and 11j (5 
mM) together with 0.5 µL of 0.1 M HEPES pH 7.5, 2 M ammonium sulfate. Plate-like 
crystals formed within two weeks and were used as seeds for subsequent 
crystallization. Diffraction quality crystals were grown by streak-seeding in 0.5 µL of 
FimH-CRD (10 mg/mL) with 11j (2.5 mM) and 0.5 µL of 0.1 M HEPES pH 7.5, 1.25 M 
ammonium sulfate. The drops were covered with perfluoropolyether cryo oil prior to 
flash cooling to 100 K. Data was collected with synchrotron radiation (λ = 1.00003 Å) 
at the PXIII beamline, Swiss Light Source, Switzerland. 
 
Structure Determination and Refinement. Data were indexed and integrated with 
the XDS package79 for the FimH-CRD-11e co-crystal structure, and with mosflm807 
for the FimH-CRD-11j co-crystal structure. Scaling was performed with XDS and 
SCALA included in the CCP4 suite, respectively.81 Structures were solved by 
molecular replacement with PHASER82 using the FimH-CRD-butyl α-D-
mannopyranoside complex  (PDB code 1UWF) as search model. The structures 
were iteratively built using the COOT software83 and refined with the PHENIX 
software.84 Geometric restraints for 11e and 11j were generated with PRODRG.85 
The models were validated using molprobity.86 Residues 113-115 were not modeled 
in the 11e structure due to disorder. Furthermore, the ligand was modeled in two 
possible conformations. For both ligands, electron density is reduced on the second 
aromatic ring due to flexibility of the ligand. 
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Table 6. Data Collection and Refinement Statistics for FimH-CRD-11e and FimH-CRD-11j co-crystals. 
 FimH-CRD-11e FimH-CRD-11j 
PDB code 4CSS 4CST 
Space group P 21 21 21 P 21 21 21 
No. of molecules in the 
asymmetric unit 
1 1 
Cell dimensions 
a, b, c (Å) 48.38, 56.23, 61.59  48.84, 55.89, 61.00 
     a, b, c (°)  90, 90, 90 90, 90, 90 
Data Collection 
Beamline Swiss Light Source 
PXIII 
Swiss Light Source 
PXIII 
Resolution range (Å)a 30.0 - 1.07 (1.13 – 
1.07) 
23.5 – 1.10 (1.12 – 
1.10) 
Unique observationsa 72000 (9354) 66470 (2500) 
Average multiplicitya 10.9 (3.7) 5.4 (2.4) 
Completeness (%) 96.1 (78.0) 97.2 (76.5) 
Rmergea 0.056 (0.57) 0.051 (0.305) 
Mean I / σ(I)a 21.5 (2.22) 15.5 (2.9) 
Refinement 
Resolution range (Å) 15.7 – 1.07 23.5 – 1.10 
R, Rfree 11.2, 13.2 11.4, 13.0 
Rms deviation from ideal bond 
length (Å) 
0.010 0.010 
Rms deviation from ideal bond 
angle (deg) 
1.170 1.420 
 
aValues in parentheses are for highest-resolution shell. 
 
Physicochemical and in vitro pharmacokinetic studies. 
 
Materials. Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol, Dulbecco’s Modified 
Eagle’s Medium (DMEM) - high glucose, L-glutamine solution, penicillin-streptomycin 
solution, Dulbecco’s Phosphate Buffered Saline (DPBS), trypsin-EDTA solution, 
magnesium chloride hexahydrate, and reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) were purchased from Sigma-Aldrich. MEM nonessential amino 
acid (MEM-NEAA) solution, fetal bovine serum (FBS), and DMEM without sodium 
pyruvate and phenol red were bought from Invitrogen (Carlsbad, CA, USA). PRISMA 
HT universal buffer, GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered 
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from pIon (Woburn, MA, USA). Human plasma was bought from Biopredic (Rennes, 
France) and acetonitrile (MeCN) and methanol (MeOH) from Acros Organics (Geel, 
Belgium). Pooled male rat liver microsomes were purchased from BD Bioscience 
(Franklin Lakes, NJ, USA). Tris(hydroxymethyl)-aminomethane (TRIS) was obtained 
from AppliChem (Darmstadt, Germany). The Caco-2 cells were kindly provided by 
Prof. G. Imanidis, FHNW, Muttenz, and originated from the American Type Culture 
Collection (Rockville, MD, USA).  
 
pKa. The pKa values were determined as described elsewhere.87 In brief, the pH of a 
sample solution was gradually changed and the chemical shift of protons adjacent to 
ionizable centers was monitored by 1H nuclear magnetic resonance (NMR) 
spectroscopy. The shift was plotted against the pH of the respective sample, and the 
pKa was read out from the inflection point of the resulting sigmoidal curve. 
 
Log D7.4. The in silico prediction tool ALOGPS88 was used to estimate log P values of 
the compounds. Depending on these values, the compounds were classified into 
three categories: hydrophilic compounds (log P below zero), moderately lipophilic 
compounds (log P between zero and one) and lipophilic compounds (log P above 
one). For each category, two different ratios (volume of 1-octanol to volume of buffer) 
were defined as experimental parameters (Table 7). 
 
Table 7. Compound classification based on estimated log P values. 
Compound type log P ratio (1-octanol / 
buffer) 
hydrophilic < 0 30:140, 40:130 
moderately 
lipophilic 
0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and 
shaken vigorously for 5 min to saturate the phases. The mixture was left until 
separation of the two phases occurred, and the buffer was retrieved. Stock solutions 
of the test compounds were diluted with buffer to a concentration of 1 µM. For each 
compound, six determinations, that is, three determinations per 1-octanol/buffer ratio, 
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were performed in different wells of a 96-well plate. The respective volumes of buffer 
containing analyte (1 µM) were pipetted to the wells and covered by saturated 1-
octanol according to the chosen volume ratio. The plate was sealed with aluminum 
foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 plate-shaker 
(Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and centrifuged 
(2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The 
aqueous phase was transferred to a 96-well plate for analysis by LC-MS. 
 
The log D7.4 coefficient was calculated from the 1-octanol/buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 µM), and the concentration of the analyte in 
buffer (cB) with Equation 3: 
  (3) 
 
Aqueous Solubility. Solubility was determined in a 96-well format using the µSOL 
Explorer solubility analyzer (pIon, version 3.4.0.5). For each compound, 
measurements were performed at pH 3.0 and 7.4 in triplicates. For this purpose, six 
wells of a deep well plate, that is, three wells per pH value, were filled with 300 µL of 
PRISMA HT universal buffer, adjusted to pH 3.0 or 7.4 by adding the requested 
amount of NaOH (0.5 M). Aliquots (3 µL) of a compound stock solution (10-50 mM in 
DMSO) were added and thoroughly mixed. The final sample concentration was 0.1-
0.5 mM, the residual DMSO concentration was 1.0% (v/v) in the buffer solutions. 
After 15 h, the solutions were filtrated (0.2 µm 96-well filter plates) using a vacuum to 
collect manifold (Whatman Ltd., Maidstone, UK) to remove the precipitates. Equal 
amounts of filtrate and 1-propanol were mixed and transferred to a 96-well plate for 
UV/Vis detection (190 to 500 nm, SpectraMax 190). The amount of material 
dissolved was calculated by comparison with UV/Vis spectra obtained from reference 
samples, which were prepared by dissolving compound stock solution in a 1:1 
mixture of buffer and 1-propanol (final concentrations 0.017-0.083 mM). 
 
Parallel Artificial Membrane Permeation Assay (PAMPA). Effective permeability 
(log Pe) was determined in a 96-well format with the PAMPA.50 For each compound, 
measurements were performed at pH 5.0 and 7.4 in quadruplicates. Eight wells of a 
deep well plate, that is, four wells per pH-value, were filled with 650 µL of PRISMA 
€ 
logD7.4 = log
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HT universal buffer adjusted to pH 5.0 or 7.4 by adding the requested amount of 
NaOH (0.5 M). Samples (150 µL) were withdrawn from each well to determine the 
blank spectra by UV/Vis-spectroscopy (190 to 500 nm, SpectraMax 190). Then, 
analyte dissolved in DMSO was added to the remaining buffer to yield 50 µM 
solutions. To exclude precipitation, the optical density was measured at 650 nm, with 
0.01 being the threshold value. Solutions exceeding this threshold were filtrated. 
Afterwards, samples (150 µL) were withdrawn to determine the reference spectra. 
Further 200 µL were transferred to each well of the donor plate of the PAMPA 
sandwich (pIon, P/N 110163). The filter membranes at the bottom of the acceptor 
plate were infused with 5 µL of GIT-0 Lipid Solution, and 200 µL of Acceptor Sink 
Buffer was filled into each acceptor well. The sandwich was assembled, placed in the 
GutBoxTM, and left undisturbed for 16 h. Then, it was disassembled and samples 
(150 µL) were transferred from each donor and acceptor well to UV-plates for 
determination of the UV/Vis spectra. Effective permeability (log Pe) was calculated 
from the compound flux deduced from the spectra, the filter area, and the initial 
sample concentration in the donor well with the aid of the PAMPA Explorer Software 
(pIon, version 3.5). 
 
Colorectal Adenocarcinoma (Caco-2) Cell Permeation Assay. Caco-2 cells were 
cultivated in tissue culture flasks (BD Biosciences) with DMEM high glucose medium, 
containing L-glutamine (2 mM), nonessential amino acids (0.1 mM), penicillin (100 
U/mL), streptomycin (100 µg/mL), and fetal bovine serum (10%). The cells were kept 
at 37 °C in humidified air containing 5% CO2, and the medium was changed every 
second day. When approximately 90% confluence was reached, the cells were split 
in a 1:10 ratio and distributed to new tissue culture flasks. At passage numbers 
between 60 and 65, they were seeded at a density of 5.3 × 105 cells per well to 
Transwell 6-well plates (Corning Inc.) with 2.5 mL of culture medium in the 
basolateral and 1.8 mL in the apical compartment. The medium was renewed on 
alternate days. Permeation experiments were performed between days 19 and 21 
post seeding. Prior to the experiment, the integrity of the Caco-2 monolayers was 
evaluated by measuring the transepithelial electrical resistance (TEER) with an 
Endohm tissue resistance instrument (World Precision Instruments Inc., Sarasota, 
FL, USA). Only wells with TEER values higher than 250 Ω cm2 were used. 
Experiments were performed in the apical-to-basolateral (absorptive) and 
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basolateral-to-apical (secretory) directions in triplicates. Transport medium (DMEM 
without sodium pyruvate and phenol red) was withdrawn from the donor 
compartments of three wells and replaced by the same volume of compound stock 
solution (10 mM in DMSO) to reach an initial sample concentration of 62.5 µM. The 
Transwell plate was then shaken (600 rpm, 37 °C) on a Heidolph Titramax 1000 
plate-shaker. Samples (40 µL) were withdrawn from the donor and acceptor 
compartments 30 min after initiation of the experiment and the compound 
concentrations were determined by LC-MS (see below). Apparent permeability (Papp) 
was calculated according to Equation 4: 
  (4) 
where dQ/dt is the compound flux (mol s-1), A is the surface area of the monolayer 
(cm2), and c0 is the initial concentration in the donor compartment (mol cm-3).50 After 
the experiment, TEER values were assessed again for each well and results from 
wells with values below 250 Ω cm2 were discarded. 
 
Plasma Protein Binding (PPB). PPB was determined in a 96-well format using a 
high throughput dialysis block (HTD96b; HTDialysis LCC, Gales Ferry, CT, USA). For 
each compound, measurements were performed in triplicate. Dialysis membranes 
(MWCO 12-14 K; HTDialysis LCC) were hydrated according to the instructions of the 
manufacturer and placed into the dialysis block. Human plasma was centrifuged 
(5800 rpm, 5 °C, 10 min), the pH of the supernatant (without floating plasma lipids) 
was adjusted to 7.4 by adding the requested amount of HCl (4 M), and analyte was 
added to yield a final concentration of 10 µM. Equal volumes (150 µL) of plasma 
containing the analyte or TRIS-HCl buffer (0.1 M, pH 7.4) were transferred to the 
compartments separated by the dialysis membrane. The block was covered with a 
sealing film and left undisturbed (5 h, 37 °C). Afterwards, samples (90 µL) were 
withdrawn from the buffer compartments and diluted with plasma (10 µL). From the 
plasma compartments, samples (10 µL) were withdrawn and diluted with TRIS-HCl 
buffer (90 µL). The solutions were further diluted with ice-cooled MeCN (300 µL) to 
precipitate the proteins and centrifuged (3600 rpm, 4 °C, 10 min). The supernatants 
(50 µL) were retrieved, and the analyte concentrations were determined by LC-MS 
(see below). The fraction bound (fb) was calculated as follows (Equation 5): 
 
€ 
fb = 1−
cb
cp
 (5) 
€ 
Papp =
dQ
d t ×
1
A × c0
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where cb is the concentration of the analyte withdrawn from the buffer compartment 
before dilution and cp is the concentration in the plasma compartment. The values 
were accepted if the recovery of analyte was between 80 and 120% of the initial 
amount. 
 
Cytochrome P450-mediated metabolism. Incubations consisted of pooled male rat 
liver microsomes (0.5 mg microsomal protein/mL), test compound (2 µM), MgCl2 (2 
mM), and NADPH (1 mM) in a total volume of 300 µL TRIS-HCl buffer (0.1 M, pH 
7.4) and were performed in a 96-well plate on a Thermomixer Comfort (Eppendorf). 
Compounds and microsomes were preincubated (37 °C, 700 rpm, 10 min) before 
NADPH was added. Samples (50 µL) at t = 0 min and after an incubation time of 5, 
10, 20, and 30 min were quenched with 150 µL of ice-cooled MeOH, centrifuged 
(3600 rpm, 4 °C, 10 min), and 80 µL of supernatant was transferred to a 96-well plate 
for LC-MS analysis (see below). The metabolic half-life (t1/2) was calculated from the 
slope of the linear regression from the log percentage remaining compound versus 
incubation time relationship. Control experiments without NADPH were performed in 
parallel. 
 
LC-MS measurements. Analyses were performed using an 1100/1200 Series HPLC 
System coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, 
Inc., Santa Clara, CA, USA) equipped with electrospray ionization. The system was 
controlled with the Agilent MassHunter Workstation Data Acquisition software 
(version B.01.04). The column used was an Atlantis® T3 C18 column (2.1 x 50 mm) 
with a 3-µm particle size (Waters Corp., Milford, MA, USA). The mobile phase 
consisted of eluent A: H2O containing 0.1% formic acid (for 11a-f, h-i), or 10 mM 
ammonium acetate, pH 5.0 in 95:5, H2O/MeCN (for 11g, j); and eluent B: MeCN 
containing 0.1% formic acid. The flow rate was maintained at 0.6 mL/min. The 
gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 
5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, 
resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, 
collision energy, polarity were optimized individually for each analyte, and the 
molecular ion was followed for each compound in the multiple reaction monitoring 
mode. The concentrations of the analytes were quantified by the Agilent Mass Hunter 
Quantitative Analysis software (version B.01.04). 
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In Vivo Pharmacokinetic Studies. 
 
Materials. DMSO and PBS were purchased from Sigma-Aldrich. The 96-well plates 
were bought from Agilent Technologies (0.5 mL, polypropylene). The gavage was 
obtained from Fine Science (Heidelberg, Germany) and the syringes (BD Micro Fine, 
U-100 Insuline, 30 G) and needles (BD Microlance 3, 25 G) from Becton Dickinson 
(USA, Ireland) and Henke Sass Wolf in Germany (Soft-Ject, 1 mL syringes). 
 
Animals. Female C3H/HeN mice weighing between 19 and 25 g were obtained from 
Charles River Laboratories (Sulzfeld, Germany) and were housed three or four per 
cage. The mice were kept under specific pathogen-free conditions in the Animal 
House of the Department of Biomedicine, University Hospital of Basel, and animal 
experimentation guidelines according to the regulations of the Swiss veterinary law 
were followed. After 7 d of acclimatization, 9-10 week old mice were used for the 
studies. Animals had free access to chow and water at any time and were kept in a 
12h/12h light/dark cycle. For administration volumes and sampling the good practice 
guidelines were followed.89 
 
Pharmacokinetic studies. The single-dose studies for the first experiment set were 
performed by intravenous application of FimH antagonists at a dosage of 50 mg/kg 
body weight, followed by plasma and urine sampling. Antagonists were diluted in 
PBS for injection into the tail vein. Blood and urine samples (10 µL) were taken at 6 
and 30 min, and 1, 2, 4, 6, and 8 h after injection. For the PK studies with 11j, the 
antagonist was dissolved in PBS with 5 % DMSO and injected into the tail vain 
(0.625 mg/kg) or given orally (1.25 mg/kg) using a gavage. Blood and urine were 
sampled (10 µL) after 7, 13, 20, 30, 45 min, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 h. 
Both, blood and urine samples, were directly diluted after sampling with MeOH to 
precipitate the proteins and centrifuged for 11 min at 13000 rpm. The supernatants 
were transferred to a 96-well plate and the analyte concentrations were determined 
by LC-MS (see above). 
 
Infection study. For all infection studies, the drinking water of the mice was replaced 
by 5% glucose (monohydrate from AppliChem, BioChemica) containing water, three 
days before the start of the experiment. 11j was dosed at 1.25 mg/kg (in 5% DMSO 
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and PBS) and 10 mg/kg (5% DMSO in PBS containing 1% Tween 80) applied orally 
to 6 and 4 mice, respectively, as described in the pharmacokinetic studies, 40 min 
prior to infection. Ciprofloxacin was dosed with 8 mg/kg, which would correspond to a 
human dose of 400 mg,70 subcutaneously 10 minutes prior to infection with UTI89 to 
4 mice. Control values resulted from the infection of 11 mice. Before infection, 
remaining urine in the bladder was expelled by gentle pressure on the abdomen. 
Mice were anaesthetised in 2.5 vol% isoflurane/oxygen mixture (Attane, Minrad Inc, 
Buffalo, NY, USA) and placed on their back. Infection was performed transurethrally 
using a polyethylene catheter (Intramedic polyethylene tubing, inner diameter 0.28 
mm, outer diameter 0.61 mm, Beckton Dickinson, Allschwil, Switzerland), on a 
syringe (Hamilton Gastight Syringe 50 µl, removable 30G needle, BGB Analytik AG, 
Boeckten, Switzerland). After gentle insertion of the catheter into the bladder, 50 µl of 
bacterial suspension of UTI89 (5.5x109-2.25x1010 CFU/ml) was slowly injected. This 
corresponded to approximately 107-108 CFU per mouse. Mice were killed by CO2 
three hours after inoculation and bladder and kidneys were aseptically removed. 
Organs were homogenized in 1 ml PBS using a tissue lyser (Retsch, Haan, 
Germany). Serial dilutions of bladder and kidneys were plated on Levine Eosin 
Methylene Blue Agar plates (Beckton Dickinson, France) and CFU were counted 
after overnight incubation at 37°C. 
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Synthesis 
 
General methods. NMR spectra were recorded on a Bruker Avance DMX-500 
(500.1 MHz) spectrometer. Assignment of 1H and 13C NMR spectra was achieved 
using 2D methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm 
using residual CHCl3, CHD2OD or HDO as references. Optical rotations were 
measured using Perkin-Elmer Polarimeter 341. Electron spray ionization mass 
spectra (ESI-MS) were obtained on a Waters micromass ZQ. The LC/HRMS analysis 
were carried out using a Agilent 1100 LC equipped with a photodiode array detector 
and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Microwave-
assisted reactions were carried out with a CEM Discover and Explorer. Reactions 
were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) and 
visualized by using UV light and/or by charring with a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10% H2SO4). MPLC separations were carried out on a 
CombiFlash Companion or Rf (Teledyne Isco) equipped with RediSep normal-phase 
or RP-18 reversed-phase flash columns. LC-MS separations were done on a Waters 
system equipped with sample manager 2767, pump 2525, PDA 2525 and micromass 
ZQ. All compounds used for biological assays are at least of 95% purity based on 
HPLC analytical results. Commercially available reagents were purchased from 
Fluka, Aldrich, Alfa Aesar or abcr GmbH & Co. KG (Germany). Solvents were 
purchased from Sigma-Aldrich or Acros and were dried prior to use where indicated. 
Methanol (MeOH) was dried by refluxing with sodium methoxide and distilled 
immediately before use. Dimethoxyethane (DME) was dried by filtration over Al2O3 
(Fluka, type 5016 A basic).  
 
General procedure A for palladium-catalyzed Miyaura-Suzuki coupling. A 
Schlenk tube was charged with aryl iodide 12S1 (1.0 eq), boronic acid or boronate 
13a-f (1.1 eq), Pd(dppf)Cl2⋅CH2Cl2 (0.03 eq), K3PO4 (1.5 eq) and a stirring bar. The 
tube was closed with a rubber septum and was evacuated and flushed with argon. 
This procedure was repeated once, and then anhydrous DMF (2 mL) was added 
under a stream of argon. The mixture was degassed in an ultrasonic bath and 
flushed with argon for 5 min, and then stirred at 80°C overnight. The reaction mixture 
was cooled to rt, diluted with EtOAc (50 mL), and washed with water (50 mL) and 
brine (50 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. 
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The residue was purified by MPLC on silica gel (petroleum ether/EtOAc) to afford 
14a-f. 
 
General procedure B for deacetylation. To a solution of 14a-f (1.0 eq) in dry 
MeOH (5 mL) was added freshly prepared 1 M NaOMe/MeOH (0.1 eq) under argon. 
The mixture was stirred at rt until the reaction was complete (monitored by TLC), 
then neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated 
in vacuo. The residue was purified by MPLC on silica gel (DCM/MeOH, 10:1-7:1) to 
afford 11a-f as white solids. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-carboxamide 
(14a). Prepared according to general procedure A from 12 (150 mg, 0.27 mmol), (4-
carbamoylphenyl)boronic acid (13a, 49 mg, 0.30 mmol), Pd(dppf)Cl2⋅CH2Cl2 (6.6 mg, 
0.008 mmol) and K3PO4 (86 mg, 0.41 mmol). Yield: 108 mg (73%) as yellow oil. 
[α]D20 +70.7 (c 0.6, EtOAc); 1H NMR (500 MHz, CDCl3): δ = 7.89-7.87 (m, 2H, Ar-H), 
7.63-7.62 (m, 2H, Ar-H), 7.57-7.55 (m, 2H, Ar-H), 7.19-7.17 (m, 2H, Ar-H), 6.18 (br, 
1H, NH), 5.85 (br, 1H, NH), 5.60-5.57 (m, 2H, H-1, H-3), 5.48 (dd, J = 1.8, 3.5 Hz, 
1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.30 (dd, J = 5.3, 12.4 Hz, 1H, H-6a), 4.17-
4.03 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 
MHz, CDCl3): δ = 170.68, 170.17, 170.14, 169.88, 169.12 (5 CO), 155.77, 144.07, 
134.85, 131.83, 128.58, 128.10, 127.04, 117.02 (Ar-C), 95.89 (C-1), 69.47 (C-5), 
69.38 (C-2), 68.96 (C-3), 66.00 (C-4), 62.20 (C-6), 21.03, 20.86, 20.84, 20.83 (4 
COCH3); ESI-MS: m/z: Calcd for C27H29NNaO11 [M+Na]+: 566.2, found: 566.2. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-N-methyl-biphenyl-4-
carboxamide (14b). Prepared according to general procedure A from 12 (50 mg, 
0.09 mmol), (4-(methylcarbamoyl)phenyl)boronic acid (13b, 18 mg, 0.10 mmol), 
Pd(dppf)Cl2⋅CH2Cl2 (3 mg, 0.003 mmol) and K3PO4 (29 mg, 0.14 mmol). Yield: 32 mg 
(63%) as colorless oil. [α]D20 +76.1 (c 0.6, EtOAc); 1H NMR (500 MHz, CDCl3): δ = 
7.83-7.81 (m, 2H, Ar-H), 7.60-7.53 (m, 4H, Ar-H), 7.17-7.15 (m, 2H, Ar-H), 6.30 (d, J 
= 4.8 Hz, 1H, NH), 5.58-5.56 (m, 2H, H-1, H-3), 5.46 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 
5.38 (t, J = 10.0 Hz, 1H, H-4), 4.28 (dd, J = 5.1, 12.1 Hz, 1H, H-6a), 4.12-4.06 (m, 
2H, H-5, H-6b), 3.03 (d, J = 4.8 Hz, 3H, NHCH3), 2.20, 2.05, 2.03, 2.02 (4 s, 12H, 4 
COCH3); 13CNMR (126 MHz, CDCl3): δ = 170.66, 170.14, 170.11, 169.86, 167.99 (5 
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CO), 155.65, 143.36, 134.97, 133.17, 128.51, 127.53, 126.96, 116.98 (Ar-C), 95.88 
(C-1), 69.46 (C-5), 69.35 (C-2), 68.96 (C-3), 65.98 (C-4), 62.19 (C-6), 26.99 
(NHCH3), 21.02, 20.84, 20.82, 20.81 (4 COCH3); ESI-MS: m/z: Calcd for C28H32NO11 
[M+H]+: 558.2, found: 558.3. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-yl-(morpholino)-
methanone (14c). Prepared according to general procedure A from 12 (110 mg, 
0.20 mmol), pinacol 4-(morpholine-4-carbonyl)phenylboronate (13c, 70 mg, 0.22 
mmol), Pd(dppf)Cl2⋅ CH2Cl2 (5 mg, 0.006 mmol) and K3PO4 (64 mg, 0.30 mmol). 
Yield: 139 mg (99%) as yellow oil. [α]D20 +62.0 (c 0.4, MeOH); 1H NMR (500 MHz, 
CDCl3): δ = 7.60-7.47 (m, 6H, Ar-H), 7.19-7.17 (m, 2H, Ar-H), 5.60-5.58 (m, 2H, H-1, 
H-3), 5.47 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.30 (dd, J = 
5.1, 12.2 Hz, 1H, H-6a), 4.14-4.08 (m, 2H, H-6b, H-5), 3.78-3.45 (m, 8H, 4 CH2), 
2.22, 2.09, 2.07, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.55, 
170.26, 170.05, 170.01, 169.76 (5 CO), 155.50, 142.00, 135.03, 133.82, 128.36, 
127.80, 126.94, 116.90 (Ar-C), 95.81 (C-1), 69.38 (C-5), 68.85 (C-2), 66.94 (C-3), 
65.90 (C-4), 62.09 (C-6), 20.92, 20.74, 20.72, 20.71 (4 COCH3); ESI-MS: m/z: Calcd 
for C31H35NNaO12 [M+Na]+: 636.2, found: 636.3. 
 
4'-(Methylsulfonyl)-biphenyl-4-yl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
(14d). Prepared according to general procedure A from 12 (50 mg, 0.09 mmol), 4-
(methylsulfonyl)-phenylboronic acid (13d, 20 mg, 0.10 mmol), Pd(dppf)Cl2⋅CH2Cl2 (3 
mg, 0.003 mmol) and K3PO4 (29 mg, 0.14 mmol). Yield: 23 mg (44%) as a yellow 
solid. [α]D20 +78.3 (c 0.6, EtOAc); 1H NMR (500 MHz, CDCl3): δ = 8.00-7.99 (m, 2H, 
Ar-H), 7.74-7.72 (m, 2H, Ar-H), 7.59-7.56 (m, 2H, Ar-H), 7.23-7.18 (m, 2H, Ar-H), 
5.60-5.56 (m, 2H, H-1, H-3), 5.47 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 5.40 (t, J =10.0 Hz, 
1H, H-4), 4.30 (dd, J = 4.9, 12.0 Hz, 1H, H-6a), 4.13-4.08 (m, 2H, H-5, H-6b), 3.10 (s, 
3H, SO2CH3), 2.22, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, 
CDCl3): δ = 170.53, 170.05, 170.02, 169.73 (4 CO), 156.11, 145.82, 138.86, 133.89, 
128.71, 128.00, 127.61, 117.05 (Ar-C), 95.77 (C-1), 69.32 (2C, C-2, C-5), 68.80 (C-
3), 65.84 (C-4), 62.06 (C-6), 44.65 (SO2CH3), 20.91, 20.74, 20.72 (4C, 4 COCH3); 
ESI-MS: m/z: Calcd for C27H30NaO12S [M+Na]+: 601.1, found: 601.1. 
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4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-N-methyl-biphenyl-4-
sulfonamide (14e). Prepared according to general procedure A from 12 (116 mg, 
0.21 mmol), 4-(N-methylsulfamoyl)-phenylboronic acid (13e, 50 mg, 0.23 mmol), 
Pd(dppf)Cl2⋅CH2Cl2 (5 mg, 0.006 mmol) and K3PO4 (67 mg, 0.32 mmol). Yield: 105 
mg (84%) as a white solid. [α]D20 +56.4 (c 0.5, MeOH); 1H NMR (500 MHz, CDCl3): δ 
= 7.92-7.90 (m, 2H, Ar-H), 7.70-7.68 (m, 2H, Ar-H), 7.57-7.55 (m, 2H, Ar-H), 7.21-
7.19 (m, 2H, Ar-H), 5.60-5.57 (m, 2H, H-1, H-3), 5.48 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 
5.40 (t, J =10.0 Hz, 1H, H-4), 4.38 (dd, J = 5.4, 10.8 Hz, 1H, NH), 4.30 (dd, J = 4.9, 
12.3 Hz, 1H, H-6a), 4.13-4.08 (m, 2H, H-5, H-6b), 2.72 (d, J = 5.4 Hz, 3H, NCH3), 
2.22, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.55, 
170.06, 170.03, 169.75 (4 CO), 155.97, 144.81, 137.16, 134.09, 128.62, 127.85, 
127.39, 117.01 (Ar-C), 95.78 (C-1), 69.34 (C-5), 69.31 (C-2), 68.81 (C-3), 65.86 (C-
4), 62.07 (C-6), 29.44 (NHCH3), 20.92, 20.74, 20.72 (4C, 4 COCH3); ESI-MS: m/z: 
Calcd for C27H31NNaO12S [M+Na]+: 616.1, found: 616.1. 
 
3',5'-Difluoro-4'-hydroxy-biphenyl-4-yl 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranoside (14f). Prepared according to general procedure A from 12 (100 
mg, 0.18 mmol), pinacol (3,5-difluoro-4-hydroxyphenyl)boronate (13f, 51 mg, 0.20 
mmol), Pd(dppf)Cl2⋅CH2Cl2 (5 mg, 0.006 mmol) and K3PO4 (57 mg, 0.27 mmol). 
Yield: 57 mg (52%) as colorless oil. [α]D20 +64.9 (c 0.7, MeOH); 1H NMR (500 MHz, 
CDCl3): δ = 7.44-7.38 (m, 2H, Ar-H), 7.15-7.11 (m, 2H, Ar-H), 7.10-7.02 (m, 2H, Ar-
H), 5.90 (bs, 1H, OH), 5.59 (dd, J = 3.6, 10.1 Hz, 1H, H-3), 5.56 (d, J = 1.8 Hz, 1H, 
H-1), 5.47 (dd, J = 1.8, 3.5 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.30 (dd, J = 
4.8, 12.0 Hz, 1H, H-6a), 4.14-4.08 (m, 2H, H-6b, H-5), 2.22, 2.07, 2.06, 2.05 (4 s, 
12H, 4 COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.83, 170.31, 170.25, 169.99 (4 
CO), 155.43 (Ar-C), 152.19 (d, J = 241.0 Hz, Ar-C), 152.14 (d, J = 241.0 Hz, Ar-C), 
133.82 (Ar-C), 132.29 (d, J = 20.6 Hz, Ar-C), 127.93, 117.02 (Ar-C), 110.04 (d, J = 
6.4 Hz, Ar-C), 109.91 (d, J = 6.4 Hz, Ar-C), 95.90 (C-1), 69.53 (C-5), 69.34 (C-2), 
68.97 (C-3), 66.02 (C-4), 62.23 (C-6), 21.02, 20.85, 20.82, 20.81 (4 COCH3); ESI-
MS: m/z: Calcd for C26H26F2NaO11 [M+Na]+: 575.1, found: 575.2. 
 
4’-(α-D-Mannopyranosyloxy)-biphenyl-4-carboxamide (11a). Prepared according 
to general procedure B from 14a (30 mg, 0.05 mmol). Yield: 6 mg (29%) as a white 
solid. [α]D20 +133.0 (c 0.3, dioxane/H2O, 2:1); 1H NMR (500 MHz, DMSO-d6): δ = 
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7.98-7.94 (m, 2H, Ar-H), 7.72-7.70 (m, 2H, Ar-H), 7.67-7.64 (m, 2H, Ar-H), 7.27-7.23 
(m, 2H, Ar-H), 5.57 (d, J = 1.6 Hz, 1H, H-1), 4.05 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 3.95 
(dd, J = 3.4, 9.4 Hz, 1H, H-3), 3.85-3.70 (m, 3H, H-4, H-6a, H-6b), 3.64 (m, 1H, H-5); 
13C NMR (126 MHz, DMSO-d6): δ = 167.80 (CO), 156.39, 142.33, 132.78, 132.36, 
128.13, 127.96, 125.93, 117.16 (Ar-C), 98.73 (C-1), 74.89 (C-5), 70.59 (C-3), 70.00 
(C-2), 66.62 (C-4), 60.96 (C-6); HRMS: m/z: Calcd for C19H22NO7 [M+H]+: 376.1391, 
found: 376.1394. 
 
4’-(α-D-Mannopyranosyloxy)-N-methyl-biphenyl-4-carboxamide (11b). Prepared 
according to general procedure B from 14b (30 mg, 0.05 mmol). Yield: 13 mg (62%) 
as a white solid. [α]D20 +117.0 (c 0.3, MeOH/H2O, 5:1); 1H NMR (500 MHz, CD3OD): 
δ = 7.85-7.83 (m, 2H, Ar-H), 7.66-7.64 (m, 2H, Ar-H), 7.61-7.58 (m, 2H, Ar-H), 7.21-
7.19 (m, 2H, Ar-H), 5.52 (d, J = 1.5 Hz, 1H, H-1), 4.00 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 
3.90 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.75-3.69 (m, 3H, H-4, H-6a, H-6b), 3.59 (ddd, J = 
2.4, 5.1, 9.7 Hz, 1H, H-5), 2.91 (s, 3H, NHCH3); 13C NMR (126 MHz, CD3OD): δ = 
170.51 (CO), 158.04, 145.09, 135.28, 133.78, 129.29, 128.80, 127.64, 118.20 (Ar-C), 
100.13 (C-1), 75.49 (C-5), 72.41 (C-2), 71.98 (C-3), 68.32 (C-4), 62.67 (C-6), 26.94 
(NHCH3); HRMS: m/z: Calcd for C20H24NO7 [M+H]+: 390.1547, found: 390.1551. 
 
4’-(α-D-Mannopyranosyloxy)-biphenyl-4-yl-(morpholino)methanone (11c). 
Prepared according to general procedure B from 14c (50 mg, 0.08 mmol). Yield: 27 
mg (75%) as a white solid. [α]D20 +96.5 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): 
δ = 7.71-7.70 (m, 2H, Ar-H), 7.63-7.63 (m, 2H, Ar-H), 7.52-7.50 (m, 2H, Ar-H), 7.25-
7.23 (m, 2H, Ar-H), 5.56 (d, J = 1.7 Hz, 1H, H-1), 4.05 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 
3.95 (dd, J = 3.5, 9.5 Hz, 1H, H-3), 3.78-3.54 (m, 12H, H-4, H-5, H-6a, H-6b, 4 CH2); 
13C NMR (126 MHz, CD3OD): δ = 172.29 (CO), 158.00, 143.86, 135.30, 134.66, 
129.25, 128.90, 127.85, 118.23 (Ar-C), 100.14 (C-1), 75.50 (C-5), 72.42 (C-3), 71.99 
(C-2), 68.33, 62.69 (6C, C-4, C-6, 4 CH2); HRMS: m/z: Calcd for C23H28NO8 [M+H]+: 
446.1809, found: 446.1813. 
 
4'-(Methylsulfonyl)-biphenyl-4-yl α-D-mannopyranoside (11d). Prepared 
according to general procedure B from 14d (20 mg, 0.03 mmol). Yield: 12 mg (86%) 
as a white solid. [α]D20 +105.8 (c 0.2, DCM/MeOH, 1:3); 1H NMR (500 MHz, DMSO-
d6): δ = 7.90-7.88 (m, 2H, Ar), 7.76-7.74 (m, 2H, Ar), 7.58-7.56 (m, 2H, Ar-H), 7.17-
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7.15 (m, 2H, Ar-H), 5.46 (d, J = 1.7 Hz, 1H, H-1), 3.93 (dd, J = 1.9, 3.5 Hz, 1H, H-2), 
3.81 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.69-3.61 (m, 3H, H-4, H-6a, H-6b), 3.50 (ddd, J = 
2.5, 5.4, 9.7 Hz, 1H, H-5), 3.05 (SO2CH3); 13C NMR (126 MHz, DMSO-d6): δ = 
156.95, 144.60, 138.94, 131.86, 128.36, 127.57, 126.98, 117.24 (Ar-C), 98.78 (C-1), 
75.07 (C-5), 70.63 (C-3), 70.00 (C-2), 66.67 (C-4), 61.02 (C-6), 43.58 (SO2CH3); 
HRMS: m/z: Calcd for C19H22NaO8S [M+Na]+: 433.0928, found: 433.0928. 
 
4’-(α-D-Mannopyranosyloxy)-N-methyl-biphenyl-4-sulfonamide (11e). Prepared 
according to general procedure B from 14e (40 mg, 0.07 mmol). Yield: 22 mg (76%) 
as a white solid. [α]D20 +105.7 (c 0.3, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.90-
7.88 (m, 2H, Ar-H), 7.80-7.79 (m, 2H, Ar-H), 7.66-7.64 (m, 2H, Ar-H), 7.26-7.25 (m, 
2H, Ar-H), 5.58 (d, J = 1.7 Hz, 1H, H-1), 4.06 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 3.96 (dd, 
J = 3.4, 9.5 Hz, 1H, H-3), 3.79-3.74 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 2.5, 5.2, 
9.7 Hz, 1H, H-5), 2.57 (s, 3H, NHCH3); 13C-NMR (126 MHz, CD3OD): δ = 158.34, 
146.13, 138.67, 134.55, 129.53, 128.82, 128.21, 118.29 (Ar-C), 100.09 (C-1), 75.53 
(C-5), 72.42 (C-3), 71.96 (C-2), 68.32 (C-4), 62.68 (C-6), 29.31 (NHCH3); HRMS: 
m/z: Calcd for C19H23NNaO8S [M+Na]+: 448.1037, found: 448.1038. 
 
3',5'-Difluoro-4'-hydroxy-biphenyl-4-yl α-D-mannopyranoside (11f). Prepared 
according to general procedure B from 14f (40 mg, 0.07 mmol). Yield: 21 mg (78%) 
as a white solid. [α]D20 +117.6 (c 0.4, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.52-
7.49 (m, 2H, Ar-H), 7.19-7.14 (m, 4H, Ar-H), 5.54 (d, J = 1.7 Hz, 1H, H-1), 4.04 (dd, J 
= 1.8, 3.4 Hz, 1H, H-2), 3.94 (dd, J = 3.5, 9.5 Hz, 1H, H-3), 3.78-3.73 (m, 3H, H-4, H-
6a, H-6b), 3.63 (ddd, J = 2.5, 5.1, 9.8 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD): δ = 
157.56 (Ar-C), 154.26 (d, J = 240.0 Hz, Ar-C), 154.21 (d, J = 240.0 Hz, Ar-C), 134.38 
(t, J = 2.3 Hz, Ar-C), 132.92, 128.64, 118.16 (Ar-C), 110.59 (d, J = 6.6 Hz, Ar-C), 
110.46 (d, J = 6.6 Hz, Ar-C), 100.15 (C-1), 75.44 (C-5), 72.42 (C-3), 71.99 (C-2), 
68.32 (C-4), 62.66 (C-6); HRMS: m/z: Calcd for C18H18F2NaO7 [M+Na]+: 407.0913, 
found: 407.0913. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-carboxylic acid 
(16). To a solution of 6S2 (59 mg, 0.16 mmol) in pyridine (6 mL) was added acetic 
anhydride (2 mL) at 0°C under argon. The mixture was allowed to warm up to rt and 
stirred overnight. The mixture was concentrated and the residue was treated with 
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DCM/satd. aq. NaHCO3 (1:1, 50 mL) for 1 h. The organic layer was washed 
subsequently with 1 N aq. HCl (25 mL) and water (25 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by MPLC on silica gel (DCM/iPrOH, 
15:1) to afford 16 (45 mg, 53%) as a white solid. [α]D20 +71.9 (c 0.4, EtOAc); 1H NMR 
(500 MHz, CDCl3): δ = 8.25-8.15 (m, 2H, Ar-H), 7.70 - 7.63 (m, 2H, Ar-H), 7.60-7.55 
(m, 2H, Ar-H), 7.20-7.17 (m, 2H, Ar-H), 5.64-5.55 (m, 2H, H-1, H-3), 5.49 (dd, J = 
1.8, 3.4 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.5, 12.5 Hz, 1H, 
H-6a), 4.10-4.08 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4s, 12H, 4 COCH3); 13C 
NMR (126 MHz, CDCl3): δ = 171.72, 170.71, 170.16, 170.14, 169.90 (5 CO), 155.86, 
145.61, 134.75, 130.87, 128.65, 128.49, 127.97, 127.18, 126.84, 122.22, 117.00 (Ar-
C), 95.82 (C-1), 69.43 (C-5), 69.34 (C-2), 68.94 (C-3), 65.97 (C-4), 62.18 (C-6), 
20.98, 20.80, 20.79, 20.77 (4 COCH3); ESI-MS: m/z: Calcd for C27H28NaO12 [M+Na]+: 
567.1, found: 567.1. 
 
N-Cyano-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carboxamide (11i). To a 
solution of 16 (40 mg, 0.07 mmol) in toluene was added 1-chloro-N,N-2-trimethyl-1-
propenylamine (19 µL, 0.15 mmol) at 0 °C under argon. The mixture was allowed to 
warm up to rt in 4 h. Then the reaction mixture was concentrated and dried in vacuo 
overnight. The residue was dissolved in DMF (1 mL) and treated at 0 °C with a 
freshly prepared solution of NaNHCN in DMF [NH2CN (6 mg, 0.15 mmol) and 60% 
NaH (6 mg, 0.15 mmol) in DMF (0.5 mL)]. The reaction mixture was stirred at rt 
overnight and then concentrated in vacuo. The residue was deacetylated according 
to general procedure B and the crude product was purified by MPLC (H2O/MeOH, 
1:1) on RP18 to afford 11i (6 mg, 21% for three steps) as a white solid. [α]D20 +44.7 
(c 0.1, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.02-7.95 (m, 2H, Ar-H), 7.80-7.63 
(m, 4H, Ar-H), 7.30-7.22 (m, 2H, Ar-H), 5.57 (s, 1H, H-1), 4.05 (s, 1H, H-2), 3.95 (dd, 
J = 3.2, 9.4 Hz, 1H, H-3), 3.84-3.71 (m, 3H, H-4, H-6a, H-6b), 3.66-3.62 (m, 1H, H-5); 
13C NMR (126 MHz, CD3OD): δ = 158.37, 134.86, 130.09, 129.46, 127.82, 118.28 
(Ar-C), 101.41 (CN), 100.16 (C-1), 75.54 (C-5), 72.44 (C-3), 71.98 (C-2), 68.37 (C-4), 
62.71 (C-6); HRMS: m/z: Calcd for C20H20N2NaO7 [M+Na]+: 423.1163, found: 
423.1167. 
 
2-Chloro-4-iodophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (19). In a 
dry flask activated molecular sieves 4Å (300 mg), α-D-mannose pentaacetate (17, 
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390 mg, 0.77 mmol) and 2-chloro-4-iodophenol (18, 235 mg, 0.90 mmol) were 
dissolved in dry CH2Cl2 (3 mL) under argon. BF3·Et2O (freshly distilled, 290 µL, 2.3 
mmol) was added dropwise and the mixture was stirred for 20 h at 40 °C. After 
cooling to rt the mixture was diluted with CH2Cl2 (75 mL), filtered through celite and 
subsequently washed with satd. aq. NaHCO3 (75 mL), water (75 mL) and brine (75 
mL). The organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified via flash column chromatography 
(petroleum ether/EtOAc, 1:0 to 1:1) to yield 19 (345 mg, 76%). Spectroscopic data 
were in accordance with reported values.S3 
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Synthesis of n-heptyl 2-deoxy-α-D-mannopyranoside (24) 
 
 
 
Scheme S1. a) PhCH(OMe)2, p-TsOH, DMF, 50 °C, 5 h (94%); b) Bu2Sn(O), toluene, TBAB, BnBr, 
reflux (91%); c) TCDI, DCE, reflux (91%); d) Bu3SnH, toluene, reflux, 6 h (58%); e) 80% aq. AcOH, 80 
°C, 30 min (64%); f) H2 (4 bar), cat. Pd(OH)2/C, rt, (72%). 
 
n-Heptyl 4,6-O-benzylidene-α-D-mannopyranoside (25). To a solution of 1[S4] (527 
mg, 1.89 mmol) in dry DMF (6.0 mL) were added benzaldehyde dimethylacetal (0.56 
mL) and p-TsOH (18 mg) at rt. The reaction mixture was stirred at 50 °C for 5 h, then 
diluted with DCM, washed with 5% aq. NaHCO3 and brine. The organic layer was 
dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 3:1-3:2) to give 25 (650 mg, 
94%) as a glassy solid. 1H NMR (500 MHz, CD3OD): δ = 7.51-7.49 (m, 2H Ar-H), 
7.37-7.33 (m, 3H, Ar-H), 5.60 (s, 1H, CHPh), 4.77 (d, J = 1.0 Hz, 1H, H-1), 4.18 (dd, 
J = 4.5, 10.0 Hz, 1H, H-6a), 3.95-3.90 (m, 2H, H-3, H-4), 3.88 (m, 1H, H-2), 3.81 (t, J 
= 10.0 Hz, 1H, H-6b), 3.76-3.41 (m, 2H, H-5, OCH2), 3.46 (dt, J = 6.5, 9.5 Hz, 1H, 
OCH2), 1.62 (m, 2H, CH2), 1.36 (m, 8H, 4 CH2), 0.91 (t, J = 7.0 Hz, 3H, CH3); 13C 
NMR (126 MHz; CD3OD): δ = 139.31, 129.87, 129.02, 127.52 (Ar-C), 103.36 (CHPh), 
102.59 (C-1), 80.20 (C-3), 72.74 (C-2), 69.87 (C-6), 69.61 (C-4), 68.77 (OCH2), 65.25 
(C-5), 33.01, 30.57, 30.17, 27.29, 23.70 (5 CH2), 14.46 (CH3); ESI-MS: m/z: Calcd for 
C20H30NaO6 [M+Na]+: 389.2, found: 389.1. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (26). To a solution 
of 25 (152 mg, 0.414 mmol) in dry toluene (8 mL) was added dibutyltin oxide (112 
mg, 0.456 mmol) at rt. The suspension was refluxed for 6 h and concentrated to 
dryness under reduced pressure. To a solution of the residue in dry toluene (8 mL) 
were added tetrabutylammonium bromide (TBAB) (147 mg, 0.456 mmol) and benzyl 
O(CH2)6CH31S4
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bromide (59 µL, 0.5 mmol). The mixture was stirred at 95 °C overnight, concentrated 
to dryness, and purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 9:1-4:1) to give 26 (172 mg, 91%) as colorless oil. [α]D20 +34.2 (c 1.43, 
MeOH); 1H NMR (500 MHz, CDCl3): δ = 7.51-7.49 (m, 2H, Ar-H), 7.40-7.33 (m, 8H, 
Ar-H), 5.62 (s, 1H, PhCH), 4.86 (m, 1H, H-1), 4.87 (d, J = 11.5 Hz, 1H, CH2Ph), 4.73 
(d, J = 11.5 Hz, 1H, CH2Ph), 4.27 (m, 1H, H-6a), 4.14-4.06 (m, 2H, H-4, H-2), 3.94 
(dd, J = 3.0, 9.5 Hz, 1H, H-3), 3.88-3.82 (m, 2H, H-5, H-6b), 3.67 (m, 1H, OCH2), 
3.41 (m, 1H, OCH2), 2.64 (s, 1H, OH), 1.57 (m, 2H, CH2), 1.29 (m, 8H, 4 CH2), 0.89 
(t, J = 7.0 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): δ = 138.05, 137.53, 128.90, 
128.45, 128.22, 127.88, 127.77, 126.01 (Ar-C), 101.52 (CHPh), 99.87 (C-1), 78.93 
(C-4), 75.79 (C-3), 73.04 (CH2Ph), 70.10 (C-2), 68.92 (C-6), 67.97 (OCH2), 63.19 (C-
5), 32.75, 29.37, 29.05, 26.04, 22.61 (5 CH2), 14.09 (CH3); HRMS: m/z: Calcd for 
C27H36NaO6 [M+Na]+: 479.2410, found: 479.2414. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-2-O-(thiocarbonylimidazol-1-yl)-α-D-
mannopyranoside (27). A mixture of 26 (210 mg, 0.46 mmol) and N,N’-
thiocarbonyldiimidazole (246 mg, 1.38 mmol) in DCE (5.0 mL) was refluxed 
overnight. The solution was concentrated in vacuo, the residue was diluted with 
DCM, and washed with 1 N aq. HCl and brine. The organic layer was dried over 
Na2SO4 and evaporated to dryness. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 3:1-3:2) to afford 27 (238 mg, 
91%) as yellow oil. [α]D20 -9.8 (c 0.44, CH2Cl2); 1H NMR (500 MHz, CDCl3): δ = 8.39 
(s, 1H, Ar-H), 7.67 (s, 1H, Ar-H), 7.51 (dd, J = 7.5, 2.5 Hz, 2H, Ar-H), 7.42-7.36 (m, 
3H, Ar-H), 7.29-7.27 (m, 5H, Ar-H), 7.07 (d, J = 0.5 Hz, 1H, Ar-H), 5.90 (dd, J = 1.5, 
3.5 Hz, 1H, H-2), 5.67 (s, 1H, CHPh),  5.01 (d, J = 1.5 Hz, 1H, H-1), 4.73 (q, J = 12.0 
Hz, 2H, CH2Ph), 4.31 (dd, J = 4.5, 10.0 Hz, 1H, H-6a), 4.19 (dd, J = 3.5, 10.0 Hz, 1H, 
H-3), 4.04 (t, J = 10.0 Hz, 1H, H-4), 3.94 (td, J = 4.5, 10.0 Hz, 1H, H-5), 3.85 (t, J = 
10.0 Hz, 1H, H-6b), 3.69 (dt, J = 6.5, 9.5 Hz, 1H, OCH2), 3.46 (dt, J = 6.5, 9.5 Hz, 1H, 
OCH2), 1.61 (m, 2H, CH2), 1.31 (m, 8H, 4 CH2), 0.90 (t, J = 7.0 Hz, 3H, CH3); 13C 
NMR (126 MHz, CDCl3): δ = 183.59 (CS), 137.65, 137.17, 131.04, 129.05, 128.37, 
128.24, 127.77, 127.57, 126.07, 109.96 (Ar-C), 101.75 (PhCH), 97.24 (C-1), 79.24 
(C-4), 78.80 (C-2), 73.91 (C-3), 72.87 (CH2Ph), 68.80 (C-6), 68.54 (OCH2), 63.68 (C-
5), 31.73, 29.24, 29.00, 25.93, 22.60 (5 CH2), 14.09 (CH3); HRMS: m/z: Calcd for 
C31H38N2NaO6S [M+Na]+: 589.2348, found: 589.2351. 
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n-Heptyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-mannopyranoside (28). A 
solution of 27 (238 mg, 0.419 mmol) in dry toluene (2 mL) was added dropwise over 
10 min to a stirred solution of refluxing toluene (6 mL) and tributylstannane (0.169 
mL, 0.63 mmol) under argon. The reaction mixture was refluxed for 6 h, then the 
solvent was removed in vacuo and the residue was purified by chromatography on 
silica gel (petroleum ether/EtOAc, 16:1-4:1) to afford 28 (107 mg, 58%) as colorless 
oil. [α]D20 +49.9 (c 1.07, MeOH); 1H NMR (500 MHz, CDCl3): δ = 7.52 (dd, J = 7.5, 2.5 
Hz, 1H, Ar-H), 7.41-7.25 (m, 9H, Ar-H), 5.63 (s, 1H, CHPh), 4.90 (d, J = 3.5 Hz, 1H, 
H-1), 4.86 (d, J = 12.0 Hz, 1H, CH2Ph), 4.69 (d, J = 12.0 Hz, 1H, CH2Ph), 4.26 (dd, J 
= 4.5, 10.0 Hz, 1H, H-6a), 4.05 (ddd, J = 5.0, 9.0, 11.0 Hz, 1H, H-3), 3.83 (m, 1H, H-
5), 3.77 (t, J = 10.0 Hz, 1H, H-6b), 3.70 (t, J = 9.0 Hz, 1H, H-4), 3.62 (dt, J = 6.5, 9.5 
Hz, 1H, OCH2), 3.35 (dt, J = 6.5, 9.5 Hz, 1H, OCH2), 2.28 (ddd, J = 1.0, 5.0, 13.5 Hz, 
1H, H-2e), 1.81 (ddd, J = 3.5, 11.5, 13.5 Hz, 1H, H-2a), 1.58 (m, 2H, CH2), 1.30 (m, 
8H, 4 CH2), 0.89 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): δ = 138.76, 
137.63, 128.84, 128.32, 128.21, 127.62, 127.49, 126.02 (Ar-C), 101.29 (CHPh), 
97.93 (C-1), 83.99 (C-4), 73.12 (C-3), 72.97 (CH2Ph), 69.16 (C-6), 67.65 (OCH2), 
62.89 (C-5), 36.58 (C-2), 31.75, 29.49, 29.08, 26.13, 22.61 (5 CH2), 14.09 (CH3); 
HRMS: m/z: Calcd for C27H36NaO5 [M+Na]+: 463.2460, found: 463.2453. 
 
n-Heptyl 3-O-benzyl-2-deoxy-α-D-mannopyranoside (29). A solution of 28 (66 mg, 
0.15 mmol) in 80% aq. AcOH (1.25 mL) was stirred at 80 °C for 1 h and then 
concentrated to dryness. The residue was purified by chromatography on silica gel 
(petroleum ether/EtOAc, 4:1-3:2) to afford 29 (33.7 mg, 64%), which was directly 
used in the next step. 
 
n-Heptyl 2-deoxy-α-D-mannopyranoside (24). A suspension of 29 (30 mg, 0.085 
mmol) and 10% Pd(OH)2/C (5.2 mg) in MeOH (5.0 mL) was hydrogenated (4 bar H2) 
in a Parr shaker at rt for 5 h. Then, the mixture was filtered through a pad of celite 
and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (DCM/MeOH, 10:1) to give 24 (18 mg, 72%) as a white 
solid. [α]D20 +106.1 (c 0.12, MeOH); 1H NMR (500 MHz, CD3OD): δ = 4.87 (d, J = 2.5 
Hz, 1H, H-1),  3.85-3.79 (m, 2H, H-3, H-6a), 3.70-3.66 (m, 2H, H-6b, OCH2), 3.52 (m, 
1H, H-5), 3.33 (m, 1H, OCH2), 3.23 (t, J = 9.5 Hz, 1H, H-4), 2.04 (dd, J = 5.0, 13.0 
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Hz, 1H, H-2a), 1.62-1.57 (m, 3H, H-2e, CH2), 1.32 (m, 8H, 4 CH2), 0.91 (t, J = 7.0 Hz, 
3H, CH3); 13C NMR (125 MHz, CD3OD): δ = 98.58 (C-1), 73.97 (C-5), 73.34 (C-4), 
69.99 (C-3), 68.26 (OCH2), 62.85 (C-6), 39.00 (C-2), 33.02, 30.70, 30.30, 27.40, 
23.71 (5 CH2), 14.43 (CH3); HRMS: m/z: Calcd for C13H26NaO5 [M+Na]+: 285.1678, 
found: 285.1678. 
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HPLC data of the target compounds: 
 
Method A: System: Beckman Coulter Gold, consisting of pump 126, DAD 168 (190-
400 nm) and auto-sampler 508. Column: Waters Atlantis T3, 3 µm, 2.1 × 100 mm. A: 
H2O + 0.1% TFA; B: MeCN + 0.1% TFA. Gradient: 0% B → 70% B (20 min); 70% B 
(2 min); 70% B → 5% B (3 min); 5% B → 0% B (2 min); flow rate: 0.5 mL/min.  
 
Method B: System: Agilent 1100/1200 with UV detector (190-410 nm) and Waters 
2420 ELSD. Column: Waters Atlantis T3, 3 µm, 2.1 × 100 mm. A: H2O + 0.1% TFA; 
B: H2O/MeCN (90:10) + 0.1% TFA. Detection: UV (214 nm) and light scattering (LS). 
ELSD parameters: Nebulizer control 70%, drift tube temperature 50°C, gas pressure 
50 psi, gain 500. Gradient: 5% B (1 min), 5% B → 70% B (15 min), 70% B (1 min), 
70% B → 5% B (3 min); flow rate: 0.5 mL/min. 
 
Table S1. HPLC data of the target compounds. 
Compound Formula Method 
Retention 
[min] 
Detection Purity [%] 
11a C19H21NO7 A 13.25 254 nm > 99.5 
11b C20H23NO7 A 15.10 254 nm 99.3 
11c C23H27NO8 A 12.63 254 nm 98.6 
11d C19H22O8S A 15.78 254 nm 98.7 
11e C19H23NO8S A 13.17 285 nm 98.9 
11f C18H18F2O7 A 13.43 285 nm > 99.5 
11g C19H19NO6 B 10.68 LS > 99.5 
11h C19H20N4O6 A 12.73 254 nm > 99.5 
11i C20H20N2O7 A 14.73 296 nm > 80a) 
11j C19H18ClNO6 B 9.79 LS > 99.5 
21 C39H30ClNO12 B 12.82 LS 93 
22 C42H36ClN3O12S B 9.89 LS > 99.5 
23 C47H46ClN3O14S B 12.10 LS > 99.5 
24 C13H26O5 B 15.12 LS > 99.5 
 
a) The minor peaks presumably stem from the possible tautomers of the cyanamide substituent. 
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HPLC traces of the target compounds: 
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1H NMR spectra of the synthetic compounds: 
 
1H NMR (500 MHz) of 11a 
 
 
 
1H NMR (500 MHz) of 11b 
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1H NMR (500 MHz) of 11c 
 
 
 
1H NMR (500 MHz) of 11d 
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1H NMR (500 MHz) of 11e 
 
 
 
1H NMR (500 MHz) of 11f 
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1H NMR (500 MHz) of 11g 
 
 
 
1H NMR (500 MHz) of 11h 
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1H NMR (500 MHz) of 11i 
 
 
 
1H NMR (500 MHz) of 11j 
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1H NMR (500 MHz) of 14a 
 
 
 
1H NMR (500 MHz) of 14b 
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1H NMR (500 MHz) of 14c 
 
 
 
1H NMR (500 MHz) of 14d 
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1H NMR (500 MHz) of 14e 
 
 
 
1H NMR (500 MHz) of 14f 
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1H NMR (500 MHz) of 14g 
 
 
 
1H NMR (500 MHz) of 15 
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1H NMR (500 MHz) of 16 
 
 
 
1H NMR (500 MHz) of 21 
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1H NMR (500 MHz) of 22 
 
 
 
1H NMR (500 MHz) of 23 
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1H NMR (500 MHz) of 24 
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Abstract 
 
The increasing resistance against most of the currently available antimicrobials is a 
major challenge in public health. Therefore, new treatment strategies targeting 
alternative mechanisms avoiding selection pressure on bacteria and thereby implying 
a reduced risk of resistance are urgently needed. A promising target for an anti-
virulence therapy is FimH, a mannose-binding adhesin, which is expressed on the 
bacterial surface and is mediating attachment to host urothelial cells. This is the initial 
step for a successful establishment of urinary tract infections (UTIs), predominantly 
caused by uropathogenic Escherichia coli (UPEC). Here, we present a new class of 
highly active anti-adhesion molecules, targeting the virulence factor FimH. All squaric 
acid derivatives showed very high potency in the in vitro cell-based assays. The in 
vitro pharmacokinetic (PK) analysis revealed a candidate with optimal PK parameters 
for i.v. application in the UTI mouse model. The in vivo PK analysis showed a dose 
dependent elevation of urine and plasma concentrations and in the UTI prevention 
study, the colony-forming units in the bladder could be reduced by 5 orders of 
magnitude. Results were compared to ciprofloxacin, with FimH antagonists showing 
a more than one order of magnitude better efficacy compared with standard 
antimicrobial treatment. 
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Introduction 
 
Since the discovery of the first antimicrobials almost a century ago, there is a 
continuous battle between the development of new and the improvement of existing 
antimicrobial drugs and resistant pathogens. Up to date all antibiotics target essential 
bacterial functions (DNA, cell wall structures and their synthesis, protein expression 
or metabolic pathways) and therefore they impose high selection pressure upon 
bacteria, resulting in resistant or multidrug-resistant pathogens, which are difficult to 
treat [1, 2]. Targeting bacterial virulence mechanisms recently gained interest as a 
novel strategy to fight against bacterial infections [3 – 6]. Bacterial virulence factors 
actively cause damage to host tissue and consequently enhance the fitness of the 
infecting microorganism to successfully colonize different niches in the host [5, 6]. If 
these essential functions for colonization are missing, the infectivity of bacteria is 
often impaired. 
 
Urinary tract infection (UTI) is one of the most common infectious disease worldwide 
and is primarily caused by uropathogenic Escherichia coli (UPEC) (70 - 95%) [7, 8]. 
Responsible for the initial colonization are type 1 pili, which are filamentous 
structures expressed on the bacterial surface. These pili allow UPEC to adhere to 
oligomannosides, which are part of the glycoprotein uroplakin Ia on the urinary 
bladder mucosa [9 – 11]. Type 1 pili consist of the four subunits, FimA, forming the 
pilus rod, FimF, FimG and FimH, the latter located at the tip of the pili. As a part of 
the FimH subunit, a carbohydrate-recognition domain (CRD) is responsible for the 
protein-sugar interactions between the bacteria and the host cells in the urinary tract 
[10, 13 – 15]. The adhesion is the first and most crucial step in the infection process 
and prevents the rapid clearance of E. coli from the urinary tract by the bulk flow of 
urine and at the same time, enables the invasion of host cells [9, 10]. α-D-
Mannopyranosides are able to effectively prevent the FimH dependent adhesion, 
hence bacteria are cleared from the urinary tract and no infection can occur [16]. 
 
To date, various classes of mono- and multivalent FimH antagonists were 
investigated in vitro [17], but only a few monovalent α-D-mannopyranosides were 
tested in vivo [15, 18 – 25]. The most promising and recently presented compound 
families are biphenyl [20 - 24], indolinylphenyl and indolylphenyl [25] α-D-
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mannopyranoside derivatives. All compound classes showed high activity in the UTI 
mouse model, being equally effective than antibiotic treatment (ciprofloxacin (CIP) 
[25] or trimethoprim-sulfamethoxazole (TMP-SMZ) [21]). Furthermore, biphenyl 
antagonists applied together with antibiotics were reported to have a synergistic 
effect on the treatment outcome and were able to improve the efficacy of TMP-SMZ 
treatment on catheter associated UTI [24]. 
 
In this communication, we present a new series of squaric acid derivatives, which 
were developed from previosly described squaric acid FimH antagonists [26] to 
improve their pharmacokinetic properties. The squaric acid derivatives were 
investigated for their in vitro efficacy and pharmacokinetics to evaluate their potential 
for in vivo studies. The most potent compound was selected for prevention studies in 
the UTI mouse model and results were compared with a standard antibiotic 
treatment. 
 
 
Results and Discussion 
 
Synthesis of FimH antagonists. Squaric acid derivatives were previously described 
as high affinity FimH antagonists [26], though their PK properties lack in vivo 
bioavailability. Besides high affinity, drug-like pharmacokinetic properties are a 
prerequisite for a successful in vivo application. In the UTI mouse model, 
intravenously or orally available FimH antagonists are required that, once absorbed 
to circulation, are metabolically stable and undergo fast renal elimination. Sufficient 
bioavailability requires a combination of high solubility and permeability to maximize 
absorption and low hepatic clearance to minimize first pass extraction. Furthermore, 
for efficient renal elimination, active and/or passive membrane permeability and low 
re-absorption in the renal tubuli is required in order to reach the target organ, the 
bladder. A new series of squaric acid derivatives was synthesized (Scheme 1) to 
improve the PK properties to allow intravenous (i.v.) and more important per oral 
(p.o.) application. 
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The mannosylated ethyl squarate 5 was synthesized according to a strategy reported 
by Lindhorst et al. [26] (Scheme 1). The known nitrophenyl mannoside 2 [27] was 
deacetylated (→ 3) and reduced to aniline 4 by catalytic hydrogenation on platinum 
dioxide in the presence of morpholine [28]. In contrast to the results obtained by 
Lindhorst et al. [26], the use of palladium on charcoal as catalyst in our hands 
resulted in substantial loss of the chloro-substituent. Finally, treatment of ester 5 with 
primary and secondary amines yielded amides 6a-f in 51-90% ready for biological 
testing. 
 
 
Scheme 1. a) NaOMe/MeOH, 1 h, 86%; c) H2 (1 atm), cat. PtO2, morpholine, MeOH, 45 min, quant; d) 
DES, MeOH, 1 d, 61% [26]; e) HNR1R2, DIPEA, MeOH, 51-90%. 
 
 
In vitro pharmacokinetic characterization. To evaluate wether newly synthesized 
squaric acid derivatives (6a-f) are suitable for in vivo application, their 
physicochemical parameters such as pKa-values, lipophilicity (distribution 
coefficients, logD7.4), solubility and permeability were determined (Table 1). 
 
For in vivo studies, the application of the compound in a physiological solution (PBS) 
without further needs to develop suitable formulations is favorable. Furthermore, for 
absorption in the gastrointestinal tract and then efficient renal excretion high solubility 
is a prerequisite. Due to their hydrophilicity, 5, 6b and 6c showed excellent solubility 
for all tested pH conditions (3.0, 5.0 and 7.4). 6d is well soluble at pH of 3.0 but not at 
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pH of 7.4, a requirement for an i.v. application. 6a and 6d-f have a more lipophilic 
character, consequently they exhibited very poor solubility and are therefore not 
suitable for in vivo studies (Table 1). 
 
For a sucessful treatment of UTI it is essential that FimH antagonists reach the target 
organ (bladder) by renal clearance. The estimated negative logD7.4 in the range of -
0.45 to -1.33 and pKa values of approximately 10 for antagonists 6a-c is expected to 
fulfill these specifications for an efficient renal elimination and a low re-absorption 
[29]. The logD7.4 for all other tested antagonists (5 and 6d-f) showed positive values, 
predicting lower renal excretion and high re-absorption in the kidneys (Table 1). 
 
For later use in patients, oral application is eligible. To determine oral availability of 
the squaric acid derivatives a parallel artificial membrane permeation assay (PAMPA) 
[30] was carried out. To allow oral absorption, logPe values above -5.7 and/or 
membrane retention above 80% [31] are required, however although compounds 6d-
f have a more lipophilic behavior, intended to improved their permeability, the 
corresponding values for all tested squaric acid derivatives (5 and 6a-f) showed that 
permeation is not expected. 
 
Based on these in vitro PK parameters, only antagonists 6b and 6c fulfill the 
requirements for i.v. application in the UTI mouse model. The other antagonists are 
predicted either to be re-absorbed in the kidneys (5, 6d-f) or insoluble (6a, 6d-f), 
making them unsuitable for in vivo studies. All tested squaric acid derivatives are not 
permeable and therefore not suited for oral application. 
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Table 1. Pharmacokinetic paramters of FimH antagonists. Passive permeation through an artificial 
membrane and retention were determined by PAMPA (parallel artificial membrane permeation assay). 
Distribution coefficients (logD7.4 values) were measured by a miniaturized shake flask procedure. pKa 
values were determined by NMR spectroscopy. Thermodynamic solubility was measured by an 
equilibrium shake flask approach. Pe: effective permeation; n.p.: not permeable; n.d.: not detected. 
Compound Structure 
PAMPA 
logPe 
[cm/s] 
logD7.4 
(mean ±  
SD) 
pKa 
Solubility 
[µg/ml]/pH 
5 
(OS-394) 
 
n.p. 0.09 ± 0.04 9.3 
> 150 / 3.0 
> 150 / 5.0 
> 150 / 7.4 
6a 
(OS-420) 
 
n.p. -0.45 ± 0.07 10.1 
42.8±4.2 / 3.0 
42.0±1.3 / 5.0 
40.8±2.1 / 7.4 
6b 
(OS-421) 
 
n.p. -1.33 ± 0.14 
6.4 
9.3 
> 150 / 3.0 
> 150 / 5.0 
> 150 / 7.4 
6c 
(OS-464) 
 
n.p. -1.13 ± 0.12 9.4 
> 150 / 3.0 
> 150 / 5.0 
> 150 / 7.4 
6d 
(OS-396) 
 
n.p. 0.80 ± 0.10 
5.7 
9.2 
> 150 / 3.0 
90.2±8.6 / 5.0 
23.0±1.0 / 7.4 
6e 
(OS-395) 
 
n.p. 1.05 ± 0.04 10.0 
14.6±1.2 / 3.0 
15.8±1.4 / 5.0 
15.9±0.9 / 7.4 
6f 
(OS-397) 
 
n.p. 1.12 ± 0.04 n.d. 
4.3±0.4 / 3.0 
4.2±0.1 / 5.0 
3.9±0.2 / 7.4 
 
 
Evaluation of the in vitro potency. For the evaluation of the in vitro potency of the 
squaric acid derivatives two cell-based assay formats have been developed, an 
aggregation assay [32] and a flow cytometry based infection assay [33]. In the 
aggregometry assay, the potential of the FimH antagonists to disaggregate E. coli 
from guinea pig erythrocytes (GPE) was determined. Antagonists were measured in 
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triplicates and the corresponding IC50 values were calculated by plotting the area 
under the curve (AUC) of disaggregation against the concentration of the 
antagonists. In the flow cytometry based infection assay, human bladder cells (5637) 
were infected with GFP labeled UPEC (UTI89), which were pre-incubated with FimH 
antagonists, followed by flow cytomertry analysis of 10’000 bladder cells. The IC50 
values were calculated by plotting the mean fluorescent intensity (MFI) of the cells 
against the concentration of the antagonists. The background was determined using 
the GFP labeled type 1 pili deficient UPEC strain UTI89 ∆fimA-H. 
 
Table 2. IC50 values of the squaric acid derivatives measured by aggregometry (hemagglutination) 
and flow cytometry based infection assay. The relative inhibitory potencies (RIPs) were calculated 
compared to the reference compound 7 (n-heptyl α-D-mannopyranoside). RIPagg: relative inhibitory 
potency of the aggregometry assay, RIPfc: relative inhibitory potency of the flow cytometry infection 
assay, n.d.: not determined. 
Compound 
Aggregometry 
[µM] 
RIPagg 
Flow Cytometry 
[µM] 
RIPfc 
7 77.1 ± 8.7 1 3.9 ± 1.6 1 
5 (OS-394) 0.85 ± 0.13 91 0.035 ± 0.008 111 
6a (OS-420) 3.3 ± 1.3 23 0.13 ± 0.02 30 
6b (OS-421) 5 ± 1.3 15 0.11 ± 0.2 35 
6c (OS-464) 5.3 ± 2.3 15 0.12 ± 0.06 33 
6d (OS-396) 4.5 ± 1.2 17 n.d. - 
6e (OS-395) 4.4 ± 0.5 18 n.d. - 
6f (OS-397) 1.9 ± 0.5 41 0.09 ± 0.01 44 
 
 
n-Heptyl α-D-mannopyranoside (7) was used as reference compound [15]. All 
squaric acid derivatives showed high activity in the low µM range in the 
aggregometry and in the nM range in the flow cytometry assay, respectively (Table 
2). Results of the two assay formats correlate well. 
 
The aim of our project was the identification of FimH antagonists suitable for 
intravenous (i.v.) or preferably oral (p.o.) application in the UTI mouse model. In vitro 
PK studies revealed that this series of squaric acid derivatives are not orally available 
but once in circulation they are predicted to be highly renally excreted and are 
therefore suitable for i.v. application. All antagonists exhibit similar binding potencies. 
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However, compound 6b was chosen for in vivo studies because of its optimal in vitro 
PK properties (high solubility and renal permeation). 
 
In vivo pharmacokinetics and efficacy. To evaluate the availability of the 
antagonist in the bladder, the in vivo pharmacokinetic parameters were determined. 
Therefore, plasma and urine concentrations of 6b after single i.v. applications were 
measured. With dosages of 25, 50 and 100 mg/kg, 6b showed an availability in the 
bladder over a period of 4 h after administration (Figure 1). Higher availability of the 
antagonist in the urine was observed compared to the plasma indicating the fast 
renal clearance. 
 
Dosage Compartment 
AUC0-24 i.v. 
[µg x h/mL] 
25 mg/kg 
Plasma 
Urine 
6.6 ± 3.3 
3518 ± 2083 
50 mg/kg 
Plasma 
Urine 
23.4 ± 11.9 
4660 ± 1909 
100 mg/kg 
Plasma 
Urine 
6.7 ± 1.8 
11183 ± 2386 
 
    
Figure 1. Determination of antagonist concentration in urine and plasma after a single i.v. application 
of 25, 50 and 100 mg/kg of 6b. The data (table and graphs) show time-dependent urine and plasma 
concentrations. 
 
 
A dose dependent elevation of the AUC0-24 i.v. values in urine was observed, however 
although there is a linear correlation between 50 and 100 mg/kg (4660 vs. 11183 µg 
x h/mL), no correlation between 25 and 50 mg/kg (3518 vs. 4660 µg x h/mL) was 
observed. Once applied, the antagonist is rapidly renally excreted, which is favored 
for the treatment of UTI, because it enables high availability in the target organ. 
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Simultaneously, fast renal excretion is also a drawback, because it limits the 
exposure time in the bladder. 
 
For the in vivo UTI treatment studies, different concentrations of 6b (25, 50 and 100 
mg/kg) were applied 10 minutes prior to infection with UPEC (UTI89). The results 
were compared to ciprofloxacin (CIP), used as a standard antibiotic therapy against 
UTI [34] at a dosage of 8 mg/kg, representing the murine dose equivalent to a human 
standard dose [35]. For each treatment study, a group of 6 animals were used. The 
animals were sacrificed 3 h after inoculation and urine and homogenized organs 
(bladder, kidneys) were examined for bacterial counts. The mean values in the 
untreated reference group showed 1.6 x 107 CFU/ml in the urine, 7.8 x 107 CFU in 
the bladder and 6.7 x 106 CFU in the kidneys. The bar diagram in Figure 2 
summarizes the reduction of bacterial counts after i.v. treatment of 6b and CIP. The 
baseline represents the values obtained for the control group and was used as 
reference for CFU reductions. 
 
 
Figure 2. Treatment efficacy of 6b (25, 50, 100 mg/kg) and CIP (8 mg/kg) in the UTI mouse model 
after 3 hours of infection (n = 6). 6b was applied i.v. into the tail vein, whereas CIP was applied 
subcutaneously (s.c) into the neck. As baseline (reference), the mean counts of mice treated with PBS 
only were subtracted from the results of the tested antagonists. 
 
 
Infection studies (Figure 2) showed that antagonist 6b at a dosage of 25 mg/kg 
exhibited -1 log10 CFU in the urine, -4.5 log10 CFU in the bladder and -2 log10 CFU in 
the kidneys. 50 mg/kg resulted in a reduction of bacterial counts of -2.5 log10 CFU in 
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the urine, a substantial decrease of bacteria in the bladder of -5 log10 CFU and -3.8 
log10 CFU in the kidneys. Surprisingly, the highest dosage of 6b (100 mg/kg) showed 
only a minor reduction of bacterial counts in the urine (-0.5 log10 CFU), -4 log10 CFU 
in the bladder and -2.5 log10 CFU in the kidneys. The comparison with standard 
antibiotic treatment with CIP [34, 35] showed a reduction of the bacterial counts in 
the bladder by -3.7 log10 CFU, thus being less potent than all tested concentrations of 
6b, and -4 log10 CFU in the kidneys. The large differences in CFU counts in urine, 
bladder and kidneys were found probably due to sampling problems and different 
adhesion mechanisms (see below). 
 
Our in vivo PK studies revealed high availability of 6b in the urine of mice and 
treatment studies resulted in a substantial decrease of bacteria in the bladder. As 
mentioned in previous publications [20, 25], urine samples showed higher bacterial 
counts and larger standard deviations compared to the bladder (Figure 2). This could 
be due to difficulties during urine sampling and varying urine volumes, leading to 
either a concentration or dilution of bacteria in the samples. Consequently, the lower 
urine volume leads to a higher concentration of bacteria in the collected urine and 
furthermore, non-adherent bacteria, which were detached from the bladder and 
kidneys after application of the FimH antagonists, accumulate in the urine. The 
bacterial concentration in the urine of mice treated with antibiotics was excluded, 
because of the bactericidal activity of CIP no viable bacteria were found in the urine. 
 
Also kidney counts were reduced to a lower extend in all treated animals (Figure 2), 
probably due to different bacterial adhesion mechanisms in bladder and kidneys 
(mannose dependent type 1 pili vs. galactose dependent P pili interactions) [12]. 
Furthermore, in patients, UTI is an ascending infection, which is usually initiated by 
bacteria ascending from the periurethral area into the urinary tract [36] or by 
spreading of quiescent intracellular bacteria in the bladder [37]. If a FimH antagonist 
is applied at this stage of infection, ascending bacteria are hindered, hence less 
kidney infections should occur. In the UTI mouse model, the application of bacteria 
directly into the bladder and concomitantly also into the kidneys (vesicourethral reflux 
(VUR)) during the inoculation process is a prevalent problem [38], hence high kidney 
counts were already observed 3 h after infection (negative control, 6.7 x 106 CFU). 
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Due to the above mentioned problems with bacterial counts in urine and kidneys, 
evaluation of the efficacy of FimH antagonists was exclusively limited to bladder 
counts. Organs were immediately frozen on dry ice after collection and plated within 
1 h after thawing. Within this hour of organ processing (homogenization, plating) CIP 
was also present in the samples and able to further kill extra cellular bacteria in the 
organ samples, which could additionally reduce bacterial counts in the bladder and 
kidneys compared to FimH antagonists. 
 
6b at a dosage of 50 mg/kg, reduced bacterial counts in the bladder by -5 log10 CFU 
(Figure 2), which is an over 1 log10 more efficient reduction than standard antibiotic 
treatment (CIP). One reason could be the more direct mode of action of FimH 
antagonists, that once present in the bladder, are able to immediately bind to their 
target (FimH), detaching bacteria from the bladder wall and inhibiting further 
adhesion. In comparison, ciprofloxacin needs longer time to deploy its mode of 
action, because it first has to penetrate the cell wall of the bacteria to reach its 
intracellular target (bacterial DNA gyrase). The direct mode of action is a key 
advantage of the FimH antagonists compared to antibiotics for treatment of UTI and 
might explain their higher efficacy in the mouse model. 
 
 
Conclusion 
 
Therapeutic targeting of bacterial virulence factors gained interest during the last few 
years as an alternative to antibiotics. Aiming the development of a new treatment 
against UTI targeting type 1 pili, we have synthesized a series of potent small 
molecular weight FimH antagonists. Starting from the known squaric acid derivative 
(5), six equally potent derivatives were synthesized (6a-f). According to their 
pharmacokinetic properties, all the squaric acid derivatives were predicted not to be 
orally available. 6b was chosen for i.v. application in animal studies (PK and 
infection) because of ist superior pharmacokinetic properties, i.e. high solubility and 
was predicted to be renally permeable. In vivo PK studies in mice exhibited a fast 
renal excretion of 6b to the target organ, the bladder. In the UTI mouse model, the 
colony forming units (CFU) in homogenized bladders were reduced by five orders of 
magnitude. Furthermore, a comparison with ciprofloxacin, used as standard 
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antimicrobial in the clinics, showed, that 6b was more than one log10 unit more 
potent. This indicates the therapeutic potential of α-D-mannopyranosides for a 
successful treatment of UTI, resulting in less resistance problems. 
 
However, the drawback of the squaric acid family of FimH antagonists, is their 
missing oral availability. In addition, due to fast renal elimination, the exposure time 
of 6b in the bladder is limited to approximately 4 h. An improvement of the 
corresponding pharmacokinetic parameters should allow the oral application and 
positively influence the duration of action for an optimal treatment of urinary tract 
infection. 
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Experimental Section 
 
Methods 
FimH antagonist. n-Heptyl α-D-mannopyranoside was synthesized as described in 
[32]. 
 
Synthesis 
2-Chloro-4-nitrophenyl α-D-mannopyranoside (3). To a solution of 2 (748 mg, 
1.49 mmol) in MeOH (15 mL) was added 0.5 M NaOMe/MeOH (1.0 mL) under argon. 
The mixture was stirred at rt for 1 h, then neutralized with Dowex 50X8 (H+) ion-
exchange resin, filtered, and concentrated in vacuo. The residue was purified by 
MPLC on silica (DCM/MeOH) to afford 3 (430 mg, 86%) as a yellowish solid. 
1H NMR (500 MHz, CD3OD): δ 3.49 (ddd, J = 2.3, 5.9, 9.6 Hz, 1H, H-5), 3.68 (dd, J = 
5.9, 12.1 Hz, 1H, H-6a), 3.74 (t, J = 9.7 Hz, 1H, H-4), 3.77 (dd, J = 2.3, 12.1 Hz, 1H, 
H-6b), 3.97 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 4.11 (dd, J = 1.9, 3.3 Hz, 1H, H-2), 5.75 (d, 
J = 1.5 Hz, 1H, H-1), 7.57 (d, J = 9.2 Hz, 1H, C6H3), 8.19 (dd, J = 2.7, 9.2 Hz, 1H, 
C6H3), 8.32 (d, J = 2.7 Hz, 1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 62.6 (C-6), 
68.0 (C-4), 71.5 (C-2), 72.3 (C-3), 76.5 (C-5), 100.6 (C-1), 117.0, 124.9, 124.9, 
126.7, 143.6, 158.1 (C6H3); ESI-MS Calcd for C12H14ClNNaO8 [M+Na]+: 358.03, 
Found: 357.98. 
 
4-Amino-2-chlorophenyl α-D-mannopyranoside (4). A suspension of 3 (430 mg, 
1.28 mmol), morpholine (30 µL) and PtO2 (50 mg) in MeOH (20 mL) was 
hydrogenated (1 atm H2) for 45 min. Then the mixture was filtered and concentrated 
in vacuo to give crude 4 (443 mg) as a colorless oil, which contained approx. 15% 
morpholine and was used in the next step without further purification. 
1H NMR (500 MHz, CD3OD): δ 3.71-3.81 (m, 3H, H-4, H-5, H-6a), 3.83 (dd, J = 1.7, 
12.7 Hz, 1H, H-6b), 3.95 (dd, J = 3.4, 9.1 Hz, 1H, H-3), 4.11 (dd, J = 1.8, 3.4 Hz, 1H, 
H-2), 5.27 (d, J = 1.7 Hz, 1H, H-1), 6.61 (dd, J = 2.7, 8.7 Hz, 1H, C6H3), 6.78 (d, J = 
2.7 Hz, 1H, C6H3), 7.09 (d, J = 8.7 Hz, 1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 
62.6 (C-6), 68.4 (C-4), 71.9 (C-2), 72.3 (C-3), 75.7 (C-5), 102.1 (C-1), 115.7, 117.4, 
121.2, 153.2 (6C, C6H3); ESI-MS Calcd for C12H17ClNO6 [M+H]+: 306.07, Found: 
306.02. 
 
MANUSCRIPT I 
 
224 
2-Chloro-4-[(2-ethoxy-3,4-dioxocyclobuten-1-yl)amino]phenyl α-D-
mannopyranoside (5) [26]. To a solution of 4 (443 mg) in MeOH (15 ml) was added 
diethyl squarate (379 µL, 2.56 mmol) under argon and the reaction mixture was 
stirred at rt for 1 d. Then, the solvent was removed in vacuo and the residue was 
purified by MPLC on RP-18 (H2O/MeOH) to yield 5 (337 mg, 61% from 3) as a yellow 
solid. 
1H NMR (500 MHz, CD3OD): δ 1.47 (t, J = 7.1 Hz, 3H, OCH2CH3), 3.66 (dt, J = 3.7, 
9.9 Hz, 1H, H-5), 3.75 (d, J = 3.7 Hz, 2H, H-6), 3.79 (t, J = 9.8 Hz, 1H, H-4), 4.00 (dd, 
J = 3.4, 9.6 Hz, 1H, H-3), 4.16 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.81 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 5.56 (d, J = 1.5 Hz, 1H, H-1), 7.23 (m, 1H, C6H3), 7.32 (d, J = 9.0 Hz, 1H, 
C6H3), 7.47 (s, 1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 15.7 (OCH2CH3), 61.4 (C-
6), 67.2 (C-4), 70.8 (C-2), 71.4 (C-3), 71.6 (OCH2CH3), 74.9 (C-5), 100.0 (C-1), 
119.2, 120.2, 122.4, 124.7, 134.6, 152.5 (C6H3), 168.9, 176.2 (C=C), 183.3, 186.9 (2 
CO); ESI-MS Calcd for C18H21ClNO9 [M+H]+: 430.09, Found: 430.13. 
 
General procedure for the synthesis of mannosylated squaric acid amides 6a-f. 
The squaric acid monoester 5 (1.0 eq) was dissolved in MeOH (1 mL/10 mg of 5) at 
50°C. After cooling to rt, the amine (1.5 eq) and DIPEA (20 µL/10 mg of 5) were 
added and the reaction mixture was stirred overnight at rt. Then the solvent was 
removed in vacuo and the residue was purified by MPLC on RP-18 (H2O/MeOH) or 
by LC-MS (RP-18, H2O/MeCN + 0.2% HCO2H) to give compounds 6a-f as a white 
powder after a final lyophilization from H2O/dioxane. 
 
2-Chloro-4-[(2-(ethylamino)-3,4-dioxocyclobuten-1-yl)amino]phenyl α-D-
mannopyranoside (6a). Following the general procedure, 5 (30.0 mg, 69.6 µmol) 
was treated with ethylamine hydrochloride (8.51 mg, 104 µmol) and DIPEA (60 µL) in 
MeOH (3 mL) to yield 6a (15.4 mg, 51%) after purification by LC-MS. 
[α]D +84.4 (c 0.10, MeOH); 1H NMR (500 MHz, CD3OD): δ 1.30 (t, J = 7.2 Hz, 3H, 
CH3), 3.65-3.75 (m, 5H, H-4, H-5, H-6a, NCH2), 3.80 (dd, J = 2.0, 11.8 Hz, 2H, H-6b), 
3.95 (dd, J = 3.4, 9.3 Hz, 1H, H-3), 4.09 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 5.46 (d, J = 
1.4 Hz, 1H, H-1), 7.27 (dd, J = 2.6, 8.9 Hz, 1H, C6H3), 7.34 (d, J = 8.9 Hz, 1H, C6H3), 
7.61 (bs, 1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 16.3 (CH3), 40.2 (NCH2), 62.2 
(C-6), 67.7 (C-4), 71.3 (C-2), 71.9 (C-3), 75.5 (C-5), 100.8 (C-1), 119.0, 119.3, 121.2, 
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125.0, 135.8, 150.1 (C6H3), 164.6, 169.1 (C=C), 183.0, 185.8 (2 CO); HR-MS Calcd 
for C18H21ClN2NaO8 [M+Na]+: 451.0884, Found: 451.0882. 
 
2-Chloro-4-[(2-(4-methylpiperazin-1-yl)-3,4-dioxocyclobuten-1-yl)amino]phenyl 
α-D-mannopyranoside (6b). Following the general procedure, 5 (72.5 mg, 0.169 
mmol) was treated with 1-methylpiperazine (28.0 µL, 0.252 mmol) and DIPEA (145 
µL) in MeOH (7.5 mL) to yield 6b (73.9 mg, 90%) after purification by MPLC on RP-
18 (H2O/MeOH). 
[α]D +74.5 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): δ 2.47 (s, 3H, NCH3), 2.76 
(m, 4H, 2 CH2), 3.66 (ddd, J = 2.1, 5.6, 9.8 Hz, 1H, H-5), 3.71 (dd, J = 5.6, 11.8 Hz, 
2H, H-6a), 3.74 (t, J = 9.7 Hz, 1H, H-4), 3.79 (dd, J = 2.1, 11.8 Hz, 2H, H-6b), 3.88 
(m, 4H, 2 CH2), 3.96 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 4.09 (dd, J = 1.8, 3.3 Hz, 1H, H-
2), 5.48 (d, J = 1.4 Hz, 1H, H-1), 7.15 (dd, J = 2.7, 8.9 Hz, 1H, C6H3), 7.33 (d, J = 8.9 
Hz, 1H, C6H3), 7.35 (d, J = 2.7 Hz, 1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 45.4 
(NCH3), 47.4 (2C, 2 CH2), 55.0 (2C, 2 CH2), 62.7 (C-6), 68.2 (C-4), 71.8 (C-2), 72.3 
(C-3), 76.0 (C-5), 101.2 (C-1), 119.0, 121.6, 123.8, 125.0, 135.1, 150.2 (C6H3), 164.9, 
169.2 (C=C), 183.3, 185.9 (2 CO); HR-MS Calcd for C21H26ClN2NaO8 [M+Na]+: 
506.1306, Found: 506.1303. 
 
2-Chloro-4-[(2-morpholino-3,4-dioxocyclobuten-1-yl)amino]phenyl α-D-
mannopyranoside (6c). Following the general procedure, 5 (18.1 mg, 42.2 µmol) 
was treated with morpholine (5.6 µL, 63 µmol) and DIPEA (50 µL) in MeOH (2.5 mL) 
to yield 6c (14.5 mg, 73%) after purification by MPLC on RP-18 (H2O/MeOH). 
[α]D +82.2 (c 0.52, MeOH); 1H NMR (500 MHz, CD3OD): δ 3.66 (ddd, J = 2.0, 5.4, 9.6 
Hz, 1H, H-5), 3.70-3.84 (m, 11H, H-4, H-6, 4 CH2), 3.96 (dd, J = 3.3, 9.5 Hz, 1H, H-
3), 4.09 (dd, J = 1.8, 3.0 Hz, 1H, H-2), 5.47 (d, J = 1.2 Hz, 1H, H-1), 7.14 (dd, J = 2.7, 
8.8 Hz, 1H, C6H3), 7.31 (d, J = 9.0 Hz, 1H, C6H3), 7.34 (d, J = 2.7 Hz, 1H, C6H3); 13C 
NMR (125 MHz, CD3OD): δ 48.9 (2C, 2 NCH2), 62.7 (C-6), 67.7 (2C, 2 OCH2), 68.2 
(C-4), 71.9 (C-2), 72.4 (C-3), 76.0 (C-5), 101.2 (C-1), 118.9, 121.5, 123.7, 125.0, 
135.2, 150.1 (C6H3), 164.5, 169.3 (C=C), 183.0, 186.0 (2 CO); HR-MS Calcd for 
C20H23ClN2NaO9 [M+Na]+: 493.0990, Found: 493.0990. 
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4-[(2-(4-Benzylpiperazin-1-yl)-3,4-dioxocyclobuten-1-yl)amino]-2-chlorophenyl 
α-D-mannopyranoside (6d). Following the general procedure, 5 (50.0 mg, 0.116 
mmol) was treated with 1-benzylpiperazine (30.2 µL, 0.174 mmol) and DIPEA (100 
µL) in MeOH (5 mL) to yield 6d (46.9 mg, 72%) after purification by LC-MS. 
[α]D +72.3 (c 0.40, MeOH); 1H NMR (500 MHz, CD3OD): δ 2.74 (m, 4H, 2 CH2), 3.66 
(ddd, J = 2.3, 5.5, 9.8 Hz, 1H, H-5), 3.70-3.75 (m, 4H, H-4, H-6a, CH2Ph), 3.78 (dd, J 
= 2.2, 12.4 Hz, 2H, H-6b), 3.85 (m, 4H, 2 CH2), 3.96 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 
4.10 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 5.46 (d, J = 1.5 Hz, 1H, H-1), 7.12 (dd, J = 2.6, 
8.9 Hz, 1H, C6H3), 7.28 (d, J = 8.9 Hz, 1H, C6H3), 7.30-7.38 (m, 6H, C6H3, C6H5); 13C 
NMR (125 MHz, CD3OD): δ 48.0 (2C, 2 CH2), 53.4 (2C, 2 CH2), 62.7 (C-6), 63.3 
(CH2Ph), 68.2 (C-4), 71.8 (C-2), 72.4 (C-3), 75.9 (C-5), 101.2 (C-1), 118.9, 121.5, 
123.7, 125.0, 129.0, 129.6, 130.8, 135.9, 136.8, 150.1 (12C, C6H3, C6H5), 164.6, 
169.1 (C=C), 183.0, 185.8 (2 CO); HR-MS Calcd for C27H30ClN2NaO8 [M+Na]+: 
582.1619, Found: 582.1619. 
 
4-[(2-(Benzylamino)-3,4-dioxocyclobuten-1-yl)amino]-2-chlorophenyl α-D-
mannopyranoside (6e). Following the general procedure, 5 (50.0 mg, 0.116 mmol) 
was treated with benzyl amine (19.0 µL, 0.174 mmol) and DIPEA (100 µL) in MeOH 
(5 mL) to yield 6e (38.9 mg, 68%) after purification by LC-MS. 
[α]D +74.0 (c 0.20, MeOH); 1H NMR (500 MHz, CD3OD): δ 3.66 (ddd, J = 2.2, 5.6, 9.8 
Hz, 1H, H-5), 3.70 (dd, J = 5.6, 11.8 Hz, 2H, H-6a), 3.73 (t, J = 9.7 Hz, 1H, H-4), 3.79 
(dd, J = 2.2, 11.8 Hz, 2H, H-6b), 3.94 (dd, J = 3.4, 9.3 Hz, 1H, H-3), 4.09 (dd, J = 1.8, 
3.4 Hz, 1H, H-2), 4.87 (s, 2H, CH2Ph), 5.45 (d, J = 1.7 Hz, 1H, H-1), 7.25 (dd, J = 
2.7, 8.9 Hz, 1H, C6H3), 7.30-7.33, 7.37-7.39 (m, 6H, C6H3, C6H5), 7.58 (d, J = 2.0 Hz, 
1H, C6H3); 13C NMR (125 MHz, CD3OD): δ 49.3 (CH2Ph), 62.7 (C-6), 68.3 (C-4), 71.9 
(C-2), 72.4 (C-3), 76.0 (C-5), 101.3 (C-1), 119.6, 121.8, 125.7, 128.8, 129.0, 130.0, 
135.5, 139.4, 149.8 (12C, C6H3, C6H5), 165.1, 173.3 (C=C), 182.4, 183.8 (2 CO); HR-
MS Calcd for C23H23ClN2NaO8 [M+Na]+: 513.1041, Found: 513.1039. 
 
2-Chloro-4-[(3,4-dioxo-2-(phenylamino)cyclobuten-1-yl)amino]phenyl α-D-
mannopyranoside (6f). Following the general procedure, 5 (50.0 mg, 0.116 mmol) 
was treated with aniline (15.9 µL, 0.174 mmol) and DIPEA (100 µL) in MeOH (5 mL) 
to yield 6f (30.7 mg, 56%) after purification by LC-MS. 
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[α]D +75.0 (c 0.19, MeOH); 1H NMR (500 MHz, CD3OD): δ 3.67 (ddd, J = 2.3, 5.5, 9.6 
Hz, 1H, H-5), 3.73 (dd, J = 5.5, 11.8 Hz, 2H, H-6a), 3.75 (t, J = 9.7 Hz, 1H, H-4), 3.80 
(dd, J = 2.3, 11.9 Hz, 2H, H-6b), 3.96 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 4.10 (dd, J = 1.8, 
3.3 Hz, 1H, H-2), 5.48 (d, J = 1.6 Hz, 1H, H-1), 7.11 (t, J = 7.4 Hz, 1H, C6H5), 7.34-
7.37 (m, 4H, C6H3, C6H5), 7.49 (d, J = 7.8 Hz, 2H, C6H5), 7.67 (s, 1H, C6H3); 13C NMR 
(125 MHz, CD3OD): δ 61.0 (C-6), 66.6 (C-4), 70.0 (C-2), 70.6 (C-3), 75.4 (C-5), 99.9 
(C-1), 118.4, 118.6, 118.7, 120.2, 123.3, 123.4, 129.4, 133.9, 138.6, 147.7 (12C, 
C6H3, C6H5), 165.4, 165.6 (C=C), 181.5, 181.8 (2 CO); HR-MS Calcd for 
C22H21ClN2NaO8 [M+Na]+: 499.0884, Found: 499.0883. 
 
 
In vitro pharmacokinetics 
Materials 
Dimethyl sulfoxide (DMSO), 1-propanol, and 1-octanol were purchased from Sigma-
Aldrich (Sigma-Aldrich, St. Louis MI, USA). PAMPA System Solution, GIT-0 Lipid 
Solution, and Acceptor Sink Buffer were ordered from pIon (pIon, Woburn MA, USA). 
Acetonitrile (MeCN) was bought from Acros (Acros Organics, Geel, Belgium).  
 
LogD7.4 determination. The in silico prediction tool ALOGPS [39] was used to 
estimate the logP values of the compounds. Depending on these values, the 
compounds were classified into three categories: hydrophilic compounds (logP below 
zero), moderately lipophilic compounds (logP between zero and one) and lipophilic 
compounds (logP above one). For each category, two different ratios (volume of 1-
octanol to volume of buffer) were defined as experimental parameters (Table 3).  
 
 
Table 3 
Compound type logP 
Ratios (1-octanol: 
buffer) 
hydrophilic < 0 30:140, 40:130 
moderately 
lipophilic 
0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
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Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and 
shaken vigorously for 5 min to saturate the phases. The mixture was left until 
separation of the two phases occurred, and the buffer was retrieved. Stock solutions 
of the test compounds were diluted with buffer to a concentration of 1 µM. For each 
compound, six determinations, i.e., three determinations per 1-octanol:buffer ratio, 
were performed in different wells of a 96-well plate. The respective volumes of buffer 
containing analyte (1 µM) were pipetted to the wells and covered by saturated 1-
octanol according to the chosen volume ratio. The plate was sealed with aluminium 
foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidoph Titramax 1000 plate-shaker 
(Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and centrifuged 
(2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The 
aqueous phase was transferred to a 96-well plate for analysis by liquid 
chromatography-mass spectrometry (LC-MS).  
 
logD7.4 was calculated from the 1-octanol:buffer ratio (o:b), the initial concentration of 
the analyte in buffer (1 µM), and the concentration of the analyte in buffer (cB) with 
equation:  
€ 
logD7.4 = log
1µM − cB
cB
×
1
o :b
$ 
% 
& 
' 
( 
) 
The average of the three logD7.4 values per 1-octanol:buffer ratio was calculated. If 
the two mean values obtained for a compound did not differ by more than 0.1 unit, 
the results were accepted. 
 
Parallel artificial membrane permeation assay (PAMPA). logPe was determined in 
a 96-well format with the PAMPA [30] permeation assay. For each compound, 
measurements were performed at three pH values (5.0, 6.2, 7.4) in quadruplicates. 
For this purpose, 12 wells of a deep well plate, i.e., four wells per pH-value, were 
filled with 650 µL System Solution. Samples (150 µL) were withdrawn from each well 
to determine the blank spectra by UV-spectroscopy (SpectraMax 190, Molecular 
Devices, Silicon Valley Ca, USA). Then, analyte dissolved in DMSO was added to 
the remaining System Solution to yield 50 µM solutions. To exclude precipitation, the 
optical density was measured at 650 nm, with 0.01 being the threshold value. 
Solutions exceeding this threshold were filtrated. Afterwards, samples (150 µL) were 
withdrawn to determine the reference spectra. Further 200 µL were transferred to 
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each well of the donor plate of the PAMPA sandwich (pIon, Woburn MA, USA, P/N 
110 163). The filter membranes at the bottom of the acceptor plate were impregnated 
with 5 µL of GIT-0 Lipid Solution and 200 µL of Acceptor Sink Buffer were filled into 
each acceptor well. The sandwich was assembled, placed in the GutBoxTM, and left 
undisturbed for 16 h. Then, it was disassembled and samples (150 µL) were 
transferred from each donor and acceptor well to UV-plates. Quantification was 
performed by both UV-spectroscopy and LC-MS. logPe-values were calculated with 
the aid of the PAMPA Explorer Software (pIon, version 3.5). 
 
pKa values. The pKa values were determined as described elsewhere [40]. Briefly, 
the pH of a sample solution was gradually changed and the chemical shift of protons 
adjacent to ionizable centers was monitored by 1H nuclear magnetic resonance 
(NMR) spectroscopy. The shift was plotted against the pH of the respective sample 
and the pKa was read out from the inflection point of the resulting sigmoidal curve. 
 
Solubility. Solubility was determined in a 96-well format using the µSOL Explorer 
solubility analyzer (pIon, version 3.4.0.5). For each compound, measurements were 
performed at three pH values (3.0, 5.0, 7.4) in triplicates. For this purpose, nine wells 
of a deep well plate, i.e. three wells per pH value, were filled with 300 µL of an 
aqueous universal buffer solution. Aliquots (3 µL) of a compound stock solution (40-
100 mM in DMSO) were added and thoroughly mixed. The final sample 
concentration was 0.4-1.0 mM, the residual DMSO concentration was 1.0% (v/v) in 
the buffer solutions. After 15 h, the solutions were filtrated (0.2 µm 96-well filter 
plates) using a vacuum to collect manifold (Whatman Ltd., Maidstone, UK) to remove 
any precipitates. Equal amounts of filtrate and n-propanol were mixed and 
transferred to a 96-well plate for UV detection (190 to 500 nm). The amount of 
material dissolved was calculated by comparison with UV spectra obtained from 
reference samples, which were prepared by dissolving compound stock solution in a 
1:1 mixture of buffer and n-propanol (final concentrations 0.067-0.167 mM).  
 
LC-MS measurements. Analyses were performed using a 1100/1200 Series HPLC 
System coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, 
Inc., Santa Clara CA, USA) equipped with electrospray ionization. The system was 
controlled with the Agilent MassHunter Workstation Data Acquisition software 
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(version B.01.04). The column used was an Atlantis® T3 C18 column (2.1 x 50 m) 
with a 3-µm particle size (Waters Corp., Milford MA, USA). The mobile phase 
consisted of two eluents: solvent A (H2O, containing 0.1% formic acid, v/v) and 
solvent B (acetonitrile, containing 0.1% formic acid, v/v), both delivered at 0.6 
mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and 
then hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% 
A/5% B, resulting in a total duration of 4 min. MS parameters such as fragmentor 
voltage, collision energy, polarity were optimized individually for each drug, and the 
molecular ion was followed for each compound in the multiple reaction monitoring 
mode. The concentrations of the analytes were quantified by the Agilent Mass Hunter 
Quantitative Analysis software (version B.01.04).  
 
In vitro activity 
Bacteria and growth. The clinical E. coli isolate UTI89 [41] (UTI89wt) and the FimA-
H knock-out strain UTI89 ∆fimA-H were kindly provided by the group of Prof. Urs 
Jenal, Biocenter, University of Basel. Bacterial strains (UTI89 wt and UTI89 ∆fimA-H) 
labeled with green fluorescence protein (GFP) were prepared as previously 
described by Scharenberg et al. [33]. Microorganisms were stored at -70 °C and 
before experiments incubated for 24 h under static conditions at 37 °C in 10 mL 
Luria-Bertani broth (Becton, Dickinson and Company, Le Pont de Claix, France) 
using 50 mL tubes. Prior to each experiment, the microorganisms were washed twice 
and re-suspended in phosphate buffered saline (PBS, Sigma, Steinheim, Germany) 
for aggregometry measurements or in RPMI 1640 without supplements for infection 
experiments. Bacterial concentration was determined by plating serial 1:10 dilutions 
on blood agar, followed by colony counting with 20 - 200 colonies after overnight 
incubation at 37 °C. 
 
Cultivation of 5637 cells. The human epithelial bladder carcinoma cell line 5637 
was obtained from the German Collection of Microorganisms and Cell Cultures 
(DSMZ, Braunschweig, Germany). The cells were grown in RPMI 1640 medium, 
supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin and 100 µg/mL 
streptomycin at 37 °C, 5% CO2. All solutions were purchased from Invitrogen (Basel, 
Switzerland). The cells were sub-cultured 1:5 twice per week for six passages before 
using them in the infection assay. Two days before infection, 1.8 x 105 cells were 
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seeded in each well of a 24-well plate in RPMI 1640 containing 10% FCS without 
antibiotics. The cell density was approximately 3-5 x 105 cells/well prior the infection. 
 
Aggregometry assay. The aggregometry assay was carried out as previously 
described [32]. In short, the percentage of aggregation of E. coli UTI89 with guinea 
pig erythrocytes (GPE) was quantitatively determined by measuring the optical 
density at 740 nm and 37 °C under stirring at 1000 rpm using an APACT 4004 
aggregometer (Endotell AG, Allschwil, Switzerland). Bacteria were cultivated as 
described above. GPE were separated from guinea pig blood (Charles River 
Laboratories, Sulzfeld, Germany) using Histopaque (density of 1.077 g/mL at 24 °C, 
Sigma-Aldrich, Buchs, Switzerland). Prior to the measurements, the cell densities of 
E. coli and GPE were adjusted to an OD600 of 4, corresponding to 1.9 × 108 CFU/mL 
and 2.2 × 106 cells/mL respectively. For the calibration of the instrument, the 
aggregation of protein poor plasma (PPP) using PBS alone was set as 100% and the 
aggregation of protein rich plasma (PRP) using GPE as 0%. After calibration, 
measurements were performed with 250 µL GPE and 50 µL bacterial suspension 
and the aggregation monitored over 600 s. After the aggregation phase of 600 s, 25 
µL of antagonist in PBS was added to each cuvette and disaggregation was 
monitored for 1400 s. UTI89 ∆fimA-H was used as negative control. IC50 values were 
determined by plotting the concentration of the antagonist in logarithmic mode versus 
the area under the disaggregation curves (AUC600-2000s) by fitting the curve log c with 
the prism software (GraphPad, inhibition curve, variable slope). 
 
Flow cytometry infection assay. The infection assay was carried out as previously 
described [33]. Briefly, 5637 cells, grown in 24-well plates (as described above), were 
infected with 200 µL bacterial suspension at a multiplicity of infection (MOI) of 1:50 
(cell:bacteria). To homogenize the infection, plates were centrifuged at room 
temperature for 3 min at 600 g. After an incubation of 1.5 h at 37 °C, infected cells 
were washed four times with RPMI 1640 medium and suspended in ice-cold PBS for 
5-20 min. Cells were then kept in the dark until analysis. All measurements were 
made within 1 h after the termination of the infection. Samples were acquired in a 
CyAn ADP flow cytometer (Becton Dickinson, San Jose, CA) and analyzed by gating 
on the eukaryotic cells based on forward (FSC) and side scatter (SSC), which 
excludes unbound labeled bacteria and debris from analysis. A total of 104 cells were 
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measured per sample. Data were acquired in a linear mode for the side scatter 
(SSC) and logarithmic mode for the forward scatter (FSC), and the green fluorescent 
channel FL1-H (e.g. GFP). The mean fluorescence intensity (MFI) of FL1-H was 
counted as a surrogate marker for the adherence of bacteria. Quantification of 
adhesion was evaluated with the FlowJow software 9.0.1 (Tree Star, Inc., Ashland, 
OR, USA). 
 
Inhibition assay. To evaluate FimH antagonists, a serial dilution of the antagonists 
in 5% DMSO was prepared. Before infection, bacterial suspension (200 µL) and 25 
µL of the test compound were pre-incubated for 10 min at room temperature. The 
bacteria-antagonist mixture was then added to the monolayer of 5637 cells. Infection, 
measurement, and quantification of adhesive bacteria were performed as described 
above. IC50 values were determined by plotting the concentration of the antagonist in 
logarithmic mode versus the MFI and by fitting the curve log c with the prism software 
(GraphPad, inhibition curve, variable slope), (n=2-3, in duplicates/ triplicates). 
 
In vivo pharmacokinetic and disease model 
Animals. Female C3H/HeN mice weighting between 19 and 25 g were obtained from 
Charles River (Sulzfeld, Germany) and were housed three to a cage. Mice were kept 
under specific-pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital Basel, and animal experimentation guidelines 
according to the regulations of Swiss veterinary law were followed. After seven days 
of acclimatization, 9- to 10-week old mice were used for the PK and infection studies. 
During the studies, animals were allowed free access to chow and water. Three days 
before infection studies and during infection, 5 % D-(+)-glucose (AppliChem, Baden-
Dättwil, Switzerland) was added to the drinking water [43]. 
 
Pharmacokinetic studies. Single-dose pharmacokinetic studies were performed by 
i.v. application of the FimH antagonist (6b) at concentrations of 25, 50 and 100 
mg/kg. The antagonist was diluted in 100 µL PBS and injected into the tail vein, 
followed by blood and urine sampling (10 µL) after 6 min, 30 min, 45 min, 1 h, 1 h 15 
min, 1 h 30 min, 1 h 45 min, 2 h, 2 h 30 min, 3 h, 4 h, 5 h 6 h, 8 h and 24 h. Before 
analysis, proteins in blood and urine samples were precipitated using methanol 
(Acros Organics, Basel, Switzerland) and centrifuged for 11 min at 13’000 rpm. The 
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supernatant was transferred into a 96-well plate (0.5 mL, polypropylene, Agilent 
Technologies, Basel, Switzerland) and analyzed by LC-MS as described above. 
 
UTI mouse model. Mice were infected as previously described [42]. In brief, before 
infection all remaining urine was depleted form the bladder by gentle pressure on the 
abdomen. Mice were anesthetized with 1.1 vol% isoflurane/oxygen mixture (Attane, 
Minrad Inc, Buffalo, NY, USA) and placed on their back. Anesthetized mice were 
inoculated transurethrally with the bacterial suspension by use of a 2 cm 
polyethylene catheter (Intramedic polyethylene tubing, inner diameter 0.28 mm, outer 
diameter 0.61 mm, Beckton Dickinson, Allschwil, Switzerland), which was placed on 
a syringe (Hamilton Gastight Syringe 50 µL, removable 30G needle, BGB Analytik 
AG, Boeckten, Switzerland). The catheter was gently inserted through the urethra 
until it reached the top of the bladder, followed by slow injection of 50 µL bacterial 
suspension at a concentration of approximately 109 to 1010 CFU/mL. 
 
Treatment studies. Three concentrations of 6b (25, 50, 100 mg/kg) were applied i.v. 
in 100 - 200 µL PBS into the tail vein and ciprofloxacin (8 mg/kg, Bayer Scherig 
Pharma, Germany) was injected subcutaneously. Both, the FimH antagonist and 
antibiotic were applied 10 minutes before infection. 3 h after the onset of infection, 
urine was collected by gentle pressure on the abdomen and then the mouse was 
sacrificed with CO2. Organs were removed aseptically and homogenized in 1 mL 
PBS by using a tissue lyser (Retsch, Haan, Germany). Serial dilutions of urine, 
bladder and kidneys were plated on Levine Eosin Methylene Blue Agar plates 
(Beckton Dickinson, Le Pont de Claix, France). CFU counts were determined after 
over night incubation at 37 °C and expressed as CFU/mL for the urine and 
CFU/bladder and CFU/2 kidneys for the organs. 
 
MANUSCRIPT I 
 
234 
References 
 
1 Hamad, B. The antibiotics market. Nat. Rev. Drug Discov. 2010, 9, 675. 
2 Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens. Science 
2009, 325, 1089. 
3 Rasko, D. A.; Sperandio, V. Anti-virulence strategies to combat bacteria-
mediated disease. Nat Rev Drug Discov. 2010, 9, 117-128. 
4 Lee, Y. M.; Almqvist, F,; Hultgren, S. J. Targeting virulence for antimicrobial 
chemotherapy. Curr Opin Pharmacol 2003, 3, 513–519. 
5 Alksne, L. E.; Projan, S. J. Bacterial virulence as a target for antimicrobial 
chemotherapy. Curr Opin in Biotech 2000, 11, 625–636. 
6 Clatworthy, A. E.; Pierson, A.; Hung, D. T. Targeting virulence: a new 
paradigm for antimicrobial therapy. Nat Chem Biol 2007, 3, 541–548. 
7 Fihn, S. D. Clinical practice. Acute uncomplicated urinary tract infection in 
women. N. Engl. J. Med. 2003, 349, 259-266. 
8 Hooton, T. M. Recurrent urinary tract infection in women. Int. J. Antimicrob. 
Agents 2001, 17, 259-268. 
9 Wiles, T. J.; Kulesus, R. R.; Mulvey, M. A. Origins and virulence mechanisms 
of uropathogenic Escherichia coli. Exp. Mol. Pathol. 2008, 85, 11-19. 
10 Gouin, S. G.; Wellens, A.; Bouckaert, J.; Kovensky, J. Synthetic Multimeric 
Heptyl Mannosides as Potent Antiadhesives of Uropathogenic Escherichia 
coli. ChemMedChem 2009, 4, 749-755. 
11 Rosen, D. A.; Hung, C. S.; Kline, K. A.; Hultgren, S. J. Streptozocin-induced 
diabetic mouse model of urinary tract infection. Infect. Immun. 2008, 76, 4290-
4298. 
12 Mulvey, M. A. Adhesion and entry of uropathogenic Escherichia coli. Cell 
Microbiol. 2002, 4, 257-271. 
13 Capitani, G.; Eidam, O.; Glockshuber, R.; Grutter, M. G. Structural and 
functional insights into the assembly of type 1 pili from Escherichia coli. 
Microbes Infect. 2006, 8, 2284-2290. 
14 Choudhury, D.; Thompson, A.; Stojanoff, V.; Langermann, S.; Pinkner, J.: 
Hultgren, S. J.; Knight, S. D. X ray structure of the FimC–FimH chaperone–
adhesin complex from uropathogenic Escherichia coli. Science 1999, 285, 
1061-1066. 
MANUSCRIPT I 
 
235 
15 Wellens, A.; Garofalo, C.; Nguyen, H.; Van Gerven, N.; Slättergård, R.; 
Hernalsteens, J.-P.; Wyns, L.; Oscarson, S.; De Greve, H.; Hultgren, S.; 
Bouckaert, J. Intervening with urinary tract infections using anti-adhesives 
based on the crystal structure of the FimH-oligomannose-3 complex. PLoS 
ONE 2008, 3, 4-13. 
16 Bouckaert, J.; Mackenzie, J.; de Paz, J. L.; Chipwaza, B.; Choudhury, D.; 
Zavialov, A.; Mannerstedt, K.; Anderson, J.; Pierard, D.; Wyns, L.; Seeberger, 
P. H.; Oscarson, S.; De Greve; H., Knight, S. D. The affinity of the FimH 
fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli 
pathotypes. Mol. Microbiol. 2006, 61, 1556-1568. 
17 Hartmann, M. and Lindhorst, T. K. The Bacterial Lectin FimH, a Target for 
Drug Discovery – Carbohydrate Inhibitors of Type 1 Fimbriae-Mediated 
Bacterial Adhesion. Eur J Org Chem 2011, 3583-3609. 
18 Aronson, M.; Medalia, O.; Schori, L.; Mirelman, D.; Sharon, N.; Ofek, I. 
Prevention of colonization of the urinary tract of mice with Escherichia coli by 
blocking of bacterial adherence with methyl α-D-mannopyranoside. J. Infect. 
Dis. 1979, 139, 329-332. 
19 Svanborg Eden, C.; Freter, R.; Hagberg, L.; Hull, R.; Leffer, H.; Schoolnik, G. 
Inhibition of experimental ascending urinary tract infection by an epithelial cell-
surface receptor analog. Nature 1982, 298, 560-562. 
20 Klein, T.; Abgottspon, D.; Wittwer, M.; Rabbani, S.; Herold, J.; Jiang, X.; 
Kleeb, S.; Lüthi, C.; Scharenberg, M.; Bezenc¸on, J.; Gubler, E.; Pang, L.; 
Smiesko, M.; Schwardt, O.; Ernst, B. FimH Antagonists for the oral treatment 
of urinary tract infections: from design and synthesis to in vitro and in vivo 
evaluation. J Med Chem 2010, 53, 8627–8641. 
21 Han Z, Pinker JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, 
Ellenberger T, Cusumano CK, SJ, Janetka JW. Structure-based drug design 
and optimization of mannoside bacterial FimH antagonists. J. Med. Chem. 
2010, 53, 4779. 
22 Cusumano, C. K.; Pinkner, J. S.; Han, Z.; Greene, S. E.; Ford, B. A.; Crowley, 
J. R.; Henderson, J. P.; Janetka, J. W.; Hultgren, S. J. Treatment and 
prevention of urinary tract infection with orally active FimH inhibitors. Sci 
Transl Med 2011, 3, 109-115. 
MANUSCRIPT I 
 
236 
23 Han, Z.; Pinkner, J. S.; Ford, B.; Chorell, E.; Crowley, J. R.; Cusumano, C. K.; 
Campbell, S.; Henderson, J. P.; Hultgren, S. J. Lead optimization studies on 
FimH antagonists: discovery of potent and orally bioavailable ortho-substituted 
biphenyl mannosides. J Med Chem 2012, 55, 3945-3959. 
24 Guiton, P. S.; Cusumano, C. K.; Kline, K. A.; Dodson, K. W.; Han, Z.; Janetka, 
J. W.; Henderson, J. P.; Caparon, M. G.; Hultgren, S. J. Combination small 
molecule therapy prevents uropathogenic Escherichia coli catheter-associated 
urinary tract infections in mice. Antimicrob Agents Chemother 2012, 56, 4738-
4745. 
25 Jiang, X.; Abgottspon, D.; Kleeb, S.; Rabbani, S.; Scharenberg, M.; Wittwer, 
M.; Haug, M.; Schwardt, O.; Ernst, B. Antiadhesion Therapy for Urinary Tract 
Infections – A Balanced PK/PD Pofile Proved to be Key for Success. J Med 
Chem 2012, 55, 4700-4713. 
26 Sperling, O., Fuchs, A. & Lindhorst, T. K. Evaluation of the carbohydrate 
recognition domain of the bacterial adhesin FimH: design, synthesis and 
binding properties of mannoside ligands. Org. Biomol. Chem. 2006, 4, 3913–
3922. 
27 (a) A. Vervoort, C. K. De Bruyne, Carbohydr. Res. 1970, 12, 277-280; (b) J. 
De Prijcker, A. De Bock, C. K. De Bruyne, Carbohydr. Res. 1978, 60, 141-53. 
28 J. R. Kosak, Ann. N. Y. Acad. Sci. 1970, 172, 175-185. 
29 Varma, M. V. S.; Feng, B.; Obach, R. S.; Troutman, M. D.; Chupka, J.; Miller, 
H. R.; El-Kattan, A. Physicochemical Determinants of Human Renal 
Clearance. J. Med. Chem. 2009, 52, 4844-4852. 
30 Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput 
Screening: Parallel Artificial Membrane Permeation Assay in the Description of 
Passive Absorption Processes. J. Med. Chem. 1998, 41, 1007-1010. 
31 Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. 
Parallel artificial membrane permeability assay (PAMPA)-critical factors for 
better predictions of absorption. J. Pharm. Sci. 2007, 96, 2893-2909. 
32 Abgottspon, D.; Rölli, G.; Hosch, L.; Steinhuber, A.; Jiang, X.; Schwardt, O.; 
Cutting, B.; Smiesko, M.; Jenal, U.; Ernst, B.; Trampuz, A. Development of an 
Aggregation Assay to Screen FimH Antagonists. J. Microbiol. Methods 2010, 
82, 249–255. 
MANUSCRIPT I 
 
237 
33 Scharenberg, M.; Abgottspon, D.; Ciceck, E.; Jiang, X., Schwardt, O.; 
Rabbani, S.; Ernst, B. Flow Ctometry-Based Assay for Screening FimH 
Antagonists. Assay Drug Dev Technol. 2011, 9, 455-464. 
34 Hooton, T. M.Fluoroquinolones and resistance in the treatment of 
uncomplicated urinary tract infection. Int. J. Antimicrob. Agents 2003, 22, 65– 
72 
35 Jakobsen, L.; Cattoir, V.; Hammerum, A. M.; Nordmann, P.; Frimodt-Møller, N. 
Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19, and 
qnrS1 on ciprofloxacin treatment of Escherichia coli urinary tract infection in 
murine model. Poster presented at the 50th Interscience Conference on 
Antimicrobial Agents and Chemotharapy, 2010, Sep 12–15, Boston, MA. 
36 Langermann, S.; Palaszynski, S.; Barnhart, M.; Auguste, G.; Pinkner, J. S.; 
Burlein, J.; Barren, P.; Koenig, S.; Leath, S.; Jones, C. H.; Hultgren, S. J. 
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based 
systemic vaccination. Science 1997, 276, 607-611. 
37  Mulvey, M. A.; Schilling, J. D.; Martinez, J. J.; Hultgren, S. J. Bad bugs and 
beleaguered bladders: interplay between uropathogenic Escherichia coli and 
innate host defense. Proc. Natl. Acad. Sci. USA 2000, 97, 8829-8835. 
38 Johnson, J. R. and Brown J. J. Defining Inoculation Conditions fort he Mouse 
Model of Ascending Urinary Tract Infection that Avoidf Immediate 
Vesicourethral Reflux yet Produce Renal and Bladder Infection. J. Inf. Dis. 
1996, 173, 746-749. 
39 (a) VCCLAB, Virtual Computational Chemistry Laboratory; 
http://www.vcclab.org, 2005; (b) Tetko,I. V.; Gasteiger, J.; Todeschini, R.; 
Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, 
N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual 
computational chemistry laboratory – design and description. J. Comput. Aid. 
Mol. Des. 2005, 19, 453-463. 
40 Wittwer, M.; Bezençon, J.; Cutting, B.; Wagner, B.; Kansy M.; Ernst, B. pKa 
determination by 1H-NMR spectroscopy – an old methodology revisited. 
Unpublished results. 
41 Mulvey, M. A.; Schilling, J. D.; Hultgren, S. J. Establishment of a persistent 
Escherichia coli reservoir during the acute phase of a bladder infection. Infect. 
Immun. 2001, 69, 4572-4579. 
MANUSCRIPT I 
 
238 
42 Kerrn, M. B.; Frimodt-Møller, N.; Espersen, F. Effects of Sulfomethizole and 
Amdinocillin against Escherichia coli Strains (with Various Susceptibilities) in 
an Ascending Urinary Tract Infection Model. Antimicrob. Agents Chemother. 
2003, 47, 1002-1009. 
 
 239 
  
 240 
 
RESULTS AND DISCUSSION 
Manuscript II 
 
In vivo Pharmacokinetic/Pharmacodynamic Evaluation of JXH2372 – A 
Biphenyl FimH Antagonist for the Prevention of Urinary Tract Infection. 
	
  
Abgottspon D, Skovbo Jensen K, Jiang X, Ernst B. 
 
Preliminary manuscript: With outlook for completion. 
 
 
 
 
My contributions: 
In vitro evaluation of the inhibitory potency of the FimH antagonists in the 
flow cytometry infection assay together with Scharenberg M. 
In vivo pharmacokinetic and infection studies in the UTI mouse model. 
Manuscript preparation.
 241 
MANUSCRIPT II 
 
242 
In vivo Pharmacokinetic/Pharmacodynamic Evaluation of JXH2372 
– A Biphenyl FimH Antagonist for the Prevention of Urinary Tract 
Infection 
 
Daniela Abgottspon1, Klaus Skovbo Jensen2, Xiaouah Jiang1, Beat Ernst*1 
1Institute of Molecular Pharmacy, Pharmacenter, University of Basel, 
Klingelbergstrasse 50, CH-4056 Basel, Switzerland, 2CANDOR Simulation, 
Denmark. 
 
 
 
 
 
 
 
 
Part of this work was presented at: 
As poster (A2-039) at the Interscience Conference on Antimicrobial Agents and 
Chemotherapy (ICAAC), September 2011, Chicago, USA. 
 
As poster (F2-2057) at the Interscience Conference on Antimicrobial Agents and 
Chemotherapy (ICAAC), September 2012, San Francisco, USA. 
 
 
 
 
 
 
*Correspondence to Prof. Dr. Beat Ernst, Institute of Molecular Pharmacy, 
Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, 
Switzerland 
Tel: +41 61 267 1551, Fax: +41 61 267 1552, Email: beat.ernst@unibas.ch 
MANUSCRIPT II 
 
243 
Abstract 
 
Background and aims: Urinary tract infection (UTI) is one of the most common 
bacterial infections worldwide. UTI is commonly treated with antibiotics, leading to 
increasing development of resistance. Therefore, alternative treatment options are 
urgently needed. FimH antagonists represent a new class of antimicrobials, targeting 
bacterial adhesion. Our aim was to evaluate the pharmacokinetic/pharmacodynamic 
(PK/PD) index of the biphenyl FimH antagonist JXH2372, which best correlates with 
therapeutic outcome. 
 
Methods: Cell-based infection assay to determine the minimal anti-adhesion 
concentration (MAC). PK studies of three different concentrations (25, 50 and 100 
mg/kg) of JXH2372 were performed in uninfected mice to determine the AUC and the 
Cmax. PD studies were carried out in the UTI mouse model, using the uropathogenic 
Escherichia coli strain UTI89. Determination of the predictive PK/PD parameter 
(T>MAC, AUC0-24/MAC, Cmax/MAC) for the therapeutic outcome. 
 
Results: PK studies showed high availability of all three concentrations of JXH2372 
in the urine. PD studies resulted in a dose dependent reduction of bacterial counts in 
the bladder. The best correlation with the infection outcome in the PK/PD evaluation 
was observed by looking at the AUC0-24/MAC in the bladder (R2 = 43%). 
 
Conclusion: The FimH antagonist JXH2372 showed hight activity in the UTI mouse 
model. The most predictive PK/PD parameter suggests, that a constant mean level of 
antagonist over the MAC is required for an optimal treatment outcome.  
 
 
Keywords: Uropathogenic Escherichia coli, urinary tract infection, FimH antagonist, 
pharmacokinetics/pharmacodynamics 
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Introduction 
 
Urinary tract infection (UTI) is one of the most common bacterial infections 
worldwide. Women are the most affected population and every second woman will 
experience at least one UTI during her lifetime. Furthermore, catheter-associated UTI 
accounts for the most common hospital acquired (nosocomial) infection and UTI is 
the third most acquired infection in intensive care units (ICUs) in Europe.1 Although 
UTI is not a life threatening disease, all symptomatic infections should be treated with 
antibiotics to prevent potential devastating complications, like kidney infections 
(pyelonephritis), irreversible kidney damage and dissemination from the kidneys to 
the bloodstream (urosepsis).2 
 
The leading pathogen causing UTI is uropathogenic Escherichia coli (UPEC), 
responsible for over 90% of all infections.3 UPEC colonize the normally sterile urinary 
tract in an ascending manner. The decisive virulence mechanism of UPEC 
colonization is their adhesion capability, using filamentous multi-subunit membrane 
proteins (pili or fimbriae).4 The first and most important pili employed for the initial 
entry into the urethra (urethritis) and the bladder (cystitis) are type 1 pili, where the 
mannose-dependent attachment to the glycosylated uroplakin Ia (UPIa) present on 
bladder cells is mediated by the fimbrial adhesin H (FimH). Furthermore, bacteria can 
ascend through the urethers into the kidneys (pyelonephritis), where the adhesion is 
specifically mediated via P pili in a galactose dependent manner.5-8 
 
Type 1 pili are filamentous multi-subunit appendages (consisting of FimA, FimF, 
FimG and FimH), able to bind to α-mannoside containing glycoprotein receptors on 
the surface of uroepithelial cells, such as uroplakin 1a (UP1a).9,10 Adhesion is 
mediated via the carbohydrate-recognition domain (CRD) of FimH, a protein located 
on the distal tip of the type 1 pilus. This initial step of the infection process prevents 
the rapid clearance of E. coli from the urinary tract by the bulk flow of urine and 
enables bacteria to invade the target cells.3,11-16 FimH antagonists such as α-D-
mannopyranosides are able to effectively prevent the FimH dependent adhesion and 
invasion of host cells. No infection can occur and bacteria are cleared from the 
urinary tract by the flow of urine.17 Hence, they provide a novel therapeutic 
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opportunity for the treatment and prevention of UTIs as an alternative to conventional 
antibiotic treatment.2,18,19 
Different classes of FimH antagonists were identified as potential new anti-adhesion 
compounds, able to prevent and treat UPEC associated UTIs in mice.20-25 A 
promising compound family is a series of biphenyl α-D-mannopyranoside derivatives. 
We previously described the design, synthesis and biological evaluation (in vitro and 
in vivo) of the biphenyl FimH antagonist JXH2372 (Figure 1).20 JXH2372 showed 
high activity in the in vitro cell-based assays and resulted in a significant reduction of 
bacterial counts of over 4 orders of magnitude in the bladder of mice after a single i.v. 
application of 50 mg/kg. 
 
 
Figure 1. The chemical structure of the biphenyl α-D-mannopyranoside JXH2372 used 
through out these studies. 
 
 
The activity of antibiotics against a pathogen is traditionally determined as the 
minimal inhibitory concentration (MIC) and is defined as the lowest concentration of a 
drug that inhibits visible growth of an organism.26 Although FimH antagonists are 
antimicrobial agents, the MIC is not applicable for the determination of their activity, 
due to their different mode of action (they neither kill nor inhibit the growth of 
bacteria). Therefore, we express the activity of FimH antagonists as the minimal anti-
adhesion concentration (MAC), which can be used for the determination of the 
therapeutic dosage in vivo. The MAC is defined as the concentration of antagonist 
leading to 90% inhibition of adhesion of the pathogen to the target cells (IC90) and 
was evaluated in a cell-based infection assay.27 
 
The traditional MIC is a valuable index to determine the antimicrobial potency of a 
drug. However, it lacks the ability to inform about the time course needed for an 
optimal antimicrobial activity, which is a key factor for the choice of a successful 
therapy.28,29 To choose the optimal treatment regimen (dosage and time course), 
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pharmacokinetic/pharmacodynamic (PK/PD) studies are needed, combining the 
results from the drug concentration over time (PK) with the activity over time (PD). 
PK/PD studies are applicable and often used for antibiotics, however, nothing is 
known about the PK/PD correlation for anti-adhesion therapy using FimH 
antagonists. Therefore, we performed PK/PD studies of various dosages and dosage 
regimens of JXH2372 in the UTI mouse model.30 With these experiments, we aimed 
for the identification of the PK/PD index, which most closely predicts the efficacy of 
the FimH antagonist. 
 
 
Material and Methods 
 
Bacterial strains and growth conditions 
The clinical E. coli isolate UTI89 (UTI89wt)31 was kindly provided by the group of 
Prof. Urs Jenal, Biocenter, University of Basel. Microorganisms were stored at -70 °C 
and before experiment incubated for 24 h under static conditions at 37 °C in 10 mL 
Luria-Bertani broth (Becton, Dickinson and Company, Le Pont de Claix, France) 
using 50 mL tubes. Prior to each experiment, the microorganisms were washed twice 
and re-suspended in phosphate buffered saline (PBS, Sigma, Steinheim, Germany). 
Bacterial concentration was determined by plating serial 1:10 dilutions on blood agar, 
followed by colony counting with 20 - 200 colonies after overnight incubation at 37 
°C. 
 
Cultivation of 5637 cells 
The human epithelial bladder carcinoma cell line 5637 was obtained from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany). The cells were grown in RPMI 1640 medium, supplemented with 10% 
fetal calf serum (FCS), 100 U/mL penicillin and 100 µg/mL streptomycin at 37°C, 5% 
CO2. All solutions were purchased from Invitrogen (Basel, Switzerland). The cells 
were sub-cultured 1:5 twice per week for six passages before using them in the 
infection assay. Two days before infection, 1.8 x 105 cells were seeded in each well 
of a 24-well plate in RPMI 1640 containing 10% FCS without antibiotics. The cell 
density was approximately 3-5 x 105 cells/well prior the infection. 
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Flow cytometry infection assay for the determination of the minimal anti-
adhesion concentration (MAC) 
The infection assay was carried out as previously described.27 Briefly, to evaluate 
FimH antagonists, a serial dilution of the antagonists in 5% DMSO was prepared. 
Before infection, a suspension of green fluorescently labeled (GFP) bacteria (UTI89, 
200 µL) and 25 µL of the test compound were pre-incubated for 10 min at room 
temperature. The bacteria-antagonist mixture was then added to the monolayer of 
5637 cells (grown in 24-well plates, as described above) at a multiplicity of infection 
(MOI) of 1:50 (cell:bacteria). To homogenize the infection, plates were centrifuged at 
room temperature for 3 min at 600 g. After an incubation of 1.5 h at 37°C, infected 
cells were washed four times with RPMI 1640 medium and suspended in ice-cold 
PBS for 5-20 min. Cells were then kept in the dark until analysis. All measurements 
were made within 1 h after the termination of the infection. Samples were acquired in 
a CyAn ADP flow cytometer (Becton, Dickinson and Company) and analyzed by 
gating on the eukaryotic cells based on forward (FSC) and side scatter (SSC), which 
excludes unbound GFP-labeled bacteria and debris from analysis. A total of 104 cells 
were measured per sample. Data were acquired in a linear mode for the side scatter 
(SSC) and in a logarithmic mode for the forward scatter (FSC), and the green 
fluorescent channel FL1-H (e.g. GFP). The mean fluorescent intensity (MFI) of FL1-H 
was counted as a surrogate marker for the adherence of bacteria. Quantification of 
adhesion was evaluated with the FlowJo software 9.0.1 (Tree Star, Inc., Ashland, 
OR, USA). IC50 values were determined by plotting the concentration of the 
antagonist in logarithmic mode versus the MFI and by fitting the curve with the prism 
software (GraphPad, inhibition curve, nonlinear regression, variable slope, n = 4). 
The IC90 (F=90) was calculated from the determined IC50 value and the hill slope (H) 
as follows: 
€ 
ICF =
F
100− F
# 
$ 
% 
& 
' 
( 
1/ H
• IC50 
 
Animals 
Female C3H/HeN mice weighting between 19 and 25 g were obtained from Charles 
River (Sulzfeld, Germany) and were housed three to a cage. Mice were kept under 
specific-pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital Basel, and animal experimentation guidelines 
according to the regulations of Swiss veterinary law were followed. After seven days 
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of acclimatization, 9- to 10-week old mice were used for the PK and infection studies. 
During the studies, animals were allowed free access to chow and water. Three days 
before infection studies and during infection, 5 % D-(+)-glucose (AppliChem, Baden-
Dättwil, Switzerland) was added to the drinking water.30 
 
Pharmacokinetic studies 
Single-dose pharmacokinetic studies were performed by i.v. application of the FimH 
antagonist JXH2372 at increasing concentrations of 25, 50 and 100 mg/kg. The 
antagonist was diluted in 100 - 200 µL PBS and injected into the tail vein, followed by 
blood and urine sampling (10 µL at each time point) after 6 min, 15 min, 30 min, 45 
min, 1 h, 1 h 30 min, 2 h, 2 h 30 min, 3 h, 4 h, 5 h 6 h, 8 h and 24 h. Before analysis, 
proteins in blood and urine samples were precipitated using methanol (Acros 
Organics, Basel, Switzerland) and centrifuged for 11 min at 13’000 rpm. The 
supernatant was transferred into a 96-well plate (0.5 mL, polypropylene, Agilent 
Technologies, Basel, Switzerland) and analyzed by LC-MS as previously 
described.20 
A linear 1-compartment model was fitted to the plasma concentration data and 
thereafter expanded into a 2-compartment model (a “bladder compartment” was 
added) to be fitted to the urine concentration data. 
 
UTI mouse model 
Mice were infected as previously described.30 In brief, before infection all remaining 
urine was depleted form the bladder by gentle pressure on the abdomen. Mice were 
anesthetized with 1.1 vol% isoflurane/oxygen mixture (Attane, Minrad Inc, Buffalo, 
NY, USA) and placed on their back. Anesthetized mice were inoculated 
transurethrally with the bacterial suspension by use of a 2 cm polyethylene catheter 
(Intramedic polyethylene tubing, inner diameter 0.28 mm, outer diameter 0.61 mm, 
Beckton Dickinson, Allschwil, Switzerland), which was placed on a syringe (Hamilton 
Gastight Syringe 50 µL, removable 30G needle, BGB Analytik AG, Boeckten, 
Switzerland). The catheter was gently inserted through the urethra until it reached the 
top of the bladder, followed by slow injection of 50 µL bacterial suspension at a 
concentration of approximately 109 to 1010 CFU/mL. 
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Pharmacodynamic studies 
Various dosage regimens of length T = 3 hours were applied, starting 10 minutes 
before infection (JXH2372 bolus doses of  25, 50, or 100 mg/kg in 100 - 200 µL PBS 
were injected i.v. into the tail vein). Three hours after the onset of infection, urine was 
collected by gentle pressure on the abdomen and then the mouse was sacrificed with 
CO2. Organs were removed aseptically and homogenized in 1 mL PBS by using a 
tissue lyser (Retsch, Haan, Germany). Serial dilutions of urine, bladder and kidneys 
were plated on Levine Eosin Methylene Blue Agar plates (Beckton Dickinson, Le 
Pont de Claix, France). CFU counts were determined after over night incubation at 37 
°C and expressed as CFU/bladder and CFU/2 kidneys for the organs. 
 
Results 
 
Determination of the minimal anti-adhesion concentration (MAC) 
The MAC was determined in the flow cytometry infection assay. Therefore, human 
bladder cells were infected with GFP labeled UPEC (strain UTI89) in the presence of 
different concentrations of FimH antagonists and analyzed by flow cytometry.25,27 The 
half-maximal inhibitory concentration (IC50) was calculated by plotting the mean 
fluorescent intensity (MFI) of the cells versus the concentration of the antagonist. 
From this plot, the concentration where 90% bacterial adhesion to human bladder 
cells is inhibited (IC90) can be deduced and is defined as the minimal anti-adhesion 
concentration (MAC).25 The FimH antagonist JXH2372 exhibited an IC50 of 0.82 ± 0.6 
µM in the flow cytometry infection assay. The calculated IC90 is 11.5 µM and the 
corresponding MAC is 4.6 µg/mL. The MAC value of JXH2372 is substituting the MIC 
for the PK/PD studies during this work. 
 
PK/PD studies 
The studies described here, were carried out to determine the PK/PD index (T>MAC, 
AUC0-24/MAC, Cmax/MAC) which best correlates with the therapeutic outcome in the 
UTI mouse model. The single dose PK studies showed dose-dependent elevations of 
plasma and urine concentrations of JXH2372 in mice (Figure 2), except for urine 
concentrations of 50 mg/kg. Peak levels in both, plasma and urine were observed 
within 6 minutes after application and also show increased values for higher 
concentrations. 
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Dosage 
[mg/kg] 
Compartment AUC0-24 
[µg x h/mL] 
T>MAC 
[h] 
Cmax 
[µg/mL] 
25 
Plasma 6.3 0.52 20 
Urine 716 1.9 3620 
50 
Plasma 20 1.2 34 
Urine 49 2.3 40 
100 
Plasma 35 1.1 104 
Urine 4050 2.9 8520 
 
 
Figure 2. PK/PD study of three different dosages (25, 50, 100 mg/kg) of JXH2372. The 
concentration of antagonist in urine and plasma after a single i.v. application was determined 
using LC-MS (n = 6). Graphs show time dependent urine and plasma concentrations. T: 
time; MAC: minimal anti-adhesion concentration; AUC0-24: area under the curve over 24 
hours; Cmax: peak concentration.  
 
 
The PD studies were carried out in the UTI mouse model. The compound was 
applied 10 minutes prior to inoculation with UPEC and infection was terminated after 
3 h. Urine, bladder and kidneys were collected for determination of bacterial 
concentration. The mean bacterial counts of the untreated control group showed 
values of 1.4 x 108 colony forming units (CFU) in the bladder and 9.7 x 106 CFU in 
the kidneys. The bar diagram in Figure 3 b shows the bacterial reduction compared 
to the control group after treatment with JXH2372. A dose dependent decrease of 
bacterial counts in the bladder was observed, with 25 mg/kg resulting in a -2.1 log10 
CFU reduction, 50 mg/kg resulting in -4.6 log10 CFU and 100 mg/kg resulting in -5.1 
log10 CFU. No dose dependent reduction of bacterial counts was observed in the 
kidneys (- 2.8 log10 CFU for 25 mg/kg, -1.9 log10 CFU for 50 mg/kg, -2.8 log10 CFU for 
100 mg/kg). 
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Testing of various dosage regimens in the UTI mouse model for prediction of 
the significant PK/PD parameter 
Based on the PK studies (Figure 2), a selection of dosage regimens was chosen for 
the PD studies in the UTI mouse model (Figure 3 a). The first bolus dose in a 
regimen was always administered 10 minutes prior to infection. Regimen Y showed 
the highest efficacy with a bacterial reduction of -4.7 log10 units (Figure 3 b). 
Regimens L and Z resulted both in a -4.4 log10 CFU reduction, whereas regimens M 
and X were less effective with -3.7 log10 CFU and -2.6 log10 CFU, respectively. 
 
(a) 
    PK/PD parameter values 
Dosage 
regimen 
Dose 
[mg/kg] 
Dosing 
interval 
[h] 
Total dose 
[mg/24 
kg•h] 
T>MAC 
(%) 
AUC0-
24/MAC (h) 
Cmax/MAC 
P U P U P U 
D 25 every 3.0 25 20 76 17 1913 7 435 
E 50 every 3.0 50 28 83 34 3826 13 870 
F 100 every 3.0 100 36 91 68 7651 26 1739 
L 50 every 1.5 100 56 100 68 7596 13 882 
M 100 every 1.5 200 71 100 136 15192 26 1764 
X 12.5 every 0.75 50 54 100 33 3672 4 253 
Y 25 every 0.75 100 85 100 66 7344 7 506 
Z 50 every 0.75 200 100 100 133 14688 14 1012 
 (b) 
  
Figure 3. Pharmacodynamic study in the UTI mouse model. (a) Dosage regimens selected 
for in vivo PD studies in the UTI mouse model. T: time; MAC: minimal anti-adhesion 
concentration; AUC0-24: area under the curve over 24 hours; Cmax: peak concentration; P: 
plasma; U: urine. (b) The bar diagram represents the reduction of bacterial counts (n = 4) 
resulting from the i.v. application of JXH2372 at the indicated dosage regimen (D, E, F, L, M, 
X, Y, Z). The baseline represents the mean bacterial counts of the untreated control group. 
Reg: dosage regimen, B: bladder; K: kidneys.  
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The PK/PD index most predictive for the treatment outcome was evaluated by 
correlating the bacterial counts in the bladder and kidneys of mice after 3 h of 
infection with the applied dosage regimens (Figure 4). The best correlation for the 
infection outcome was observed by looking at the total AUC over the MAC in the 
bladder (AUC0-24/MAC) with an R2 value of 43% (Figure 4 a and b). Less correlation 
was found for the T>MAC index (R2 = 29% for plasma and 39% for urine) and very 
poor correlation for Cmax/MAC (R2 = 20% for plasma and 21% for urine). No 
correlation was observed in the kidneys (R2 < 0.1). 
 
                  (a)        (b) 
 
Figure 4. Correlation of the 24 h drug concentration in plasma and urine and the anti-
adhesion activity of JXH2372 in the UTI mouse model. PK/PD parameters (T>MAC, AUC0-
24/MAC, Cmax/MAC) for (a) plasma and (b) urine concentration-activity correlation in the 
bladder. The activity is displayed in the ordinates as change in CFU. 
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Discussion 
In this study we described for the first time the PK/PD evaluation of a FimH 
antagonist in the UTI mouse model. The goal of the study was to determine the 
PK/PD index, best correlating with the infection outcome, in order to better 
understand the in vivo behavior of this new antimicrobial. 
 
Traditionally the efficacy of antibiotics is expressed using the MIC. FimH antagonists  
exhibit a different mode of action compared to antibiotics (they neither kill nor inhibit 
growth of microorganisms), therefore, a modified definition of the MIC had to be 
elaborated. The activity of a FimH antagonist can be determined by testing its anti-
adhesion property in a cell-based assay. There we evaluated the concentration of 
antagonist needed, to totally inhibit bacterial adhesion to human bladder cells and we 
defined this concentration as the minimal anti-adhesion concentration (MAC). With 
the MAC, we were able to conduct and evaluate the results of the PK/PD studies. 
 
The in vivo PK/PD studies were carried out in the UTI mouse model using the UPEC 
strain UTI89. Due to the mode of action of FimH antagonists, the anti-adhesion 
activity is exclusively achieved by α-D-mannopyranosides present in the urine of 
mice (extracellular). There they bind to the bacterial FimH, preventing adhesion and 
invasion and concomitantly also infection. Therefore, the antagonist was always 
applied 10 minutes prior to inoculation (prevention study) and infection was 
terminated after 3 hours. 
 
As previously described,20,25 urine samples showed in general higher bacterial counts 
compared to the bladder. This could result due to difficulties during urine sampling 
and varying urine volumes of mice during experiments, leading to either a 
concentration or dilution of bacteria in urine samples. Hence, lower urine volumes 
lead to an increased concentration of bacteria in the collected urine and furthermore, 
non-adherent and detached bacteria accumulate in the urine. The same applies for 
kidney counts, which were also reduced to a lower extend in all treated animals 
(Figure 3 b). One reason could be, that compared to the bladder, bacteria exhibit a 
different adhesion mechanism in the kidneys (mannose dependent type 1 pili in the 
bladder, galactose dependent P pili interactions in the kidneys).13 Furthermore, in the 
UTI mouse model, the application of bacteria directly into the bladder and 
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concomitantly also into the kidneys (vesicourethral reflux (VUR)) during the 
inoculation process is a prevalent problem,32 hence high kidney counts were already 
observed 3 h after infection (negative control, 6.7 x 106 CFU). 
 
The PK/PD studies of the three increasing dosages (25, 50 100 mg/kg) of JXH2372 
showed a dose dependency for both, PK parameters (in plasma and urine samples) 
and CFU reductions (in bladder and kidneys) (Figure 2 and Figure 3 b). Except for 
the AUC0-24 of the middle concentration (50 mg/kg), which showed a lower value 
compared to 25 mg/kg. Since plasma values of all three concentrations are in good 
agreement, the outlying urine AUC0-24 for the dosage of 50 mg/kg could be explained 
by the problems mentioned above, that urine sampling in mice can be difficult. With 
these studies, a series of dosage regimes for further PD studies were selected, to be 
able to elicit the most predictive PK/PD index for the therapeutic outcome. 
The results of the PK and PD correlations (Figure 4) shows, that the AUC0-24/MAC in 
the bladder (for plasma and urine concentrations) is the most predictive PK/PD 
parameter for the therapeutic outcome. It indicates that the compound is binding 
loosely to the receptor, therefore continuous availability of the compound is needed 
for an effective treatment. As expected, no correlations were found for the kidneys, 
probably because of the reasons mentioned above (different adhesion mechanism). 
 
In this study we focused on the application of the antagonist in a preventive manner. 
The evaluation of the optimal PK/PD parameter suggests, that a constant mean level 
of antagonist over the MAC is the optimal for treatment. Therefore, we will improve 
the PK parameters and use an adapted dosage regimen of the compound to avoid 
high peak levels and to achieve a prolonged presence of the FimH antagonist in the 
urine. Furthermore, to elucidate the binding mode of FimH antagonists to their target 
(FimH-carbohydrate recognition domain (CRD) on UPEC), additional cell-based in 
vitro and in vivo studies in the UTI mouse model will be performed. 
 
Experimental PK/PD studies are usually conducted in animal models and decrease 
the risk (dose guessing in patients) and cost in drug development. The preclinical 
determination of the PK/PD indices for FimH antagonists provides valuable 
information for optimization and later on clinical outcome of the anti-adhesive therapy 
against UTI. 
MANUSCRIPT II 
 
255 
References 
1 Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs. Am J Med 2002; 113: 5S-13S. 
2 Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. 
Biochim Biophys Acta 2006; 1760: 527-37. 
3 Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of 
uropathogenic Escherichia coli. Exp Mol Pathol 2008; 85: 11-9. 
4 Langermann S, Palaszynski S, Barnhart M et al. Prevention of mucosal 
Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 
1997; 276: 607-11. 
5  Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. 
Nat Rev Microbiol 2010; 8: 26-38. 
6  Lane MG, Alteri CJ, Smith SN et al. Expression of flagella is coincident with 
uropathogenic Eschericia coli ascencion to the upeer urinary tract. Proc Natl 
Acad Sci USA 2007; 104: 16669-74. 
7  Connell H, Agace W, Klemm P et al. Type 1 fimbrial expression enhances 
Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 1996; 
93: 9827-32. 
8  Hunstad DA, Justice SS. Intracellular lifestyle and immune evasion strategies of 
uropathogenic Escherichia coli. Annu Rev Microbiol 2010; 64: 203-21. 
9 Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. 
N Engl J Med 2003; 349: 259-66. 
10 Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 
2001; 17: 259-68. 
11 Gouin SG, Wellens A, Bouckaert J et al. Synthetic Multimeric Heptyl 
Mannosides as Potent Antiadhesives of Uropathogenic Escherichia coli. 
ChemMedChem 2009; 4: 749-55. 
12 Rosen DA, Hung CS, Kline KA et al. Streptozocin-induced diabetic mouse 
model of urinary tract infection. Infect Immun 2008; 76: 4290-98. 
13 Mulvey MA. Adhesion and entry of uropathogenic Escherichia coli. Cell 
Microbiol 2002; 4: 257-71. 
14 Capitani G, Eidam O, Glockshuber R et al. Structural and functional insights into 
the assembly of type 1 pili from Escherichia coli. Microbes Infect 2006; 8: 2284-
90. 
MANUSCRIPT II 
 
256 
15 Choudhury D, Thompson A, Stojanoff V et al. X‑ray structure of the FimC–FimH 
chaperone–adhesin complex from uropathogenic Escherichia coli. Science 
1999; 285: 1061-6. 
16 Wellens A, Garofalo C, Nguyen H et al. Intervening with urinary tract infections 
using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 
complex. PLoS ONE 2008; 3: 4-13. 
17 Bouckaert J, Mackenzie J, de Paz JL et al. The affinity of the FimH fimbrial 
adhesin is receptor-driven and quasi-independent of Escherichia coli 
pathotypes. Mol Microbiol 2006; 61: 1556-68. 
18 Ofek I, Hasy DL, Sharon N. Anti-adhesion therapy of bacterial diseases: 
prospects and problems. FEMS Immunol Med Microbiol 2003; 38: 181-91. 
19 Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat Rev 
Drug Discov 2009; 8: 661-77. 
20 Klein T, Abgottspon D, Wittwer M et al. FimH Antagonists for the oral treatment 
of urinary tract infections: from design and synthesis to in vitro and in vivo 
evaluation. J Med Chem 2010; 53: 8627–41. 
21 Han Z, Pinker JS, Ford B et al. Structure-based drug design and optimization of 
mannoside bacterial FimH antagonists. J Med Chem 2010; 53: 4779-92. 
22 Cusumano CK, Pinkner JS, Han Z et al. Treatment and prevention of urinary 
tract infection with orally active FimH inhibitors. Sci Transl Med 2011; 3: 109-15. 
23 Han Z, Pinkner JS, Ford B et al. Lead optimization studies on FimH antagonists: 
discovery of potent and orally bioavailable ortho-substituted biphenyl 
mannosides. J Med Chem 2012; 55: 3945-59. 
24 Guiton PS, Cusumano CK, Kline KA et al. Combination small molecule therapy 
prevents uropathogenic Escherichia coli catheter-associated urinary tract 
infections in mice. Antimicrob Agents Chemother 2012; 56: 4738-45. 
25 Jiang X, Abgottspon D, Kleeb et al. Antiadhesion Therapy for Urinary Tract 
Infections – A Balanced PK/PD Pofile Proved to be Key for Success. J Med 
Chem 2012; 55: 4700-13. 
26 Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob 
Chemother 2001; 48 (Suppl 1): 5-16. 
27 Scharenberg M, Abgottspon D, Ciceck E et al. Flow cytometry-based assay for 
screening FimH antagonists. Assay Drug Dev Technol 2011; 9: 455-64. 
MANUSCRIPT II 
 
257 
28 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rational for 
antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10. 
29 Frimodt-Møller N. How predictive is PK/PD for antibacterial agents? Int J 
Antimicrob Agents 2002; 19: 333-9. 
30 Kerrn MB, Frimodt-Møller N, Espersen F. Effects of Sulfomethizole and 
Amdinocillin against Escherichia coli Strains (with Various Susceptibilities) in an 
Ascending Urinary Tract Infection Model. Antimicrob Agents Chemother 2003; 
47: 1002-9. 
31 Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia 
coli reservoir during the acute phase of a bladder infection. Infect Immun 2001; 
69: 4572-9. 
32 Johnson JR, and Brown JJ. Defining Inoculation Conditions fort he Mouse 
Model of Ascending Urinary Tract Infection that Avoidf Immediate 
Vesicourethral Reflux yet Produce Renal and Bladder Infection. J Inf Dis 1996; 
173: 746-9. 
 
 
 258 
  
 259 
 
 260 
 RESULTS AND DISCUSSION 
Manuscript III 
 
Characterization of Type 1 Pili-Dependent Binding Properties of Clinical 
Uropathogenic Escherichia coli Isolates. 
 
Scharenberg M*, Abgottspon D*, Zimmermann S, zur Werra S, Preston 
R, Rabbani S, Ernst B. 
 
* These authors contributed equally to the project. 
 
Preliminary manuscript: With outlook for completion. 
 
 
My contributions: 
Evaluation of the aggregation potential and type 1 pili expression 
profiling of the clinical isolates together with Scharenberg M. and the 
master students Zimmermann S. and Zur Werra S. 
In vivo infection studies in the UTI mouse model with the clinical isolates. 
Preparation of the results and discussion of the in vivo studies for the 
manuscript. 
 
MANUSCRIPT III 
 
261 
Characterization of Type 1 Pili-Dependent Binding Properties of 
Clinical Uropathogenic Escherichia coli Isolates 
 
Meike Scharenberg*, Daniela Abgottspon*, Sabine Zimmermann, Sirin zur Werra, 
Roland Preston, Said Rabbani, Beat Ernst 
Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Switzerland 
 
 
* These authors contributed equally to the project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence to Prof. Dr. Beat Ernst, Institute of Molecular Pharmacy, 
Pharmacenter, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, 
Switzerland 
Tel: +41 61 267 1551, Fax: +41 61 267 1552, Email: beat.ernst@unibas.ch 
 
MANUSCRIPT III 
 
262 
Abstract 
 
Urinary tract infections are caused in 70-90% of all the cases by uropathogenic 
Escherichia coli (UPEC), which express type 1 pili presenting the adhesin FimH. The 
interaction of FimH with mannose glycans expressed by urothelial cells allows 
UPECs to adhere and to invade host cells within the urinary tract epithelium. In this 
study, we investigated 72 clinical human UPEC isolates on their binding behavior, 
their fimH gene sequence similarities, and type 1 pili expression profile. Differences 
in agglutination to yeast and guinea pig erythrocytes were observed. Although 
numerous natural occurring point mutations were found in the fimH gene, we show 
that it is the type 1 pili expression profile that determines the general agglutination of 
the investigated E. coli isolates. Furthermore, in vivo mouse infection studies of two 
initially non-fimbriated clinical strains showed that while one strain was capable of 
initiating type 1 pili expression within 4 h after injection followed by infection, the 
other was not. Our study demonstrates that the rate of type 1 pili expression is 
determinant for the initiation and severity of a urinary tract infection. Consequently, 
FimH antagonists capable of blocking the initial adhesion step of UPECs to host 
tissues can be considered as potential anti-infectives. 
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Introduction 
 
Urinary tract infection (UTI) is one of the most common infection, with millions of 
people affected every year. Besides women, who bear a risk of 40 - 50% to 
experience at least one symptomatic UTI episode during a life-time [1], patients with 
diabetes, spinal cord injuries, and suppressed immune system are particularly at risk 
[2, 3]. An untreated UTI may lead to a bladder infection (cystitis) and, in a later 
infection state, to a kidney infection (pyelonephritis) [4]. The initial and most 
fundamental step in the pathogenesis of UTIs is the type 1 pili dependent adhesion of 
uropathogenic Escherichia coli (UPEC) to α-mannoside containing glycoprotein 
receptors on the surface of uroepithelial cells, such as uroplakin 1a (UP1a) [5]. The 
bacterial adhesion is mediated by the lectin FimH, localized at the tip of type 1 pili, 
which recognizes mono- as well as oligomannosides. The adhesion triggers a 
bacterial cell invasion, resulting in the development of an infection. FimH antagonists 
such as α-D-mannopyranosides have been shown to interfere with the attachment of 
UPEC to their host cells, thus providing a novel therapeutic opportunity for the 
treatment and prevention of UTIs as an alternative to conventional antibiotic 
treatment [6-8]. 
 
Type 1 fimbriae are 1-3 µm long, filamentous organelles [9, 10]. These helical rods 
with a diameter of 7 nm consist of up to 3000 FimA subunits, forming the pilus rod, 
followed by the subunits FimF, FimG and FimH, forming the tip of the fimbrium. The 
adhesin FimH, which is located at the distal end of the linear fimbrium, contains the 
mannose-specific carbohydrate recognition domain (FimH-CRD) [11-13]. FimH is 
composed of two domains, the pilin domain, which connects the fimbrial rod, and the 
lectin domain, which exhibits the carbohydrate recognition domain (CRD). The highly 
conserved CRD enables the adhesion of bacteria to the mannosylated urothelial cell 
surfaces. 
 
FimH mediates binding to these mannosylated surfaces in a shear-dependent 
manner, facilitated by force-enhanced allosteric catch bonds [14, 15]. Catch bonding 
of FimH is thought to allow sustained adhesion under flow conditions as found in the 
urinary tract, and to allow mobility under no-flow conditions. The catch-bond 
mechanism is achieved by a switch between two conformational states, the low-
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affinity state and the high-affinity state. Only recently, the crystal structures of both 
FimH conformations have become available [16]. These revealed that in the low-
affinity state, an interaction between the pilin and the lectin domain allosterically 
widens the binding site, thus weakening the interaction with mannose. In the high-
affinity state, the lectin and the pilin domain are separated, and the binding site is 
tightened. The equilibrium between the two states is shifted towards the high-affinity 
conformation by tensile force along the bond, and by interaction with a ligand [16]. 
 
Naturally occurring mutations of FimH usually arise outside of the highly conserved 
mannose-binding site, but may nonetheless invoke enhanced mannose-binding 
affinity. This is known for the S62A and the A27V mutation [17, 18]. It is presumed 
that these mutations alter the interdomain interaction, thus shifting the equilibrium 
from the low-affinity to the high-affinity state. With a specific antibody for the high-
affinity state of FimH, Tchesnokova et al. proved the allosteric link between the high-
affinity state of the mannose-binding site and the open conformation of the 
interdomain region. These mutant FimH variants evolved under positive selection, 
benefiting from augmented mannose-binding affinity even under static conditions 
[19]. 
 
In a recent study using clinical isolates obtained from urine and feces of individuals 
with acute and recurrent UTIs, distinct mutations evolving under positive selection 
were identified, all of which were located outside of the mannose-binding pocket [20]. 
Based on the found mutations, six mutant strains with the same isogenic background 
were generated and investigated, showing differences in their affinity for mannose as 
well as in their in vivo fitness. However, in this study the clinical isolates were not 
directly investigated on their binding behavior to ligands or their in vivo pathogenicity, 
hence their biological properties remained unknown. Analyzing these properties can 
be of high importance when predicting the actual anti-infective potencies of FimH 
antagonists. Investigations on the infection mechanisms of clinical UPEC strains can 
provide crucial information, especially when considering exclusive treatment with 
FimH antagonists for the prevention of infections. 
 
In this study, we evaluated the binding properties of 72 clinical UPEC isolates of 
patients suffering from acute cystitis, by performing yeast and guinea pig 
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erythrocytes (GPE) aggregation assays. Furthermore, type 1 pili immunostaining 
assays together with mutational analysis of the fimH gene were performed to 
examine if variations in pili expression or mutations in the fimH gene are responsible 
for differential binding behavior of the UPEC isolates, as observed in the aggregation 
studies. In vivo infection studies together with concurrent pili expression studies 
allowed an in vivo time-dependent type 1 pili expression profiling within 24 h post 
infection. 
 
 
Material and methods 
 
Bacteria and growth. The E. coli isolate UTI89 [21] (UTI89wt) and the FimA-H 
knock-out strain UTI89∆fimA-H were kindly provided by the group of Prof. Urs Jenal 
(Biocenter, University of Basel, Switzerland). The laboratory K12/J96 (ELT115) strain 
was used as reference strain and was kindly provided by the group of Prof. 
Sokurenko (University of Washington, USA). 72 clinical E. coli isolates were collected 
at the University Hospital Basel, Switzerland during 2009 and were selectively 
cultivated. Age and sex of the patient and the antibiotic resistances are known. 
Microorganisms were stored at -70 °C and before experiment incubated for 24 h 
under static conditions at 37 °C in 10 mL Luria-Bertani broth (Becton, Dickinson and 
Company, Le Pont de Claix, France) using 50 mL tubes. Prior to each experiment, 
the microorganisms were washed twice and resuspended in phosphate buffered 
saline (PBS, Sigma, Steinheim, Germany). CFUs were determined by plating serial 
1:10 dilutions on blood agar, followed by colony counting with 20-200 colonies after 
overnight incubation at 37 °C. 
 
Aggregometry assay. The aggregometry assay was carried out as previously 
described [22]. In short, the percentage of aggregation of E. coli with guinea pig 
erythrocytes (GPE) or Saccharomyces cerevisia (yeast) was quantitatively 
determined by measuring the optical density at 740 nm and 37 °C under stirring at 
1000 rpm using an APACT 4004 aggregometer (Endotell AG, Allschwil, Switzerland). 
Bacteria were cultivated as described above. GPE were separated from guinea pig 
blood (Charles River Laboratories, Sulzfeld, Germany) using Histopaque (density of 
1.077 g/mL at 24 °C, Sigma-Aldrich, Buchs, Switzerland). Yeast was prepared by 
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dissolving commercially available dried bakers yeast in PBS. Prior to the 
measurements, the cell densities of E. coli and GPE were adjusted to an OD600 of 4, 
corresponding to 1.9 × 108 CFU/mL and 2.2 × 106 cells/mL respectively and the 
OD600 of yeast to 2, corresponding to 1.7 × 106 cells/mL. For the calibration of the 
instrument, the aggregation of protein poor plasma using PBS alone was set as 
100% and the aggregation of protein rich plasma using GPE or yeast as 0%. After 
calibration, measurements were performed with 250 µL GPE or yeast and 50 µL 
bacterial suspension and the aggregation monitored over 600 s. After the 
aggregation phase of 600 s, 25 µL of antagonist n-heptyl α-D-mannopyranoside (HM) 
[22], 385 µM in PBS was added to each cuvette and disaggregation was monitored 
for 1400 s. UTI89∆fimA-H was used as negative control. All measurements were 
performed in triplicates on different days. The aggregation behavior was evaluated by 
calculating the maximal aggregation (%) and the maximal slope (%/min). The 
inhibitory potential was determined by calculating the area under the disaggregation 
curves (AUC600-2000s). 
 
Sequence analysis of the fimH gene. The fimH gene was amplified in PCR 
reactions using either bacterial colonies or purified genomic DNA (Wizard Genomic 
DNA Purification Kit, Promega, Madison, USA) as template. The primers used to 
amplify fimH were the fimHseq fv: 5`-ACC GCG CAA AAC ATC CAG-3` and the 
fimHseq rv: 5`-GAT CGT TTG GGC CGT ACC AC-3`, located outside of the fimH 
genes in adjacent conserved DNA sequences. PCRs were performed using the 
iProof high-fidelity DNA polymerase (Bio Rad, Caboratories, Canada) as described in 
the instruction manual. Products were separated by agarose gel electrophoresis, 
purified (GenEluate Gel extraction Kit, Sigma-Aldrich, Steinheim, Germany) and 
submitted to sequence analysis (Mycrosynth, Balgach, Switzerland). Sequencing 
primers include the PCR primers as well as the fimHseq int: 5`-CCG GTG GCG CTT 
TAT TTG AC-3` primer. Obtained sequences were analyzed with FinchTV and 
Expasy and aligned with ClustalW2-Multiple Sequence Alignment. All sequences 
were compared to the fimH in the K12/J96 strain.  
 
Type 1 pili immunostaining. With an immunostaining assay, type 1 pili expression 
of the strains was veryfied. Washed bacteria (with PBS) were incubated with rabbit 
serum raised against type-1 pili (1:300) for 1 h at 4 °C (kindly provided by Prof. Karen 
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Krogfelt, Staten Serum Institute, Copenhagen, Denmark). After washing the cells, the 
bacteria were treated with the secondary anti rabbit Alexa647 conjugated antibody 
(1:200, Invitrogen, Lucerne, Switzerland) for 1 h at 4 °C. After a thorough washing 
step, the bacteria were resuspended in 300 µL PBS. Bacteria were then kept in the 
dark until analysis. Samples were measured with a CyAn ADP flow cytometer 
(Beckman-Coulter, CA, USA) and analyzed by gating on the bacterial cells based on 
forward (FSC) and side scatter (SSC). A total of 1 x 104 – 5 x 104 bacteria were 
measured per sample. Data were acquired in a linear mode for the SSC and 
logarithmic mode for FSC and the red fluorescent channel FL8-H. Quantification of 
fluorescent labeling was evaluated with the FlowJo software 7.6.3 (Tree Star, Inc., 
Ashland, OR, USA). The UTI89∆fimA-H strain was used as negative control. 
 
Animals. Female C3H/HeN mice weighing between 19 and 25 g were obtained from 
Charles River (Sulzfeld, Germany) and were housed three to a cage. Mice were kept 
under specific-pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital Basel, and animal experimentation guidelines 
according to the regulations of Swiss veterinary law were followed. After seven days 
of acclimatization, 9- to 10-week old mice were used for infection studies. During the 
studies, animals were allowed free access to chow and water. Three days before 
infection studies and during infection, 5 % D-(+)-glucose (AppliChem, Baden-Dättwil, 
Switzerland) was added to the drinking water [23]. 
 
UTI mouse model. Mice were infected as previously described [23]. In brief, before 
infection all remaining urine was depleted form the bladder by gentle pressure on the 
abdomen. Mice were anesthetized with 1.1 vol% isoflurane/oxygen mixture (Attane, 
Minrad Inc, Buffalo, NY, USA) and placed on their back. Anesthetized mice were 
inoculated transurethrally with the bacterial suspension by use of a 2 cm 
polyethylene catheter (Intramedic polyethylene tubing, inner diameter 0.28 mm, outer 
diameter 0.61 mm, Beckton Dickinson, Allschwil, Switzerland), which was placed on 
a syringe (Hamilton Gastight Syringe 50 µL, removable 30G needle, BGB Analytik 
AG, Boeckten, Switzerland). The catheter was gently inserted through the urethra 
until it reached the top of the bladder, followed by slow injection of 50 µL bacterial 
suspension at a concentration of approximately 109 to 1010 CFU/mL. 
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Results and discussion 
 
Aggregometry screening of the clinical UPEC isolates. All strains were cultivated 
for 24 h under static conditions prior to aggregometry measurements, as 
recommended for enhanced type 1 pili expression [24]. GPE hemagglutination and 
yeast aggregation assays with the clinical UPEC isolates were performed to 
investigate their binding properties. Major differences in the aggregation behavior of 
the UPEC isolates were observed (Figure 1). The strains were classified into three 
groups, based on their aggregation capability of GPE and yeast (Figure 1 and 2). A 
maximal aggregation rate of more than 15% was considered as positive aggregation. 
 
 
Figure 1. Aggregation and disaggregation curves of clinical isolates from group 1, 2, and 3. 
Disaggregation was triggered after 600s by the addition of n-heptyl α-D-mannopyranoside 
(385 µM). 
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Isolates of group 1 (16 isolates, 22%) showed pronounced aggregation of both GPE 
and yeast, whereas isolates of group 2 (19 isolates, 26%) aggregated neither with 
GPE nor with yeast. Group 3, representing the largest group with 37 isolates (52%), 
aggregated exclusively with yeast, and not with GPE. No isolate showed aggregation 
only with GPE and not with yeast. The highly virulent clinical isolate UTI89 belongs to 
group 1.  
 
Figure 2. Aggregometry screening of the clinical E. coli isolates (ntot= 72). Group 1: Isolates 
aggregating with GPE and yeast (nG1= 16). Group 2: Isolates aggregating neither with GPE, 
nor with yeast (nG2= 19). Group 3: Isolates exclusively aggregating with yeast (nG3= 37). 
GPE: guinea pig erythrocytes, yeast: Saccharomyces cerevisiae. 
 
 
Aggregating isolates (max. aggregation ≥15%) were further analyzed by their 
disaggregation behavior after the addition of the FimH antagonist n-heptyl α-D-
mannopyranoside (385 µM final concentration, Figure 1). Disaggregation was 
monitored over 1400 s and the area under the disaggregation curve (AUC) was 
determined. The relative amount of disaggregated bacteria was calculated and 
expressed in % disaggregation effect (AUCno antagonist = 100% aggregation, 0% 
disaggregation effect, 100% - (100% • AUCwith antagonist /AUCno antagonist)). The 
aggregation of all tested strains was reverted with n-heptyl α-D-mannopyranoside, 
implying that aggregation of GPE and yeast was solely FimH dependent. For the 
bacteria-GPE aggregates, n-heptyl α-D-mannopyranoside showed an average 
disaggregation effect of 73%. For bacteria-yeast aggregates, disaggregation was 
reduced to 30% in group 1 and 23% in group 3. The aggregation results demonstrate 
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that the affinity of type 1 pili is higher for yeast than for GPE, since higher 
concentrations of antagonist are required to revert yeast aggregation, as will be 
discussed.  
 
fimH gene sequencing. Since it is known that point mutations in the fimH gene 
dramatically affects binding properties of type I fimbriated bacteria [17, 19, 25], fimH 
genes of 58 isolates were sequenced, i.e. 16, 15, and 27 strains of group 1, 2, and 3, 
respectively. The sequences were aligned to the fimH gene of the UPEC strain J96. 
We identified 26 naturally occurring amino acid mutations within the fimH gene, 
occurring with different frequencies (Table 1). 
 
 
Table 1. Mutation frequencies of the fimH gene sequencing, subdivided into group 1, 2 and 
3. fimH gene sequences were compared to UPEC strain J96, used as reference throught this 
study. The total number of sequenced isolates of each group is indicated in brackets. The 
most frequently occurring mutations and the corresponding amino acids are highlighted in 
red. 
 
Amino acids with Mutations 
7 V27A 41 62 66 68 N70S 74 S78N 101 106 117 118 
Group 1 
(16 isolates) - 12 - 1 3 1 6 3 7 - - - - 
Group 2 
(15 isolates) - 10 - - 1 - 1 - 1 - - 1 1 
Group 3 
(27 isolates) 1 25 1 - 1 - 10 - 12 1 2 - - 
Total 
(58 isolates) 1 47 1 1 5 1 17 3 20 1 2 1 1 
 
 
Amino acids with Mutations 
119 122 V128M 130 147 163 R166H 192 202 238 242 273 279 
Group 1 
(16 isolates) - - 1 - 1 1 1 - 1 1 1 - - 
Group 2 
(15 isolates) 2 - - 1 - 1 4 - - - - 1 - 
Group 3 
(27 isolates) 1 1 4 - - 1 1 1 - - 1 1 1 
Total 
(58 isolates) 3 1 5 1 1 3 6 1 1 1 2 2 1 
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As expected, none of the mutations was directly located within the mannose binding 
site, which was rather conserved among all sequenced strains. The mutations were 
either located in the interdomain region between the lectin and the pilin domain of 
FimH, or in spatial proximity to amino acids that were already associated with a 
conformational change of the protein (Figure 3). As mentioned before, the disruption 
of the interdomain interactions by structural mutations leads to a shift in the 
equilibrium towards the high-affinity state. 
 
 
 
Figure 3. Structure of the FimH pilin and lectin domains with all mutations found in the 58 
sequenced clinical isolates (red balls). The mannose-binding site was conserved in all 
strains. (PDB entry 3jwn, FimH low-affinity conformation). 
 
 
The most frequently identified mutations were V27A, N70S, S78N, V128M, and 
R166H. 12 strains contained a valine in position 27 as in the pathogenic strain J96. 
This mutation has been shown to increase adhesion to mannose and to lower the 
threshold for catch-bond activation, implying a disruption of the interdomain region 
and shifting FimH towards the high-affinity state. It is assumed that this mutation is 
responsible for the high pathogenicity of the J96 strain [26]. The R166H mutation, 
which is also known to enhance mannose binding [27], was observed in six clinical 
isolates. The V128M mutation that was found in 5 clinical isolates was also shown to 
MANUSCRIPT III 
 
272 
weaken the interaction between pilin and lectin domains [15]. To date, this mutation 
was not further analyzed. However, residue 128 is located on the adjacent β-strand 
to amino acid 62, which is mutated (S62A) in the highly uropathogenic UTI89 strain 
and is known for its enhancing effect on mannose binding [28]. Therefore, it would be 
interesting to directly compare both mutations on their influence on ligand binding 
and pathogenicity. The mutations N70S and S78N have been shown to occur 
frequently, but no biological effect was associated with these mutations to date [15, 
26]. Mutations that shift the equilibrium towards the high-affinity conformation 
emerged upon pathogenic adaptation of the fimH gene in nature, providing an 
advantage for bladder colonization during the course of an acute cystitis [17]. 
Although mutations can alter the binding behavior of UPECs, we did not observe a 
correlation between aggregation/disaggregation behavior and distinct mutations in 
the fimH genes of our isolates. Binding enhancing mutations were found in all three 
groups. Therefore, the general aggregation/disaggregation properties of the analyzed 
UPEC strains cannot be attributed to polymorphisms within the fimH gene. 
 
Type 1 pili expression profiling. To evaluate the possibility that the differential 
binding to yeast and GPEs originates from distinct expression rates of type 1 pili, we 
quantified the pili expression of UPEC strains by immunostaining assays. The 
expression of type 1 pili is phase variable and switches between fimbriated and non-
fimbriated states in individual cells. The invasion is regulated by the two 
recombinases FimB and FimE, which are both encoded upstream of the invertible 
element within the fim gene cluster. Several factors such as growth conditions [24] 
(pH, osmolarity, temperature, shaking/static incubation) and the infection state [29, 
30] influence the activity of these recombinases. This enables the bacteria to switch 
between different fimbriation states under varying environmental conditions, which is 
crucial for their survival and pathogenicity [29]. The investigated strains exhibited 
differential pili expression profiles (Figure 4), even though the strains were cultured 
identically with optimal conditions for pili expression (24 h, non-shaking [31]).  
 
 
 
 
MANUSCRIPT III 
 
273 
 
Figure 4. Examples of type 1 pili immunostaining assays for clinical isolates, belonging to 
group 1, 2, and 3. Group 1: Isolates aggregating with yeast and GPE; Group 2: Isolates 
aggregating neither with GPE, nor with yeast; Group 3: Isolates exclusively aggregating with 
yeast. Pili were stained with a rabbit anti-type 1 pili antibody and an anti-rabbit-Alexa647 
antibody. The samples were measured in a flow cytometer and analyzed with the FlowJo 
software.  
 
 
Clinical isolates from the first group binding to yeast and GPE, showed a strong and 
homogeneous expression profile. Strains from the second group, which aggregated 
neither with yeast nor with GPE, showed no type 1 pili expression. And finally, strains 
from the third group aggregating with yeast but not with GPE, either consisted of 
distinct piliated and non-piliated subpopulations, or of a single population with 
homogenously low pili density. These results indicate that the pili expression rate 
determines the aggregation properties of UPECs, with a higher percentage of piliated 
bacteria being necessary for GPE aggregation but not for yeast aggregation. This 
observation, together with the high disaggregation properties of n-heptyl α-D-
mannopyranoside implies that FimH binds with a lower affinity to carbohydrate 
ligands on GPE than on yeast. Mannan present on yeast is composed of a core 
(1→6) mannose chain with branched side chains of up to 200 mannose residues [32] 
and was shown to be a high-affinity receptor for type 1 fimbriae [33]. For GPEs, a 
single glycoprotein as putative type 1 fimbriae ligand was isolated to date. It was 
suggested that this glycoprotein bears N-linked high-mannose glycans [34], with the 
density of this glycoprotein on the cell surface of GPEs being rather low. The 
differences in mannose ligand densities and affinities for type 1 fimbriae may account 
for the distinct aggregation capabilities of clinical isolates with GPE and yeast. Only 
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strains with a high density of fimbriae were able to agglutinate GPEs. These results 
prove the importance to first determine the recombinant isogenic background of the 
mutants and to quantify type 1 pili expression before comparing the binding behavior 
of different strains, or e.g. judging the influence of mutations on the binding behavior 
of FimH variants. Only when the pili expression profile of different strains is 
comparable, one can directly compare and interpret their binding behavior in 
aggregation or binding assays. 
 
In vivo type 1 pili expression and infection study. UPECs do not constantly 
express type 1 pili. Some strains require special growth conditions or even express 
type 1 pili only under in vivo conditions [24, 29 - 31]. Therefore, we performed 
infection studies in mice with the highly uropathogenic UTI89 strain, the FimA-H 
deficient UTI89 strain (UTI89ΔfimA-H), and two different strains from group 2, which 
do not express type 1 pili under the tested in vitro conditions (B1_39 and B1_59). 
After bacterial inoculation in the UTI mouse model, urine samples were collected 
after 0, 2, 4, 6, 8, and 24 hours, and analyzed for pili expression using 
immunostaining assays. The bladder and the kidneys were taken after 24 h, 
homogenized and plated in serial dilutions for analyis of bacterial counts. 
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A 
 
B 
 
Figure 5. 24 h infection study in the UTI mouse model and type 1 pili immunostaining of 
bacteria present in the urine of infected mice after 0, 2, 4, 6, 8, and 24 hours. A. Bacterial 
counts in organs (bladder and kidneys) as colony forming units (CFU) after 24 hours of 
infection. B. Type 1 pili expression profiling of the urine samples collected from mice every 2 
hours. The MFI (mean fluorescence intensity) level reflects the density of type 1 pili 
expressed by the bacteria. 
 
 
The infection and type 1 pili expression study revealed differences in the expression 
profile between the strains in urine samples, which correlated well with the bacterial 
load in the organs (Figure 5). The negative control UTI89ΔfimA-H showed no type 1 
pili expression (Figure 5 B). The positive control UTI89 expressed high levels of type 
1 pili after in vitro cultivation, indicated by a high mean fluorescence intensity (MFI) at 
the beginning of the infection (0 h). The density of pili further increased during the 
first 4 h of infection. Isolate B1_39 showed no pili expression during the course of the 
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experiment, whereas isolate B1_59 showed a significant pili expression rate, starting 
at 2 h post-infection. Bacteria of both non-type 1 pili expressing strains, UTI89ΔfimA-
H and B1_39, were hardly detectable in the bladder and in the kidneys (Figure 5 A). 
The few bacteria present in the organs were most likely able to invade via non-
specific binding, and would probably be cleared after a longer study time period (e.g. 
36 or 48 h). For UPEC strain B1_59 we found a lower number of bacteria in the 
bladder and the kidneys compared to UTI89, representing an early stage of infection. 
The results from the expression profile and the infection outcome correlate very well 
(Figure 5 B). UPEC strain UTI89 resulted in the highest bacterial load, because it had 
already been expressing type 1 pili before infection. The B1_59 strain, which first had 
to up-regulate the expression of type 1 pili, was not instantly able to adhere to 
bladder cells after inoculation and parts of the injection load were washed out with 
the flow of urine before pili expression was initiated. Therefore, only a reduced 
number of bacteria were able to initiate an infection, which was as a consequence 
weaker than for UTI89. 
The type 1 pili expression rates of the pathogenic strains (UTI89 and B1_59) were 
down-regulated to low levels after 24 h, confirming the essential role of type 1 pili 
only for the initial infection process. The expression of other virulence factors, such 
as P fimbriae, which are crucial for the establishment of pyelonephritis in the later 
stages of a UTI, influences the expression rate of type 1 pili. Cross-talk between the 
adhesin gene clusters [30] and the activation of P fimbriae switch the fim gene to 
phase-off orientation, preventing type 1 pili expression [29]. The low type 1 pili 
expression rate 24 h post-infection indicates that the switch of type 1 pili to P fimbriae 
already occurred. P pili expression profiling would complement these observations. 
 
This study demonstrates that type 1 pili are crucial for the establishment of a severe 
infection, since the UTI89∆fimA-H and the B1-39 strain only caused minor bacterial 
counts in the kidneys and in the bladder. Furthermore, it was shown that some 
strains are capable of resetting their pili expression when subjected to the host tissue 
milieu, whereas others might have lost this capability. The initiation of an infection by 
the tested clinical isolates seemed to be exclusively mediated by type 1 pili, and not 
by other mechanisms. Treatment with FimH antagonists in the early stages of an 
infection should therefore allow preventing UPECs from adhering to host cells, and 
thus prevent UTIs.  
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Conclusion 
 
Our study of 72 clinical UPEC isolates of patients with acute cystitis on their 
aggregation properties to yeast and GPE revealed major differences in binding 
behavior. The isolates were classified into three distinct groups, depending on their 
aggregation behavior and pili expression profile. GPE agglutination required a high 
and homogenous expression profile, implying that the binding properties of each 
individual strain to GPE are determined by its pili expression rate. Sequence analysis 
of 58 strains revealed a highly conserved mannose-binding site, with variations being 
located predominantly in the interdomain region between pilin and lectin domain. 
Most of the mutations were already described to influence the conformational state of 
FimH by disrupting the interdomain interaction. This disruption results in a shift from 
the low-affinity to the high-affinity state, suggesting that these mutations emerged 
from pathogenic adaption. This study shows that the severity of an infection is not 
only determined by the fimH variant, but rather by the pili expression rate of the 
individual isolates. Furthermore, we were able to confirm that type 1 pili are critical for 
the establishment of an infection in vivo. Consequently, quantification of type 1 pili for 
each individual strain is essential when comparing binding or infection capabilities of 
different strains or fimH variants.  
 
 
Outlook 
 
In the present study we evaluated the effect of mutations in the fimH gene on the 
binding profile of various clinical UPEC isolates. Since only the fimH was analysed, 
other influencing factors of the E. coli pathogenesis were not considered (e.g. other 
virulence factor expressions). To determine if the observed effect is exclusively due 
to the mentioned mutations in the fimH gene, isogenic mutants will be constructed 
and analyzed. 
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SUPPLEMENTARY 
Aggregometry and Flow Cytometry Assay Results 
Results obtained from aggregometry and flow cytometry experiments of the different 
compound classes are listed below in Tables 1 to 7. rIC50s were calculated by 
dividing the IC50 of the compound of interest by the IC50 of the reference compound 
n-heptyl α-D-manno-pyranoside. This leads to rIC50 values below 1.0 for derivatives 
with higher activity than the reference compound and rIC50 values above 1.0 for 
compounds with lower activity than the reference compound. 
 
Table 1. IC50 values obtained for CL compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
α-D-methyl 
mannoside 
 
n.a. - 249.2 ± 62.3 63.8 
pNpα  
mannoside 
 
45.1 ± 7.8 0.6 3.2 ± 0.7 0.8 
CL14 
 
n.a. - - - 
CL15 
 
n.a. - - - 
CL16 
 
n.a. - - - 
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Table 2. IC50 values obtained for JH compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
JH14.2 
 
n.a. - - - 
JH16.2 
 
19.2 0.2 - - 
JH17.2 
 
n.a. - - - 
JH18.2 
 
8.7 0.1 - - 
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Table 3. IC50 values obtained for JXH compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
JXH001 
 
n.a. - - - 
JXH016 
 
n.a. - - - 
JXH031 
 
n.a. - - - 
JXH039 
 
n.a. - - - 
JXH041 
 
n.a. - - - 
JXH046 
 
26.8 0.3 - - 
JXH065 
 
4.1 0.05 - - 
JXH067 
 
7.1 0.09 - - 
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JXH073 
 
12.8 0.2 - - 
JXH081 
 
30.9 ± 3.7 0.4 - - 
JXH087 
 
25.3 0.3 - - 
JXH097 
 
n.a. - - - 
JXH099 
 
6.4 0.8 - - 
JXH0192 
 
n.a. - - - 
JXH0682 
 
3.1 0.04 - - 
JXH0751 
 
23 0.3 - - 
JXH101 
 
5.6 0.07 - - 
JXH224 
 
1.3 0.02 0.6 ± 0.05 0.2 
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JXH232 
 
8.3 0.1 - - 
JXH2372 
 
45.1 ± 7.8 0.6 0.9 ± 0.6 0.2 
JXH2431 
 
5 0.06 1 0.3 
JXH2432 
 
29.9 0.4 - - 
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Table 4. IC50 values obtained for MH compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
MH17 
 
25.4 ± 7 0.3 - - 
MH35 
 
105.3 1.4 - - 
MH36 
 
n.a. - - - 
MH39 
 
225.1 2.9 - - 
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Table 5. IC50 values obtained for Mha compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
Mha8 
 
n.a. - - - 
Mha10 
 
299.1 3.9 - - 
Mha11 
 
n.a. - - - 
Mha19.2 
 
n.a. - - - 
Mha20 
 
n.a. - - - 
Mha28 
 
376.4 4.9 - - 
Mha29 
 
373.8 4.9 - - 
Mha31 
 
n.a. - 21.5 ± 1.5 5.5 
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Mha52 
 
339.1 4.4 - - 
Mha53 
 
n.a. - - - 
Mha54 
 
216.2 2.8 - - 
 
 
Table 6. IC50 values obtained for OS compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
OS373 
 
298.6 3.9 - - 
OS376 
 
188.3 2.4 - - 
OS377 
 
122.9 1.6 - - 
OS380 
 
280.9 3.6 - - 
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OS381 
 
248.5 3.2 - - 
OS383 
 
n.a. - - - 
OS386 
 
14 ± 1 0.2 1.1 ± 0.5 0.3 
OS394 
 
0.85 ± 0.13 0.01 0.04 ± 0.008 0.009 
OS395 
 
4.4 ± 0.5 0.06 - - 
OS396 
 
4.5 ± 1.2 0.06 - - 
OS397 
 
2.1 ± 0.8 0.03 - - 
OS405 
 
n.a. - - - 
OS412 
 
n.a. - - - 
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OS413 
 
n.a. - -  
OS416 
 
n.a. - - - 
OS417 
 
n.a. - - - 
OS419 
 
n.a. - - - 
OS420 
 
 
3.3 ± 1.3 0.04 0.1 ± 0.02 0.03 
OS421 
 
5 ± 1.3 0.06 0.1± 0.2 0.03 
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Table 7. IC50 values obtained for PLJ compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
PLJ01066A 
 
- - 2.7 ± 0.3 0.7 
PLJ01076A 
 
27.2 ± 1.5 0.4 0.8 ± 0.2 0.2 
PLJ01089A 
 
- - 4.9 1.3 
PLJ01089B 
 
16.8 ± 1.2 0.2 - - 
PLJ01179B 
 
9.1 ± 2.7 0.1 1.8 ± 0.1 0.5 
PLJ01178B 
 
24.5 ± 2.8 0.3 2 ± 0.4 0.5 
PLJ01181B 
 
9.5 ± 8.1 0.1 4.9 ± 0.8 1.2 
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PLJ01194B 
 
3.4 ± 0.4 0.04 0.9 ± 0.1 0.2 
PLJ01175B 
 
34.4 ± 4.2 0.4 1.5 ± 0.3 0.4 
 
 
Table 8. IC50 values obtained for TK compounds using aggregometry and flow cytometry. 
n.a.: not active; dash (-): not measured. 
Compound Structure 
Aggregometry Flow cytometry 
IC50 [µM]  rIC50 IC50 [µM]  rIC50 
n-heptyl α-
D-manno-
pyranoside 
(reference)  
77.1 ± 8.7 1 3.9 ± 1.6 1 
TK05 
 
9.2 ± 3.9 0.1 0.3 ± 0.05 0.09 
TK14 
 
41.6 0.5 - - 
TK15 
 
16.8 0.2 0.5 ± 0.06 0.1 
TK 16 
 
9.2 ± 2.7 0.1 0.2 ± 0.04 0.06 
TK17 
 
32.8 0.4 - - 
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TK18 
 
50.6 ± 1.7 0.7 4.5 ± 1.9 1.1 
TK19 
 
31.2 0.4 - - 
TK20 
 
n.a. - 0.8 ± 0.2 0.2 
TK22 
 
13.8 0.2 - - 
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In vivo Pharmacokinetic Study Results 
Results obtained from the in vivo pharmacokinetic studies in mice of the different 
classes of FimH antagonists are summarized in the data-sheets below. 
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In vivo Infection Study Results 
Results obtained from the in vivo infection studies in the UTI mouse model of the 
different classes of FimH antagonists are summarized in the data-sheets below. 
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In vivo Pharmacokinetic/Pharmacodynamic Study Results 
Results obtained from the in vivo pharmacokinetic/pharmacodynamic studies in mice 
of the different classes of FimH antagonists are summarized in the data-sheets 
below. 
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